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predicting a p.K219fsX234 change in the nibrin protein. The patient 
presented with progressively growing, painless, erythematous and 
indurated plaques and ulcers on the right leg at 6 years of age.
Methods: Mutational analysis of genomic NBS1 was performed using 
the BigDye Terminator Cycle sequencing kit. Mycobacterium DNA in 
skin specimens was detected by PCR using Mycobacterium genus and 
M. tuberculosis species-speciﬁc primers. Biopsy specimens were used 
for culture. Sections of the formalin-ﬁxed parafﬁn-embedded skin 
biopsy samples were stained with Ziehl-Neelsen and H&E stainings.
Results: Both culture and Ziehl-Neelsen staining gave negative results 
but PCR testing with Mycobacterium genus- and M. tuberculosis spe-
cies-speciﬁc primers conﬁrmed the diagnosis of CTB. A unique fea-
ture of this patient was the presentation of CTB with no pulmonary or 
systemic manifestation of TB.
Conclusions: This is the ﬁrst report describing the association of NBS 
with CTB clearly showing the importance of genetic testing to deﬁne 
mycobacterial etiology of CTB.
Acknowledgements: Supported by a TÁMOP 4.2.2-08/1-2008-0015 
Grant
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Dectin-1-Mediated Immunity is Redundant for Host 
Defense against Mucocutaneous Candidiasis
Beáta Tóth1, Péter Gogolák1, Szilvia Taskó1, László Maródi1.
1University of Debrecen, Medical and Health Science Center, Debre-
cen, HU.
Background: Two groups have recently reported that genetic deﬁ-
ciency of Dectin-1 due to mutation of CLEC7A (Tyr238X/Tyr238X 
or Tyr238X/WT) or premature termination of the caspase recruit-
ment domain-containing protein 9 resulting from CARD9 mutation 
(Gln295X/Gln295X) may predispose patients to chronic mucocutane-
ous candidiasis CMC (1-3).
Materials: We studied the frequency of CLEC7A mutation in 51 Hun-
garian healthy individuals. Genomic DNA was isolated from blood 
leukocytes. Blood monocytes and monocye-derived dentritic cells 
(MDDCs) were used to study phenotypic expression of Dectin-1.
Methods: CLEC7A was sequenced with the Big Dye Termina-
tor cycles sequencing kit and analyzed using an ABI 3130 capillary 
sequencer. Mixed mononuclear cells (MCs) were isolated from hepa-
rinized venous blood. MDCCs were obtained by culture of monocytes 
isolated by using immunomagnetic cell separation assay, in AIMV 
medium supplemented with 75 ng/mL GM-CSF and 100 ng/mL IL-4 
for 5 days. Measurement of receptor expression was performed by 
using a FACSCalibur ﬂow cytometer. Secretion of IL-17A by MCs 
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Bypassing Cytokine and Cytokine Receptor Defects: Using 
Interferon Alpha to Replace Interferon Gamma
Elizabeth Sampaio1, Hannelore Bax1, Ervand Kristosturyan1, Li Ding1, 
Li Madison1, Sarah Browne1, Steven Holland1.
1NIH, Laboratory of Clinical and Infectious Diseases, Bethesda, US.
Background: Patients with mutations in the genes encoding the inter-
feron gamma receptor (IFN-gR) and signal transducer and activator 
of transcription 1 (STAT1) often present with extensive and therapy 
resistant mycobacterial infections. However, not much is known about 
STAT1 activation by IFNα in the treatment of mycobacterial infections 
and in situations in which IFN-γ signalling is impaired. We evaluated 
the effect of IFN-γ and/or IFN-α treatment on cellular responses in 
vitro in cells from patients with mutations in the IFN-γR, STAT1, or 
with high titer autoantibodies to IFN-γ.
Materials: Puriﬁed elutriated monocytes and EBV-transformed B 
cells were used in the experiments. Antibodies were purchased from 
Cell Signaling and Becton&Dickinson.
Methods: Immunoblots, co-immunoprecipitation, ﬂow cytometry, and 
real time PCR were performed on cells from normal donors and from 
patients with IFN-g signal defects. Cells were treated in vitro with 
IFN-γ(200U/ml), IFN-α(1,000U/ml) and IFN-γ/α co-treatment for 
15-30min (STAT phosphorylation) and 3h (gene expression).
Results: IFN-α activated STAT1 phosphorylation in cells lacking a 
functional IFN-γR. Both IFN-γ and IFN-α activated STAT1 in patients 
with STAT1 mutations, but usually to a lesser extent than in normal cells. 
Clinically, we used IFN-α in patients with refractory mycobacterial 
infections who had mutations in IFN-γR1, IFN-γR2, or had high level 
autoantibodies to IFN-γ. IFN-α used subcutaneously three times weekly 
or pegolated interferon once weekly were well tolerated. IFN-α was more 
effective against M. avium complex infections than M. abscessus, but 
whether this reﬂects a dose-dependence of treatment of M. abscessus or 
differential activity is still unclear. Four patients with mutations affecting 
the IFN-γR had objective improvements in infection burden and clinical 
condition after initiating IFN-α. The combined use of IFNγ and IFNαα 
was associated with increased STAT1-mediated response and activation 
of typical IFN-γγ genes (IP10, CXCL9, IRF1). Increased protein levels 
and enhanced STAT1/STAT3 association were also observed.
Conclusions: An underlying mechanism involving the crosstalk 
between STAT1 and STAT3 is proposed implying the balance between 
these opposing regulators to be central to the effects induced by IFNs. 
Our results suggest that the overlap of cytokine signal transduction 
pathways can be exploited clinically to treat severe infections.
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Association of Nijmegen Breakage Syndrome with Primary 
Cutaneous Tuberculosis
Melinda Erdős1, Beáta Tóth1, Mohamed Mahdi1, Imre Veres1, Mária 
Kiss2, Éva Remenyik1, László Maródi1.
1University of Debrecen, Medical and Health Science Center, Debre-
cen, HU; 2Szent-Györgyi University, Szeged, HU.
Background: Cutaneous tuberculosis (CTB), a very rare manifesta-
tion of mycobacterial infections tipically occurs with pulmonary or 
systemic manifestations of tuberculosis.
Materials: We report here on a 7-year-old Caucasian girl with clinical 
and immunological manifestations of Nijmegen Breakage syndrome 
(NBS) caused by a c.657del5bp deletion mutation of the NBS1 gene 
Figure 1. Facial characteristics of NBS (up) and lupus vulgaris on the right 
leg (down).
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stimulated for ﬁve days with live or killed C. albicans blastoconidia 
was measured by ELISA.
Results: We found healthy individuals with homozygous (one 38-year-
old male) or heterozygous (50 males or females) Tyr238X mutation of 
Dectin-1 who have no manifestation of CMC. Dectin-1 expression on 
monocytes and MDDCs was negligible in the homozygous male in con-
trast to intermedier expression of heterozygous individuals compared 
with that of wild type controls. A marked reduction in IL-17A produc-
tion was found in the homozygous individual compared with control 
cells and we found intermediate production of this cytokine in hetero-
zygotes. The rate of Tyr238X heterozygous individuals was 12%.
Conclusions: We suggest that Dectin-1 receptor-mediated immunity to 
host defense against CMC is redundant which might be due to multiple 
lectin receptors that are involved in recognition and uptake of Candida.
Acknowledgements: Supported by a TÁMOP 4.2.2-08/1-2008-0015 
Grant.
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Dendritic Cell Vaccination Generates Protective 
Responses against Inﬂuenzavirus Infection: A Model of 
Effective Vaccination for Immunosuppressed Cancer and 
Hematopoietic Stem Cell Transplant Patients
W.K. Decker1, S. Li1, R. Zabriskie1, A. Machado1, B. Gilbert1, E.J. 
Shpall1, A. Safdar1.
1M. D. Anderson Cancer Center, Houston, US.
Background: We have recently demonstrated the ability to generate 
robust, antigen-speciﬁc T-cell responses following priming of naïve, 
umbilical cord blood lymphocytes with recombinant inﬂuenza hemag-
glutinin (rHA) loaded dendritic cells (DC) (Safdar et al. Vaccine 2009).
Materials: Toward the goal of validating this model in vivo, we have 
developed a murine model of DC immunotherapy utilizing a Balb/c-
adapted A/New Caledonia H1N1 inﬂuenza virus.
Methods: Balb/c-adapted A/New Caledonia was generated by 4 serial 
passages of infected lung pools. Bone marrow stem cells derived from 
Balb/c donors were incubated in GM-CSF and IL-4 for six days to gener-
ate immature DCs. DCs were loaded with A/New Caledonia rHA protein 
for 3 hours and then matured in a cocktail of GM-CSF,IL-4,IL-1β,TNF-
α,IL-6, and PGE2. Mature DCs were harvested after 24 hours and deliv-
ered at a dose of 106 DC by subcutaneous or intraperitoneal routes.
Mice were bled retroorbitally 4 weeks after vaccination and serum 
was analyzed for HA-speciﬁc antibody titers by ELISA. 6 weeks 
after vaccination, mice were challenged intranasally with 50 μl of a 
Balb/c-adapted A/New Caledonia inﬂuenzavirus lung pool with a titer 
of approximately 106 TCID50/ml. Efﬁcacy of the vaccine was deter-
mined by survival.
Results: Four weeks after vaccination, 3 of 3 mice injected with DCs 
intraperitoneally had seroconverted with high titers apparent at a serum 
dilution of 1:250. In contrast, only 1 of 3 mice injected subcutaneously 
demonstrated seroconversion and only at a serum dilution of 1:25.
None of the mice injected with control DCs (not loaded with rHA) 
demonstrated rHA-speciﬁc seroconversion. At 6 weeks post-vaccina-
tion, mice were challenged intranasally with Balb/c-adapted A/New 
Caledonia. By day 17 post-inoculation, the 4 mice with HA-speciﬁc 
antibody titers were all alive, healthy, and had regained 100% of their 
pre-infection body masses whereas the 4 mice with no demonstrable 
HA-speciﬁc antibody titers had all died (p < 0.005).
Conclusions: The model demonstrates that robust HA-speciﬁc anti-
body titers may be generated by a single injection of HA-loaded DCs, 
and that such titers are protective against fulminant inﬂuenza infection. 
DC immunotherapy for the prevention of inﬂuenza in immunosup-
pressed cancer patients might be feasible and warrants further explora-
tion of the technique.
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IL-7 Expression and Responsiveness in EBV Infection and 
EBV-Associated PTLD in Allogeneic HSCT Patients
Hamdy Omar13, Raija Ahmed23, Lalite Rane23, Andreas Björklund1, 
Åsa Gustafsson.Jernberg4, Per Ljungman1, Markus Maeurer23.
1Karolinska Institutet, Department of Medicine, Huddinge, Stock-
holm, SE; 2Karolinska Institutet, Microbiology. Tumor and Cell biol-
ogy, Stockholm, SE; 3Smittskyddsinstitutet, Immunology and vaccin-
ology department, Stockholm, SE; 4Karolinska University Hospital, 
Department of Pediatrics, Stockholm, SE.
Background: IL-7 is a non-redundant growth- and differentiation factor 
for B- and T- cells. It is essential in early B lymphocyte development 
and in survival / immune memory formation in T-lymphocytes. IL-7 was 
found to be expressed in EBV + B cell lines which may impact on B-cell 
survival and/or B-cell proliferation. Lack of IL-7 responsiveness in T-cells 
may be associated with reduced cellular immune surveillance. IL-7 may 
i) contribute to malignant progression of EBV-infected B lymphoblasts in 
transplanted patients and ii) be used to gauge immune responsiveness in 
cellular immune responses. This may provide a basis to develop new tools 
to monitor for early indicators for of the development of PTLD.
Aim: To study the biological functions of IL-7 and IL-7R in peripheral 
blood mononuclear cells (PBMCs) and in serum from patients with 
EBV-PTLD.
Materials: PBMCs from 6 patients with PTLD, harvested at different 
time points after SCT and in control patients (with EBV +  after SCT) 
were used.
Methods: i) IL-7-induced STAT5 phosphorylation in CD4 +  and 
CD8 +  T-cells (functional readout for IL-7), ii) EBV speciﬁc T cells by 
tetramer analysis and iii) expression of IL-7R on B cell subsets. Serum 
IL-7 and soluble IL-7R concentrations were measured by ELISA.
Results: CD8 +  T-cells show decreased IL-7 responsiveness both in 
PTLD +  and PTLD- individuals deﬁned by STAT5 phosphorylation. 
In contrast, CD4 +  T-cells from PTLD patients, but not from (EBV + ), 
PTLD- individuals show a markedly reduced capacity to respond to 
IL-7. PBMCs from patients with PTLD and control individuals exhib-
ited EBV speciﬁc T cells directed against both latent and lytic EBV 
targets. IL-7R was not expressed on B-cells obtained from the control 
patients, but on on B-cells from patients with PTLD.
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Conclusions: EBV-speciﬁc CD8 +  T-cells with a reduced capacity to 
respond to IL-7 are present in both PTLD +  and PTLD- individuals. 
In contrast, IL-7R expression on B cells as well as reduced responsive-
ness to IL-7 in CD4 +  T-cells could exclusively be detected in PTLD + 
patients. This immunological proﬁle may aid to monitor patients after 
SCT for EBV-associated PTLD.
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Efﬁcacy and Safety of Standard Long-Term Posaconazole 
Antifungal Prophylaxis in Allogeneic Stem-Cell Transplant 
Recipients
Drew Winston1, Kathy Bartoni1, Mary Territo1, Gary Schiller1.
1UCLA Medical Center, Medicine, Los Angeles, US; 2UCLA Medical 
Center, Medicine, Los Angeles, US.
Background: Invasive fungal infections (IFI) caused by Aspergillus 
and other organisms can be a common cause of morbidity and mor-
tality in allogeneic stem cell transplants (SCT). Based on favorable 
results in randomized controlled trials (Winston DJ, CMI 12 (suppl 
7): 91-96, 2006), we use a mold-active azole as standard antifungal 
prophylaxis in all adult UCLA allogeneic SCT. Limitations of previ-
ous azoles have been GI intolerance (itraconazole, ITRA) and break-
through Zygomycetes infections (voriconazole, VORI).
Materials: We evaluated the use of oral posaconazole (POS) as stan-
dard antifungal prophylaxis in all adult allogeneic SCT at UCLA.
Methods: Oral POS (200 mg tid) was started on day 1 after SCT and 
continued until day 100. After day 100, POS was continued in patients 
still requiring corticosteroids for prevention or treatment of GVHD. If 
patients could not take oral drugs, IV ITRA or IV VORI was temporar-
ily substituted for oral POS.
Results: From 1/07 through 12/08, 106 allogeneic SCT patients 
received POS prophylaxis. These patients were at high-risk for IFI 
(median age, 46 years; advanced hematological disease, 56%; unre-
lated donor, 42%; mismatched donor, 26%; myeloablative SCT, 89%; 
high-dose corticosteroids for prevention or treatment of GVHD, 76%; 
grade 2-4 acute GVHD, 60%). Breakthrough IFI on POS occurred in 
8/106 (7.5%) patients within 6 months after SCT; 3 additional patients 
developed IFI 53-66 days after POS prophylaxis was discontinued 
and while receiving other antifungal drugs (VORI, CASPO, FLU). 
Infecting organisms were Candida (8 cases), Aspergillus (2 cases) and 
Aspergillus + Cocci (1 case). Only 2 (C. glabrata) of 9 infecting iso-
lates tested were resistant to POS (MIC > 1 μg/ml). Mortality from IFI 
occurred in 4 patients (3.7%). POS was well-tolerated. Oral mucositis 
during neutropenia after SCT was present in 85% of patients, and 
32% of patients were temporarily changed to IV ITRA or IV VORI 
(mean duration, 9.6 days). Except for nausea in 9 patients, no clinical 
adverse event or laboratory abnormality could be attributed to POS. 
At 6 months after SCT, overall patient survival was 65%; fungal-free 
survival was 62%.
Conclusions: These results suggest that standard long-term POS pro-
phylaxis can be safe and effective for prevention of fatal IFI in allo-
geneic SCT. Development of an IV formulation of POS could further 
enhance efﬁcacy.
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Combination of Voriconazole Plus Echinocandin as Salvage 
Treatment for Invasive Pulmonary Aspergillosis – Review 
of 4 Cases.
Jakub Radocha1, Alzbeta Zavrelova1, Melanie Cermanova1, Pavel Zak1.
1Teaching Hospital Hradec Kralove, Charles University Prague, 2nd 
dept of medicine - division of clinical hematology, Hradec Kralove, 
CZ.
Background: Invasive pulmonary aspergillosis (IPA) is a problem pro-
ducing signiﬁcant morbidity and mortality in immunocompromised host. 
Optimal upfront treatment is now considered to be voriconazole alone. 
Some limited data exist on use of combination therapy with voriconazole 
and echinocandins. We report 4 cases of patients who recieved combina-
tion therapy after failing to respond to single agent voriconazole.
Materials: Patients: All 4 patients were patients allogeneic stem cell 
transplant recipients for acute myeloid leukemia (AML). All patients 
developed IPA during long period of neutropenia. All 4 were classiﬁed 
as probable aspergillosis based on typical HRCT picture and presence 
of galactomannan. 3 patients recieved previous treatment with single 
agent voriconazole, one was recieving voriconazole prophylaxis. After 
failure of voriconazole (worsening of clinical condition amd increase 
in galactomannan assay) all were switched to combination treatment 
with voriconazole and caspofungin or anidulafungin. All patients 
recieved G-CSF.
Methods: Galactomannan was surveyd by Platelia test.
Results: All patients are dead at present time. One patient died 
day + 42 from diagnosis of IPA on relapse of AML. Second patient 
died day + 25 on Pseudomonas sepsis superinfection. Third patient 
died day + 93 on relapse of AML. Fourth patient died day + 24 due to 
ruptured pulmonary artery caused by aspergilloma. Galactomannnan 
was decreasing in all patients before the terminal complication and all 
of them had improved their pulmonary functions, one patient was suc-
cessfully weaned from mechanical ventilation.
Conclusions: There was a signiﬁcant improvement of clinical status of 
all 4 patients after starting of combination treatment. However because 
of their marked morbidity their condition deteriorated in all of them. 
Major drop in galactomannan values started after neutrophil count 
recovery. Combination treatment seems to be feasible option in severly 
immunocompromised host however direct impact on survival of these 
patients remains unclear.
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Candida Albicans of Unusual Resistance in Haematopoietic 
Stem Cell Transplant Recipient
Vanda Chrenkova1, Petr Hubacek12, Petr Riha2, Ivana Masova4, Jan 
Drgac3, Petr Sedlacek2, Eliska Bebrova1.
1Motol University Hospital and 2nd Faculty of Medicine Charles 
University, Department of Medical Microbiology, Prague, CZ; 2Motol 
University Hospital and 2nd Faculty of Medicine Charles University, 
Clinic of Pediatric Hematology and Oncology, Prague, CZ; 3Motol 
University Hospital and 2nd Faculty of Medicine Charles University,  
Department of Pathology and Molecular Medicine, Prague, CZ;  
4Institut of Public Health of Prague, Laboratory of Mycology, 
Dittrichova 17, Prague, CZ.
Background: Candida albicans infections are quite frequent in immu-
nocompromised host. In the case of invasive infection, early onset 
of effective therapy, is necessary to decrease mortality. Fortunately 
resistance to antifungal drugs is rare. We present a case of girl under-
going allogeneic haematopoietic stem cell transplantation for second-
ary MDS who died due to Candida sepsis resistant to echinocandin 
 treatment.
Materials: We tested whole blood from the patient during post-trans-
plant surveillance and tissue samples obtained at the autopsy.
Methods: Conventional blood culture, plate cultures and identiﬁca-
tion to species by routine laboratory methods were performed. Can-
dida DNA quantity was detected by RQ-PCR after DNA extraction 
by Qiagen DNA Mini Kit and Qiagen DNA Blood Mini Kit. Stan-
dard curve for RQ-PCR was constructed by decadic dilution of DNA 
extracted from 5x106 Candida CFU. For comparison of yeast cell 
quantity detected in different tissues, Candida quantity was normal-
ized to 100,000 human genome equivalents assessed by quantiﬁcation 
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of albumin gene. Suspected resistance to echinocandins was proved by 
phenotypic and genotypic testing.
Results: The MICs for echinocandins were > 32 mg/l for caspofun-
gin and 1,0 mg/l for micafungin. The in-vitro resistance correlated 
with clinical failure of the therapy same as with the detected mutation 
S645P in the sequence of beta-1,3-glucan synthase catalytic subunit 
(GSC1). Analysis of yeast cells quantity in the tissues post-mortem 
by RQ-PCR showed massive affection of the infection in spleen, liver, 
renal cortex and mucosa of proximal gastrointestinal tract (5.6x107; 
3.7x105; 2.6 – 5.4x105 and 0.2 – 2.1x107 CFU respectively) comparing 
to rest of the of the tissues such as brain and heart (6x103 and 2x104 
CFU).
Conclusions: Our data conﬁrmed the tissue speciﬁcity for Candida 
infection in the human tissue. We were not able to found Candida albi-
cans DNA in blood on week before decease conﬁrming the rapid clini-
cal course of the invasive infection.
Acknowledgements: Supported by MZ0FNM2005 and MSMT00-
21620813.
P9
Travel Patterns and Behaviours among Bone Marrow 
Transplant Recipients
Daniela Leto1, Shariq Haider2.
1McMaster University, Infectious Diseases, Hamilton, CA; 2McMas-
ter University, Infectious Diseases, Hamilton, CA.
Background: A substantial rise in international travel in industrial-
ized countries has been documented. Improved survival and outcomes 
of immuncompromised patients such as HIV, Solid Organ Transplant, 
and haematopoietic transplants have resulted in increased travel in 
these subgroups with potential exposure to travel related diseases. 
Travel patterns have been well described in the HIV positive popula-
tion and in solid organ transplant recipients. However no data exists 
with regard to travel behaviour among haematopoietic transplant 
recipients. This study was done to determine the frequency of travel 
and of obtaining pre-travel advice, adherence with medications, 
illness during travel, and prevalence of high risk behaviors among 
BMT recipients.
Materials: A questionnaire was sent out to 135 BMT recipients from 
a tertiary care hospital. The questionnaire was validated in studies 
addressing travel patterns among HIV positive patients and solid organ 
transplant recipients.
Methods: This qualitative study was designed as a descriptive analysis 
of travel patterns and behaviours in patients who had undergone bone 
marrow transplant at a tertiary care hospital.
Results: Of 57 respondents, 83% traveled since their transplant, and 
only 51% of these received pre-travel care. Of travelers, 57% were on 
immunosuppressive medications while abroad, and all reported com-
pliance with medications. Ninety eight percent of travelers reported no 
participation in any high risk activities. The most common location of 
travel was the Carribean and Mexico, with 12.7% reporting some form 
of travel illness, but none requiring hospitalization.
Conclusions: The study underscores the importance of pre-travel 
counseling for BMT recipients as evidenced by their propensity to 
travel, and ongoing issues including the need for continued immu-
nosuppressive drugs. High risk behaviour was uncommon while 
abroad, similar to what has been described in solid organ transplants, 
but unlike HIV patients potentially reﬂecting perceptions of risks 
amongst these groups. Limitations in this study are its retrospec-
tive design, with recall biases, small numbers, preponderance of 
travel to Caribbean and Mexico underestimating rates of systemic 
travel illnesses in this higher risk group. We would advocate that all 
immunocompromised patients should have a pre travel assessment 
in a specialized tropical medicine clinic, with the knowledge of both 
travel medicine and issues unique to the haematopoietic transplant 
patient.
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Crytospridium Spp. Diarrhea in HSCT-Recipients
Juan Ambrosioni12, Yves Chalandon3, Jakob Passweg3, Christian van 
Delden12.
1University Hospital Geneva, Service of Transplantation, Department 
of Surgery, Geneva, CH; 2University Hospital Geneva, Service of In-
fectious Diseases, Geneva, CH; 3University Hospital Geneva, Service 
of Haematology, Department of Medicine, Geneva, CH.
Background: Crytospridium Spp. are opportunistic parasites that 
cause localised digestive tract infections and infrequently dissemi-
nated infections in immunocompromised patients. Although cases in 
AIDS patients are frequent; experience in allogeneic HSCT recipi-
ents is limited. Even, if recent reports suggest favourable results with 
nitasoxanide-azithromycin combination therapy, deﬁnitive elimina-
tion requires immune reconstitution. We present two cases of Cry-
tospridium Spp. related diarrhea in allogeneic-HSCT, with probable 
nosocomial transmission, and discuss therapeutic options and infec-
tion control measures.
Materials: Clinical charts and microbiological results.
Methods: Retrospective analysis of two cases. Review of the literature 
of Crytospridium Spp. infection in allogeneic-HSCT recipients.
Results: Patient 1: an unrelated donor allogeneic HSCT was per-
formed in a 50-year-old female patient for follicular lymphoma. Evo-
lution was complicated by febrile neutropenia on day + 4 and diarrhea 
on day + 6. Stool samples revealed oocysts of Crytospridium Spp. 
Contact isolation was applied and the patient was treated with a com-
bination of nitasoxanide 500mg/bid and azithromycin 500mg/d during 
6 weeks. Digestive GvHD was diagnosed which eventually worsening 
diarrhea. Digestive symptoms were difﬁcult to control and improved 
only after 6 months in parallel with immune recovery. Stools remained 
positive for cryptosporidium 8 months after diagnosis. Patient 2: an 
unrelated donor allogeneic HSCT was performed in a 33 year-old 
female patient for AML M2. The patient was hospitalised one week 
after patient 1 in the same unit. Three days before transplantation she 
presented mild diarrhea. Samples were positive for Crytospridium 
Spp. Transmission probably occurred before contact isolation was 
applied when patient 1 became symptomatic. She was also treated by 
a combination of nitasoxanide 500mg/bid and azithromycin 500mg/d 
during 6 weeks. Digestive symptoms resolved and the parasite was 
cleared from stools only after partial recovery of the immune system 
3 months later.
Conclusions: Crytospridium Spp. diarrhea is infrequent among 
HSCT-recipients. The ﬁnal control of the disease depends mainly on 
immune reconstitution. Anti-parasitic treatment might help to improve 
symptoms, but have only minor effect on the clearance of this organ-
ism. Considering the difﬁculty to treat this infection, maximum efforts 
must be done to limit transmission when a case is suspected.
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Mortality after Sepsis in Allogeneic HSCT is Strongly 
Related to the Underlying Haematological Disease
Malgorzata Mikulska1, Valerio Del Bono1, Anna Maria Raiola2, 
Paolo Bruzzi3, Francesca Gualandi2, Maria Teresa Van Lint2, Andrea 
Bacigalupo2, Claudio Viscoli1.
1San Martino University Hospital, Department of Infections Dis-
eases, Genoa, IT; 2San Martino University Hospital, Department of 
Abstracts of the 16th International Symposium on Infections in the Immunocompromised Host s5
Haematology and HSCT Unit, Genoa, IT; 3National Cancer Research 
Institute, Clinical Epidemiology Unit, Genoa, IT.
Background: Sepsis is a frequent complication after allogeneic 
HSCT, affecting up to 30% of patients. The aim of this study was to 
identify predictors of 7 and 30-day mortality after sepsis in HSCT 
recipients.
Materials: Observational study on mortality in patients with sepsis 
occurring from conditioning to 1 year after transplant was carried out 
in 382 consecutive HSCT recipients (01/01/04-31/01/08).
Methods: Baseline and after-transplant variables were analysed as 
potential factors inﬂuencing overall mortality 7 and 30 days after the 
onset of sepsis (univariate and multivariate analysis).
Results: During the observation period 149 patients developed sepsis, 
in median 9 days after HSCT (range: -6; 322). The patients were mostly 
male (64%) and 72% had acute leukaemia. Median follow-up after 
sepsis was 144 days (range: 1-1413) and mortality at 7 and 30 days was 
15.4% (23/149) and 26.8% (40/149), respectively. The aetiology (and 
respective 7 and 30-day mortality) was as follows: single Gram posi-
tive 53.7% (10% and 23.8%), single Gram negative 32.9% (22.4% and 
30.6%), polymicrobial 10.1% (13.3% and 26.7%) and single fungus 
3.4% (40% and 40%). The results of the univariate analysis are pre-
sented in table 1. In multivariate analysis, predictors of 7-day mor-
tality were: timing of sepsis (p = 0.04, OR 3.29 for sepsis > 20 days 
after HSCT) and phase of the underlying disease (p = 0.03, OR 2.2 
for relapse at HSCT). The 30-day mortality was associated with the 
type of the underlying disease (p = 0.05, OR 0.44 for diseases other 
than acute leukaemia) and the phase (p = 0.001, OR 6.04 for relapse 
at HSCT).
Conclusions: Sepsis is a frequent complication during early post-
HSCT period. Single Gram positive bacteria are the most frequent 
pathogens. Early mortality was 15% and is inﬂuenced mostly by phase 
of malignancy at HSCT and aetiology (the highest in case of P. aeru-
ginosa). The mortality was lower in case of sepsis before engraftment 
as compared to infections occurring later, mostly during GVHD. The 
30-day mortality was inﬂuenced exclusively by factors related to the 
underlying haematological disease.
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Clostridium Difﬁcile Infection and Blood Stream Infection 
After Stem Cell Transplantation
Charulata Ramaprasad1, Clara Bertozzi-Villa1, David Pitrak1, 
Kenneth Pursell1.
1The University of Chicago, Medicine, Chicago, US.
Background: Blood stream infection (BSI) after stem cell transplan-
tation (SCT) may be related to colonic inﬂammation and subsequent 
bacterial translocation due to mucositis. Clostridium difﬁcile infection 
(CDI) has increased in the SCT population in recent years and can also 
cause colonic inﬂammation. As such, we hypothesized that patients 
with CDI would have increased risk of BSI after SCT.
Materials: CDI was diagnosed by ELISA (Meridian Premier) and BSI 
was diagnosed by routine blood culture.
Methods: This is a retrospective chart review of all patients who 
underwent autologous and allogeneic SCT between January 1, 2006 
and March 15, 2007. Patients were followed for one year after SCT. 
Dichotomous variables were analyzed using Fisher’s Exact Test or the 
Chi-Square Test.
Results: 110 patients were included. 33 developed CDI after SCT. 63 
BSIs occurred in the ﬁrst year post-SCT, for an average of 0.57 BSIs 
per patient (excluding instances in which coagulase negative Staphylo-
coccus [CONS] or a single Corynebacterium was isolated). As shown 
in Table 1, there was no increase in the number of BSIs (Gram-positive 
or Gram-negative) seen in CDI positive patients. Enterococcus species 
(n = 6) and Pseudomonas aeruginosa (n = 3) accounted for 26% and 
13%, respectively, of BSIs in the CDI positive patients. Enterococcus 
species (n = 8) and Escherichia coli (n = 9) accounted for 20% and 
23%, respectively, of the BSIs in the CDI negative cohort.
Conclusions: There was no difference in BSI rates between patients with 
and without CDI. These ﬁndings may be attributable to the high overall 
BSI rate in this critically ill population, which in turn maybe due the pres-
ence of chemotherapy induced mucositis and the frequent presence of 
central venous catheters. Enterococcus and Gram-negatives, often con-
sidered to be gastrointestinal organisms, were the most common patho-
gens recovered in both the CDI positive and negative patients.
Table 1.
Variable No.   7-day   P  30-day   P
 patients mortality,   mortality, 
  N (%)  N (%)
Age (years)    0.73    0.51
16-31  49  9 (18.4)    15 (30.6)  
32-46  48  6 (12.5)    14 (29.2)  
47-65  52  8 (15.4)    11 (21.2)  
Sex      0.87    0.56
Male  95  15 (15.8)     24 (25.3)  
Female  54  8 (14.8)    16 (29.6)   
HSCT type      0.1    0.27
Matched related  47  7 (14.9)    10 (21.3)   
MUD and  73  15 (20.5)     24 (32.9)   
 mismatched related
Cord blood  29  1 (3.4)    6 (20.7)   
Underlying disease      0.58    0.38
Acute leukaemia  92  13 (14.1)     27 (29.3)   
Other  57  10 (17.5)     13 (22.8)   
Phase of      0.01    0.004
the underlying disease
First complete   51  6 (11.8)    7 (13.7)  
 remission
Complete 40 2 (5)   9 (22.5)   
 remission ≥ 2nd
Relapse 58 15 (25.9)    24 (41.4)  
Conditioning   0.88  0.39
Myeloablative 128 20 (15.6)    36 (28.1)   
Reduced intensity 21 3 (14.3)   4 (19)  
Day of BSI   0.03  0.45
≤ 20 days after HSCT 111 13 (11.7)   28 (25.2)   
> 20 days after HSCT 38 10 (26.3)    12 (31.6)   
Year of sepsis   0.2  0.5
2004 34 2 (5.9)   6 (17.6)   
2005 33 8 (24.2)   10 (30.3)   
2006 19 3 (15.8)    7 (36.8)  
2007 24 2 (8.3)   5 (20.8)   
2008 39 8 (20.5)   12 (30.8)   
Pathogen, n   0.06  0.83
Staphylococci,  32 3 (9.4)    8 (25)
 Corynebacterium, 
 Rothia
Streptococci 48 5 (10.4)    11 (22.9)
 (enterococci and
 viridans)
Enterobacteriaceae 30 4 (13.3)   8 (26.7)   
Non-fermenting  19 7 (36.8)    7 (36.8)   
 Gram-negative rods
Polymicrobial and fungal 20 4 (20)    6 (30)  
Table 1. 
Infection Category CDI Positive CDI Negative p-value
Total Number of Patients n = 33 n = 77 
Patients With Any BSI (excluding CONS) n = 23 (70%) n = 49 (64%) 0.69
Patients with a Gram Positive BSI n = 10 (30%) n = 16 (21%) 0.4
Patients with a Gram Negative BSI n = 9 (27%) n = 15 (19%) 0.51
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Resistant Gram-negative Bacteremia after Hematopoietic 
Stem Cell Transplantation
Charulata Ramaprasad1, Clara Bertozzi-Villa1, Koen Van Besien1, 
David Pitral1, Kenneth Pursell1.
1The University of Chicago, Medicine, Chicago, US.
Background: Empirical antimicrobial selection in the setting of Gram-
negative bacteremia (GNB) after hematopoietic stem cell transplanta-
tion (HSCT) is complex given the increasing prevalence of resistant 
gram negatives and the adverse consequences associated with inad-
equate initial therapy. We sought to determine the incidence of and risk 
factors for GNB and resistant GNB in the one year after HSCT.
Materials: Automated Vitek methods were used to determine resistance.
Methods: 110 autologous and allogeneic HSCT recipients were moni-
tored for one year post-transplant. GNB was deﬁned as recovery of any 
gram-negative organism from at least one blood culture. Intermediate 
or non-susceptibility to ceftazidime, piperacillin-tazobactam, or imi-
penim-cilastin was required for an organism to be deﬁned as resistant. 
Resistance to an anti-pseudomonal ﬂuoroquinolone was also docu-
mented. Risk factor analysis was performed using Fisher’s Exact Test.
Results: Twenty three of 110 (21%) HSCT recipients had 28 episodes of 
GNB. Mean time from transplant to GNB was 48 days (median 8.5). Esch-
erichia coli was most frequently recovered (n = 10), followed by Klebsiella 
pneumoniae (n = 5) and Pseudomonas aeruginosa (n = 4). 8 of 110 (7.3%) 
HSCT recipients had 10 episodes of resistant GNB: 7 were ceftazidime, 
piperacillin-tazobactam, or imipenim-cilastin resistant and 3 were intrin-
sically resistant organisms (Stenotrophomonas maltophilia, Burkholderia 
cepacia). Ciproﬂoxacin and ceftazidime resistance were most common, 
and all E. coli isolates were resistant to ciproﬂoxacin (Table 1). 18 of the 
28 GNBs (64%) occurred while the ANC was less than 0.5 K/μμL and 
23 of the 28 GNBs occurred in inpatients (82%). A central venous 
catheter (CVC) was present at the onset of 24 GNBs (86%). 4 of these 
were peripherally inserted central catheters, and the remaining were 
tunneled lines. Risk factors for GNB were allogeneic transplantation 
(p = 0.04) and T cell depletion (p = 0.009). These same risk factors and 
WBC, ANC, presence of a CVC, and renal function did not predict 
resistant GNB. 
Conclusions: Resistant GNB affected 7.3% of HSCT recipients in the 
ﬁrst year after transplant, with ciproﬂoxacin and ceftazidime resistance 
most often seen. Given these ﬁndings, monotherapy with ceftazidime 
as empirical coverage for GNB may leave a signiﬁcant number of 
patients with inadequate antimicrobial coverage. These ﬁndings have 
implications for future empirical antibacterial recommendations.
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Subtherapeutic Posaconazole Levels During Salavage 
Treatment of Invasive Fungal Infections
Charulata Ramaprasad1, Clara Bertozzi-Villa1, Kevin Gregg1, Koen 
Van Besien1, Kathleen Mullane1, David Pitrak1, Kenneth Pursell1.
1The University of Chicago, Medicine, Chicago, US.
Background: Posaconazole (PC) is approved for prophylaxis against 
invasive fungal infections (IFIs). It is also used for salvage treatment 
of IFIs. Achievement of goal serum PC levels ( ≥ 0.700 μg/mL per an 
FDA brieﬁng document) requires proton pump inhibitor (PPI) avoid-
ance and co-administration of food or a high-fat nutritional supple-
ment. Such ideal conditions are rarely met due to co-morbid conditions 
in patients with IFIs. Low PC levels ( ≤ 0.134 μg/mL) have been asso-
ciated with therapeutic failure. We hypothesized that most patients 
receiving PC for IFI treatment have sub-therapeutic serum PC levels 
due to circumstances that adversely affect drug absorption.
Materials: PC levels were measured by Mayo Medical Laboratories.
Methods: This is a retrospective chart review of all patients who had 
PC levels obtained between March 2008 and October 2009. PPI admin-
istration and oral intake within three days of the PC level were recorded. 
Dichotomous variables were analyzed using Fisher’s exact test.
Results: Seventeen patients with 19 PC levels were included. 2 patients 
received SOT (heart and heart/liver transplant), and 15 patients had a 
hematologic malignancy (10 AML, 2 CLL, 2 large cell lymphoma, 1 
multiple myeloma), of which 6 had received a SCT. All patients were 
receiving PC as salvage therapy for an IFI. The mean PC level was 
0.48 (range 0.00 -1.86). 15 levels were ≤ 0.700 μg/mL (79%) and 4 
levels were ≥ 0.700 μg/mL (21%). All but 2 patients were on PPIs. All 
levels ≤ 0.700 μg/mL were seen in patients on a PPI, while 2 of the 
4 patients with levels ≥ ≥0.700 μg/mL were not on a PPI (p = 0.04). 
4 levels (21%) were ≤ 0.134 μg/mL. Food intake documentation was 
incomplete, but where documentation was available, intake was poor.
Conclusions: In clinical trials, therapeutic PC levels have been 
obtained in healthy subjects who are able to maintain an optimal diet 
and avoid PPI use. In this study, almost 80% of PC levels were sub-
therapeutic, and 21% of PC levels were profoundly decreased. PPI co-
administration was frequent and associated with low PC levels. These 
ﬁndings suggest that sub-therapeutic PC levels occur frequently in 
clinical settings and may place patients at increased risk of disease 
progression. Efforts to enhance PC absorption should be maximized, 
therapeutic drug monitoring should be considered, and alternative strat-
egies should be considered if therapeutic levels cannot be achieved.
P15
Unusual Presentation of Disseminated Toxoplasmosis after 
Pediatric Bone Marrow Transplantation
Valentina Kiren1, Natalia Maximova1, Gianna Dal Molin3, Daniela 
Sanabor4, Davide Zanon2, Laura Godina5, Alessandra Maestro2.
1IRCCS Burlo Garofolo, Oncology and bone marrow transplants, 
Trieste, IT; 2IRCCS Burlo Garofolo, Pharmacy and parenteral nutri-
tion, Trieste, IT; 3IRCCS Burlo Garofolo, Microbiology, Trieste, IT; 
4IRCCS Burlo Garofolo, Radiology, Trieste, IT; 5IRCCS Burlo Garo-
folo, Stomatology, Trieste, IT.
Background: Toxoplasmosis is a rare opportunistic infection after 
hematopoietic stem cell transplantation (HSCT), it is rapidly fatal and 
it is often diagnosed only at autopsy.
Abstract 13 – Table 1. 
Organism Name Number of Ciproﬂoxacin   Ceftazidime   Piperacillin-Tazobactam  Imipenim-Cilastin   Other 
 Isolates Resistance n(%) Resistance n(%) Resistance n(%)  Resistance n(%) Resistance 
      Information
E. coli 10  10 (100%)  3(33%) 0  0   
K. pneumoniae 5 1 (20%)  1 (20%) 0  0   
E. cloacae 3  1 (33%) 2 (66%) 1 (33%)  1 (33%)   
p. aeruginosa 4  1 (25%) 0  1 (25%)  0   
S. maltophilia 2  --  --  --  --  TMP-SMX Sensitive 
F. nucleatum 1  --  --  --  --  Testing Not Done 
B. cepacia 1  --  --  --  --  Meropenem Sensitive 
C. amalonaticus 1 0  0  0  0   
K. oxytoca 1  0  0  0  0   
Total 28  13 (46%)  6 (21%)  2 (7%)  1 (3.6%)   
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Materials: A 9 year old girl of South American origin underwent HSCT 
from matched unrelated donor for common LLA in second remission. 
The serologic screening showed anti toxoplasma IgG > 250 IU/mL.
Methods: On day + 10 from transplant the girl complained of persis-
tent occipital headache, nausea, dizziness and photofobia. On day + 18 
she showed frequent episodes of disorientation, absences and dyslexia, 
all short-lasting and with spontaneous recovery. Concurrently fever set 
in with a 1st degree GVHD for which the girl was given steroid treat-
ment. The fever completely disappeared. The neurological assessment 
and brain TC were negative. On day + 20 she had a prolonged crying 
spell followed by revulsion of the eyeballs, hypotonia, disorientation 
and diplopia. The EEG evidenced no parossistic abnormalities. A brain 
MRI showed only an enlargement of the periencephalic liquor spaces. 
On day + 39 there was a new onset of high fever, with a RCP increase, 
a signiﬁcant platelet drop and the disappearance of neurological signs. 
In view of a possible leukemia relapse we performed a bone marrow 
aspiration (negative) and a lumbar puncture (negative chemical-phys-
ical, microscopic and virologic tests). After 14 days of high fever not 
responding to broad-spectrum antibiotic and antifungal treatment, the 
TC showed evidence of brain and lung lesions consistent with Toxo-
plasmosis.
Results: Toxoplasma PCR gene B1 performed on liquor and on blood 
was positive. The clinical picture rapidly evolved towards ARDS 
requiring mechanical ventilation with extremely high ﬂow peaks. 
A therapy with trimethoprim-sulfamethoxazole and atovaquone 
was started. 7 days later the fever had completely disappeared, and 
inﬂammation indexes became negative. Toxoplasma PCR performed 
on blood and on liquor one month after the beginning of therapy was 
negative. Unfortunately it was not possible to wean the patient from 
mechanical ventilation due to lung damage and the girl died of kidney 
complications 21 days after fully recovering from Toxoplasmosis.
Conclusions: Toxoplasmosis is an early life threatening complication 
after transplantation, and efforts to improve early diagnosis and treat-
ment, as well as the use of prophylaxis in seropositive recipients after 
high-risk allogeneic HSCT, are appropriate.
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Four Viruses for Toxic Epidermal Necrolysis (TEN)
Valentina Kiren1, Natalia Maximova1, Davide Zanon2, Laura Godina3, 
Marilena Granzotto4, Alessandra Maestro2.
1IRCCS Burlo Garofolo, Oncolgy and bone marrow transplant, Tri-
este, IT; 2IRCCS Burlo Garofolo, Pharmacy and parenteral nutrition, 
Trieste, IT; 3IRCCS Burlo Garofolo, Stomatology, Trieste, IT; 4IRCCS 
Burlo Garofolo, Laboratory, Trieste, IT.
Background: Aquier-Dunant et al concluded in their study (Arch 
Dermatol 2002) that Erythema Multiforme Majus (EM) signiﬁcantly 
differed from Stevens-Johnson syndrome (SJS), overlap, and Toxic 
Epidermal Necrolysis (TEN). Recent or recurrent herpes infection was 
the principal risk factor for EM and had a role in SJS but not in overlap 
cases or TEN.
Materials: A 6 year old boy, suffering from LLA-T in third complete 
remission and chronic active hepatitis C with HCV RNA 7.03 x 106 
cp/ml, underwent haploidentical bone marrow transplantation from his 
mother, after conditioning inclusive of TBI.
Methods: From day + 8 since transplantation, while under treatment 
with acyclovir 30 mg/kg/die iv, mucositis of the oral cavity suddenly 
worsened with pharyngeal and oral cavity swabs positive for HSV1. 
The blood was also found positive for CMV (10938cp/ml in PCR, cor-
responding to 80 nuclei in immunoﬂuorescence). The boy started treat-
ment with foscarnet, but mucositis kept worsening, notwithstanding 
the complete resolution of neutropenia. II°-III°° degree GVHD also 
set in, for which he started treatment with cortisone 3 mg/kg/die and 
mycophenolate mofetil, in addition to cyclosporine taken from day -1. 
On day + 20 HCV RNA monitoring showed a remarkable increase 
(106 x 106 cp/ml); mucositis further worsened, with HSV1 and CMV 
isolated from mucous lesions. On day + 25 umbilicated eritematous 
skin lesions appeared on head, neck and upper chest (mantle), with 
gland involvement as well. Concurrent positivity for EBV was also 
evidenced.
Results: A skin biopsy was performed, showing necrosis of the spi-
nous layer keratinocytes associated with vacuolization and necrosis of 
the basal layer of the skin and moderate lymphocytic inﬁltrate of the 
superﬁcial derma. The histological picture conﬁrmed a suspected SJS. 
The dermatologic picture very rapidly evolved into a devastating TEN 
picture (spreading of lesions to over 50% of the body, major involve-
ment of the oral, foreskin and conjunctiva mucous membranes). Treat-
ment with i.v. immunoglobuline 5g/kg was started. The use of other 
antiviral drugs (ganciclovir, cidofovir) was considered inappropriate 
due to their well known toxicity for the marrow. On day ﬁve from the 
beginning of immunoglobuline treatment clinical improvement started, 
with complete resolution within the following 15 days.
Conclusions: Our case demonstate that TEN can be caused also by 
virus (HSV1, CMV, HCV and EBV co-infection) in seriously immu-
nodepressed patient.
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The Unknown Side of an old Acquaintance
Valentina Kiren1, Natalia Maximova1, Daniela Sanabor3, Davide 
Zanon2, Alessandra Maestro2, Laura Godina4.
1IRCCS Burlo Garofolo, Oncology and Bone Marrow Transplants, 
Trieste, IT; 2IRCCS Burlo Garofolo, Pharmacy and Parenteral Nutri-
tion, Trieste, IT; 3IRCCS Burlo Garofolo, Radiology, Trieste, IT; 
4IRCCS Burlo Garofolo, Stomatology, Trieste, IT.
Background: Despite recent great advances in transplantation tech-
niques, herpesvirus infections remain a major cause of morbidity and 
mortality in transplant recipients.
Materials: A 10 year old boy suffering from LMA M5 underwent 
a bone marrow transplant with purging from haploidentical donor 
(mother) after a myeloablative conditioning.
Methods: At day + 16, while on routine prophylaxis with acyclovir, 
he developed a high fever, persistent headache, pharyngodynia and 
aphthous-hemorragic mucositis. The swabs were positive for HSV1. 
The quantitative PCR for HSV1 performed on the blood was slightly 
positive (200 cp/ml). When acyclovir was replaced with cidofovir all 
the specimens became negative. On day + 27 we witnessed total rejec-
tion. After conditioning with antilymphocyte serum he was infused 
with the mother’s marrow blood (T-depleted in vivo with antilympho-
cyte serum), followed the infusion of CD34. On day + 15 aphthous 
mouth lesions and fever reappeared with the swab positive for HSV1, 
and a positive blood PCR with 1906 cp/ml. We saw the transplant take 
on day + 19, again followed by rejection. Therapy with cidofovir was 
resumed, but mucositis worsened with involvement of the laterocer-
vical and submental lymph nodes causing compression of the upper 
airways. On day + 33 a salvage transplantation was attempted using 
the father as donor with the same scenario: the transplant takes rapidly 
followed by rejection. The viral load shot up even after foscarnet was 
added: on day + 28 from the 3rd transplantation it was completely out 
of control with 25562 cp/ml. Even a swab of the foreskin was positive 
for HSV1.
Results: An increasingly severe respiratory failure set in with sub-
cutaneous emphysema of the chest wall and neck. The X-ray picture 
evidenced pneumomediastinum, pneumothorax and two areas of atel-
ectasis due to the breakage of the right bronchus consequent to malacia 
caused by herpes infection. The boy died of respiratory failure.
Conclusions: The transplantologist often faces difﬁcult choices: while 
on the one hand the damage originated by the herpesvirus to the marrow 
is well known, on the other the great increase in cases of pharmacologi-
cal resistance requires the use of drugs such as cidofovir or ganciclovir 
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after transplantation in spite of their well-known myelotoxicity. This is 
the ﬁrst reported case in which HSV1 infection seems the major respon-
sible of rejection of a bone marrow transplant, although a concurrent 
drug-related toxicity cannot be ruled out.
P18
Investigation of Adenovirus DNA in Plasma and Urine 
Samples Among Pediatric Hematopoietic Stem Cell 
Transplant Recipients by Real Time PCR Method
Hatice Yazisiz1, Vedat Uygun2, Betil Ozhak Baysan3, Derya Mutlu3, 
Gulsun Tezcan2, Volkan Hazar2, Tumer Vural3, Dilek Colak4.
1Ataturk State Hospital, Medical Microbiology, Antalya, TR; 2Akdeniz 
University, Faculty of Medicine, Department of Pediatric Hematology 
and Oncology, Antalya, TR; 3Akdeniz University, Faculty of Medicine, 
Medical Microbiology, Antalya, TR; 4Akdeniz University, Faculty of 
Medicine, Medical Microbiology Depatrtment, Division of Virology, 
Antalya, TR.
Background: Adenoviruses are responsible for serious and fatal infec-
tions in patients undergoing hematopoietic stem cell transplantation 
(HSCT).
Materials: In this study, peripheral blood and urine samples were col-
lected from 30 pediatric patients undergoing consecutive allogeneic 
HSCT weekly and thereafter until 100 days biweekly after transplanta-
tion.
Methods: Adenovirus DNA was examined by real-time PCR. Totally 
470 plasma and 296 urine samples were examined.
Results: Adenovirus DNA was identiﬁed in six of thirty patients 
(20%) with allogenic HSCT. Adenovirus DNA from plasma samples 
was ﬁrst detected at a median time of 27 days (range, -7 to + 41) after 
transplantation. The viral load was signiﬁcantly low and only two 
plasma samples, obtained from two different patients, contained > 102 
copies/mL. Similarly urine Adenovirus DNA levels found were below 
1000 copies/mL (Range: 305-8920). Adenovirus DNA positivity was 
temporary and a signiﬁcant increase of viral load was not shown at 
any of the patients. Three of 5 patients with plasma Adenovirus DNA 
positivity had no clinical manifestations associated with adenoviruses. 
One patient had adenovirus associated diarrhea. The other patient had 
diarrhea and hematuria. Her plasma sample was positive for Adenovi-
rus DNA, CMV DNA and BK virus DNA simultaneously, BK virus 
and Adenovirus DNA were detected in her urine sample. Adenovirus 
DNA of urine samples from three patients was found positive. Two of 
them had Adenovirus positivities in plasma samples simultaneously. 
There was no adenovirus related mortality.
Conclusions: In conclusion; adenoviruses are not associated with seri-
ous complications in our study group.
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The Utility of Aspergillus Galactomannan Assay (GM 
EIA) For Monitoring Pediatric Allogeneic Bone Marrow 
Transplant (BMT) Patients
Carlos Jaramillo1, Dick Chung1, Genovefa Papanicolaou1.
1Memorial Sloan-kettering Cancer Center, Infectious Disease, New 
York, US.
Background: GM EIA is approved for diagnosis of invasive aspergil-
losis in high risk patients. We assessed the utility of serial GM EIA for 
diagnosis and guidance of antifungal therapy in a cohort of pediatric 
BMT patients.
Materials: The platelia assay (Biorad) was used as per panufacturer’s 
instructions
Methods: From July 2006 through June 2008, 63 pediatric patients 
received 65 allogeneic BMT at MSKCC. Standard antifungal  prophylaxis 
consisted of ﬂuconazole. Patients with history of pretransplant IFI, 
 corticosteroid use, GVHD or prolonged neutropenia received mold-
active prophylaxis (MAP) with voriconazole or micafungin. Patients 
were monitored prospectively by serial GM. Work-up for Invasive fungal 
infections (IFI) and choice of antifungal therapy was at the discretio nof 
the physician. EORTC MSG criteria were used for IFI diagnosis.
Results: Sixty-three patients had 1,887 GM (median 27, range 8-54). 
Mean age 8.1 years; 69% hematologic malignancy; 58% peripheral 
stem cells; 69% unrelated donor; 63 % T-cell depleted. 17% patients 
had presumed aspergillosis pre-transplant. Nine (14%) developed 
acute GVHD (grade 2-4). Thirty-seven (57%) and 26(40%) patients 
were on MAP at 1 and 6 months post transplant. Six (9.2%) patients 
were treated for IFI; (Possible 3, probable based on GM 2, deﬁnite 1). 
All patients treatedfor IF had been on MAP. Overall GM monitoring 
lead to change in management in 1 patient. The number of GM needed 
to diagnose 1 case of IA was >600 at a cost of 160,000 US dollars.
Conclusions: 1) In our pediatric cohort GM did not have an impact 
on earlier diagnosis or management of IFI. 2) The ﬁnancial burden of 
monitoring fungal burden was 510,000 US dollars; More than 600 GM 
were performed to diagnose a single case of IA by GM. 3) The utility 
of GM needs to be reconsidered in clinical settings with high use of 
mold active therapy.
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Decreased Incidence of Infectious Complications in 
Hematopoietic Cell Transplant Recipients in 2003-2007 
Compared to those Transplanted in the Previous Decade 
1993-1997
Steven Pergam12, Ted Gooley1, Michael Boeckh12, Kieren Marr3, 
Jason Chien12, George McDonald12.
1Fred Hutchinson Cancer Research Center, Seattle, US; 2University 
of Washington, Medicine, Seattle, US; 3Johns Hopkins University, 
Medicine, Baltimore, US.
Background: Infectious diseases remain a major cause of morbid-
ity and mortality following hematopoietic cell transplantation (HCT). 
Since there have been numerous advances in the diagnosis, treatment, 
and prevention of infections over the past decade, we set out to assess 
the cumulative effect of these and other transplant changes on infec-
tious complications in patients undergoing HCT.
Materials: To examine the hypothesis that improvements in transplant 
practices have reduced infectious complications, we retrospectively 
compared two cohorts of HCT recipients undergoing their ﬁrst trans-
plant between 1993-1997 and 2003-2007 at a single center (Seattle, 
WA, USA).
Methods: We analyzed high-risk infections including: CMV reac-
tivation (antigenemia or DNAemia), CMV disease, invasive mold, 
candidemia, and Gram-negative rod bacteremia. All outcomes were 
assessed in both cohorts to day 100, and CMV disease and invasive 
fungal infections were deﬁned by standard international criteria. Out-
comes were compared using a Cox regression model adjusted for com-
ponents of the Pretransplant Assessment of Mortality (PAM) score, 
including: age, donor, disease severity, and baseline values of creati-
nine, ALT, FEV1, and DLco.
Results: The total number of patients that underwent ﬁrst transplant 
was 1418 between 1993-1997 and 1169 between 2003-2007. The 
two populations had similar demographic characteristics, however 
patients undergoing HCT between 1993-1997 were more likely to 
receive bone marrow as a graft source (1240/1418 [87%] vs. 227/1169 
[19%], p < 0.001) and to receive a related transplant (625/1418 [44%] 
vs. 455/1169 [39%], p = 0.008). In addition, more non-myeloablative 
(NM) transplants occurred between 2003-2007 (278/1169 [24%] vs 
1/1148 [ < < 1%]). There were substantial reductions in the risk of 
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developing posttransplant diseases caused by viruses, Gram-negative 
rods, and fungi (Table 1). Reanalysis of these data excluding NM trans-
plants did not signiﬁcantly alter these hazards.
Conclusions: Improvements in hematopoietic cell transplant practices 
and infectious disease prevention strategies over the last decade have 
led to substantial reductions in infectious outcomes during the high-
risk posttransplant period.
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Table 1. Comparison of Infections Complications Through Day 100 
between Hematopoietic Cell Transplant Coborts From 1993–1997 and 
2003–2007
  Number (%) Failures
  All Patients
 Event 1993–97 2003–07 Adjusted Hazard/Odds Ratio*
  (n–1418) (n–1169) (95% CI, p-value)
 Gram-negative bactermia 213(15%) 132(8%) 0.61(0.48–0.79, p<0.002)
 Invasive mold 125(9%) 81(7%) 0.49(0.35–0.70, p<0.0001)
 Yeast 53(9%) 10(1%) 0.23(0.11–0.47, p<0.0001)
  CMV scropositive patients
  (n-743) (n-671)
 CMV reactivation 420(57%) 426(63%) 1.02(0.87–1.20, p=0.81)
 CMV disease 62(8%) 33(5%) 0.51(0.31–0.83, p-0.007)
*Change over the decade is expressed as a hazard ratio (HR) or odds (OR), as calculated by 
regression models adjusted for age, donor, disease severity, and baseline values for senum 
creative, AIT, FEV
1
, and DIco
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Incidence and Outcome of Non Tuberculous Mycobacterial 
Infection after Lung Transplantation
Zakeya Bukhary2, Steven Nathan1, Oksana Shlobin1, Shahzad 
Ahmad1.
1Inova Fairfax Hospital,Advanced Lung Disease and Lung Transplant 
Program,, Advanced Lung Disease and Lung Transplant Program,, 
Falls Church, Virginia 22042, US; 2College of Medicine, Taibah Uni-
versity, Internal Medicine, Madinah Almonawwarah, SA.
Background: In lung transplant recipients, pulmonary infection 
with non-tuberculous mycobacterium (NTM) tend to occur late in 
post transplant course and has been frequently associated with pre-
existing chronic rejection. NTM species are widely distributed in the 
environment and may cause both asymptomatic infection or symp-
tomatic disease in humans. The most common clinical manifestation 
of NTM diseases is lung disease. Mycobacterium Aviam Complex 
(MAC) organisms are the most common cause of NTM disease in 
the United States. MAC often causes colonization in patients with 
chronic respiratory disease. In immunocompromized patients dis-
seminated disease typically occur. We thought to evaluate NTM in 
adult lung recipients. Our objective was to describe the incidence 
and the outcome of non-tuberculous mycobacterial (NTM) infection 
in adult lung recipients.
Materials: Medical records of adult lung transplant recipients with 
positive NTB culture in bronchalveolar lavage (BAL) were reviewed. 
BAL cultures, Chest Ct scan and treatment were subsequently 
 evaluated.
Methods: We performed a descriptive retrospective review of patients 
who underwent lung transplantation at our center from 1996 to May 
2009. Data were collected by a single investigator. NTM species were 
identiﬁed. The clinical presentation studied to ﬁnd out colonization 
compared to symptomatic disease and treatment outcome of treated 
compared to non-treated patients is summarized in table1.
Results: There were 236 patients who underwent lung transplantation 
during the study period. Of these, 56 (23.72%) had a positive NTM 
cultures in BAL at some point. The isolates included MAC in 35/56 
(63%), M. abscessus 4 (7.14% ), M.gordonae, 4 (7.14 %), M.Kansassii 
2 (3.6%), M. Fortuitum 1 (3.6% ), M. Chelonae 1 (1.8 % ) and mixture 
growth in 2 (3.6% ). In 17 (30.35%) patients NTM was treated as an 
infection and in 39(69.64%) no treatment was given as colonization. 
In 3 (5.36%) of the patients NTM cultures were isolated pretransplant, 
and the same species were isolated post transplant. The outcome of 
NTM infection is summerized in [table 1]. Mortality rate was 17/56 
(30.4 )%.
Conclusions: Non tuberculous mycobacterial infection complicates 
the course of a signiﬁcant number of lung transplant recipients. While 
tow thirds 2/3 of these infections were colonization, a third were 
requiring multi-drug treatment and mortality was high.
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Lasiodiplodia Theobromae Pneumonia in a Liver 
Transplant Recipient
Wang Ngai Chow1, Pactrick C.Y. Woo1, Susanna K.P. Lau1, Antonio 
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1The University of Hong Kong, Microbiology, Hong Kong, HK.
Background: Lasiodiplodia theobromae is a common plant patho-
gen in tropical countries. Human infections are extremely rare. Most 
human cases involved keratitis, few involved onychomycosis, but-
tock abscess and subcutaneous phaeohyphomycosis. This is the ﬁrstly 
reported pneumonia case of L. theobromae.
Materials: A 45-year-old Chinese man with severe sepsis 14 days 
after cadaveric-liver transplantation. Chest radiograph showed air 
space shadows. Numerous leukocytes and septate hyphae were found 
in KOH smear of the bronchoalveolar lavage ﬂuid. Empirical treatment 
with piperacillin-tazobactam, vancomycin, and caspofungin was given. 
An emergency laparotomy was performed and revealed portal vein and 
superior mesenteric vein thrombosis and a gangrenous descending 
colon. Peritoneal ﬂuid yielded heavy growth of Enterococcus faecium. 
The patient succumbed 11 h after the operation. The culture of two 
bronchoalveolar lavage specimens taken before and after the operation 
did not produce any bacteria but yielded heavy growth of a dematia-
ceous mold.
Methods: Microscopic examination, ITS sequencing and partial EF1α 
sequencing.
Results: Lactophenol cotton blue staining showed septate brown 
hyphae. Pycnidia were identiﬁed. Examination under higher magniﬁ-
cation showed a pycnidium with an obvious neck and conidiogenous 
cells and paraphyses lining in the internal wall. It was identiﬁed as 
Lasiodiplodia theobromae. The ITS sequence of the isolate differed 
by 6 bases from that of another strain of L. theobromae but differed 
by only 8 bases from that of a strain of L. gonubiensis. It can be con-
ﬁdently concluded that the isolate was L. theobromae from the EF1α 
gene sequence, which has been demonstrated to be useful for differen-
tiating the Lasiodiplodia species, and the results were compatible with 
those obtained by phenotypic identiﬁcation.
Conclusions: ITS sequencing was not sufﬁciently discriminatory to 
distinguish among Lasiodiplodia species. Partial EF1α sequencing is 
more reliable than ITS sequencing for identifying L. theobromae to 
the species level. In all the reported L. theobromae infections human 
cases, no patients died. Also, infections were believed to be direct 
inoculation of the fungus. In our case, the patients succumbed even in 
caspofungin treatment. Mode of acquisition remains unclear, inhaltion 
seems highly unlikely as conidia are borne inside the slimy pycnidia. 
We speculate the patient consumed infected fruits or acquired from the 
transplated liver.
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Table 1. Outcome of NTM infection in adult lung trasplant recipients
 Patients with positive NTM  Died NO.(%) Alive NO.(%)
 in BAL culture 
 among 236 lung recipients 
 No.(%)  
Treated 17(30.35) 4(23.53) 13(33.33)
Non-treated 39(69.64) 13(76.47) 26(66.67)
Total 56 (100) 17(100) 39(100)
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Background: Mucormycosis is an opportunistic infection caused by 
ubiquitous ﬁlamentous fungi of the order Mucorales. As a result of the 
increasing use of immunosuppressive agents and prolonged survival of 
these patients, mucormycosis is becoming increasingly common, but 
mortality remains very high, often above 50%.
Materials: Semiquantiﬁcation of enzymatic activities was performed 
using the API-ZYM test (bioMerieux Vitek, Hazelwood, MO). Growth 
kinetics experiments were performed on Sabouraud dextrose agar 
(SDA) and potato dextrose agar. ITS1-5.8S–ITS2 rRNA gene cluster 
(ITS), partial EF1α gene, and partial β-actin gene sequencing using 
degenerate primers were performed.
Methods: Phenotypic and phylogenetic characterizations were 
performed.
Results: Three “Absidia-like” isolates with unique morphologi-
cal characteristics were recovered and characterized. On SDA, all 
three strains grew as cottony colonies to diameter of 64-73 mm 
after incubation at 37°C for 48 h and were thermotolerant. Thiamine 
supplementation was not required for growth. Microscopic exami-
nation showed non-septate hyphae with highly branched sporangio-
phores. Uniquely, most side branches were circinate, a characteristic 
absent from other Absidia/Mycocladus/Lichtheimia species. All three 
strains produced alkaline phosphatase, esterase (C4), esterase lipase 
(C8), leucine arylamidase, acid phosphatase, naphthol-AS-BI-phos-
phohydrolase, β-glucosidase and N-acetyl-β-glucosaminidase. ITS1-
5.8S-ITS2 rRNA gene cluster (ITS), partial EF1α gene and partial 
ββ-actin gene sequencing showed that the three strains formed a 
 distinct cluster, most closely related to, but distinct from, Lich-
theimia  corymbiferus (Absidia corymbifera), Lichtheimia blakeslee-
anus (Absidia blakesleeana) and Lichtheimia hyalospora (Absidia 
hyalospora.
Conclusions: Based on the morphological and genotypic characteris-
tics, we propose a new species, Lichtheimia hongkongensis sp. nov., to 
describe this fungus, which caused rhinocerebral, gastrointestinal and 
cutaneous mucormycosis respectively in three patients. A signiﬁcant 
proportion of M. corymbiferus associated with mucormycosis reported 
in the literature may be M. hongkongensis. Reanalysis of their morpho-
logical characteristics and sequencing should reveal the relative clini-
cal importance of M. corymbiferus and L. hongkongensis.
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2009 Pandemic Inﬂuenza H1N1 among Solid Organ 
Transplant Patients
Ozlem Kurt Azap1, Funda Timurkaynak2, Hande Arslan1.
1Baskent University, Infectious Disease, Ankara, TR; 2Baskent 
 University, Infectious Disease, Istanbul, TR.
Background: The aim of this study was to evaulate the clinical spectrum 
of 2009 pandemic inﬂuenza H1N1 among solid organ transplant patients.
Materials: Laboratory-conﬁrmed and/or clinically-diagnosed H1N1 
cases were followed up prospectively via a structured form during the 
pandemic period.
Methods: Laboratory-conﬁrmed and/or clinically-diagnosed H1N1 
cases were followed up prospectively via a structured form during the 
pandemic period.
Results: Fifteen (14 renal, 1 liver) solid organ transplantation patients 
with the diagnosis of H1N1 followed up between November and 
December 2009 were included in this study. Nine of the 15 patients 
were male and six were female. Mean age was 34.2 (20-68) years. All 
patients were in the late period ( > 6 months) after transplantation. The 
immunosuppressive regimens used were corticosteroids, tacrolimus 
and mycophenolate mofetil. The underlying diseases were diabetes 
mellitus in two patients and chronic obstructive pulmonary diseases in 
one patient. The clinical symptoms and ﬁndings,  laboratory test results 
were summarized in the Table. The only complicated case had high 
serum creatinine values. Chest X-ray of four patients showed patchy 
inﬁltrations. Three of the patients, also the family in one, received 
seasonal inﬂuenza vaccines. Six patients were followed up as outpa-
tients; 8 were hospitalized for 48 hours and one was hospitalized for 
72 hours. Antiviral therapy with oseltamivir 75mg bid for 5 days was 
prescribed for all patients. Fourteen of the patients received oseltami-
vir in 48 hours after the initial symptoms. Fever resolved in 48 hours 
in 6 patients and continued for more than 3 days in 9 patients. Anti-
biotics (Levoﬂoxacin for 5, amoxicillin-clavulonate for 1, cefuroxime 
for 1) were started for 7 patients. No side effect was observed. All 
patients recovered. The recovery period lasted for more than 4 days in 
13 patients and for 3 days for 2 patients.
Conclusions: In spite of the low number of patients, no complica-
tion was observed in the transplant recipients with H1N1 inﬂuenza. 
Longer durations of the recovery period and respose to antiviral 
tretment compared to the healthy population was the most striking 
 ﬁnding.
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Background: The aim of this study to determine the clinical fea-
tures and etiologic agents of bacteremia among solid organ transplant 
 recipients.
Materials: Patient records of bacteremia episodes among solid organ 
transplant recipients were evaluated retrospectively. The diagnosis 
of bacteremia was established according to the criteria published by 
CDC.
Methods: A structured form consisting of demographic characteris-
tics, transplantation and bacteremia episode were ﬁlled.
Results: Twenty three bacteremia episodes (2 episodes in one patient, 
3 episodes in another patient) seen in 20 patients (13 male, 7 female) 
Table1. Clinical features and laboratory ﬁndings of the patients
Feature  Present on admission (n)
Duration of the symptoms (days)  
 2  12
 3-5 1
 >5  2
Symptoms   
 Elevated tempurature  
 37.3-38 ºC 7
 38.1-39 ºC 8
 Cough  15
 Sputum production  7
 Sore throat 8
 Rhinorrea  8
 Headache  8
 Myalgia,arthralgia 7
 Nausea, vomiting 14
Sign   
 Fever  15
 O
2
 Saturation <95 8
 Swelling of tonsils 13
 Enlargement of lymph nodes 3
 Ralles  6
Laboratory ﬁndings  
 Leukocyte >10.000 6
 Lymphopenia 8
 Thrombocytopenia 3
 C-reactive protein>10 mg/dl 11
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were included in this study. Fifteen of the patients were liver transplant 
recipients and 5 were renal transplant recipients. Acute rejection was 
seen in 2 patients. The immunosuppressive regimens were as follows; 
tacrolimus and mycophenolate mofetil (7), tacrolimus and corticoste-
roid (5), mycophenolate mofetil and corticosteroid (5), sirolimus (3). 
Four patients were followed in the intensive care unit. Septic shock 
developed in 3 patients. The source of bacteremia was urinary system 
infection in 3 of 6 renal transplant recipients and intrabdominal infec-
tion/biliary system in 8 of 17 episodes. Seven of 8 (87.5%) etiologic 
agents of bacteremia seen in the ﬁrst 6 months after transplantation 
were multi drug resistant whereas 4 of 15 (26.6%) of agents isolated in 
the late period were multi-drug resistant. The empirical treatment was 
compatible with the antimicrobial susceptibility results in 16 (69.5%) 
of the episodes. Three patients (15%) died and multi-drug resistant 
bacteria were isolated from all these 3 patients. In addition to this, 
the causative agent was resistant to the empirical treatment in 2 of the 
cases. The features of the bacteriemia episodes were summarized in 
the Table.
Conclusions: There was no difference in the distribution of etiologic 
agents of bacteremia when early and late periods after transplanta-
tion were compared, whereas multidrug resistant bacteria predom-
inate in the early period. Another ﬁnding, demonstrated before in 
the literature, is the changing of the source of bacteremia depend-
ing on the type of the transplanted organ. Although the number of 
the cases included in this study is limited; it is concluded that to 
reduce the mortality rates, the issue of multi-drug resistance should 
be taken into consideration for the bacteremia episodes seen in the 
early period.
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Epidemiology of Infections in Renal Transplant Recipients
Bartosz Wojciuk1, Stefania Giedrys-Kalemba1.
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Background: Infections are a signiﬁcant complication following organ 
transplantation. Urinary tract infections (UTI) are considered to domi-
nate in kidney recipients. The problem seems emergent as UTI dominate 
also in nosocomial infections.
Materials: The group of 161 kidney recipients (59 females; 102 males) 
was analyzed, only laboratory conﬁrmed infectious episodes were 
regarded.
Methods: Clinical and microbiological data was obtained from medi-
cal documentation. Whole data was collected in a Microsoft Access 
database. Results were veriﬁed with double fraction test.
Results: Total number of 170 infectious episodes were observed, 
82% during ﬁrst 12 months. Incidence in the whole group was 42%, 
females 54%, males 36% (p = 0.002). Incidence, regarding the cause 
of chronic renal disease (CRD) was observed respectively: glomeru-
lonephritis- 32.6%; non-autoimmune causes: diabetes mellitus, auto-
somal dominant polycystic kidney disease, chronic pyelonephritis, 
congenital urinary tract abonormalities- 55.5%, not known 41.5% 
(p = 0.001). No difference in incidence regarding age was observed. 
Following clinical forms of infection were diagnosed: UTI 68%; 
cytomegalovirus (CMV) infection 11%; post operative wound infec-
tion 8%, blood infection 6%; respiratory tract infection 5%; peri-
toneal cavity infection 2%. The number of episodes was similar in 
both sexes. [table 1] UTI was observed in patients suffering from all 
analyzed sorts of CRD. Other forms were also diagnosed in patients 
with non-autoimmune causes of CRD [table 2] Following pathogens 
were detected: Escherichia coli 20%, Enterobacter cloacae 15%, 
Klebsiella pneumoniae 12%, Acinetobacter baumannii 9%; CMV 
9%, Enterococcus faecalis 7%, Enterococcus faecium 5%, Candida 
spp. 5%, Pseudomonas aeruginosa 5%, other (Citrobacter freundii, 
Proteus spp., Citrobacter freundii, Morganella morganii, Trihospo-
ron asahii, Staphylococcus aureus, Streptococcus pneumoniae) 13% 
[table 3]. The spectrum was similar in different clinical materials but 
differentiated in males and females.
Conclusions: 1. UTI was the most frequent form of infection. 2. 
Majority of episodes appeared during ﬁrst 12 months after transplan-
tation. 3. Despite similar number of particular episodes, signiﬁcant 
difference in incidence as well as pathogen spectrum between males 
and females was observed. 4. Signiﬁcantly higher incidence and out-
standing variety of clinical forms among patients suffering from non-
autoimmune causes of CRD was observed.
Table 1. 
Features Number of the patients (n:23)
Onset of the bacteremia (mounth) 
 Early (<1) 5
 Middle (1-6 ) 3
 Late (>6) 15
Source of the bacteremia 
 Surgical site/drain 8
 Urinary tract 5
 Lungs 3
 CVC# 1
 Unknown 6
Etiologic agents 
 Enteric rods* 20
 Non-fermantative bacteria** 3
#CVC: central venous catheter, *E.coli:12, Klebsiella spp:7, 
Enterobacter spp:1, **Pseudomonas spp:2, Acinetobacter baumannii:1
Table 1. 
 Males Females
Urinary tract infection 59 56
CMV 9 10
Post operative wound infection 6 7
Blood infection 6 5
Respiratory tract infection 6 2
Peritoneal cavity infection 1 3
Table 2. 
 Glomeru- Diabetes Autosomal Chronic Congenital Unknown
 lonephritis mellitus dominant pyelone- urinary tract
   kidney phritis abnormalities
   disease
Urinary 25 18 9 12 19 32
 tract 
 infection
CMV 5 2 3 1 1 7
Post operative 0 1 1 1 0 10
 wound
 infection
Blood infection 1 3 3 1 2 1
Respiratory 0 1 1 0 0 6
 tract infection 
Paeritoneal cavity 0 1 1 0 0 2
 infection
Table 3. 
Pathogen Males Females
Escherichia coli 14 26
Enterobacter cloacae 14 17
Klebsiella pneumoniae 16 6
Acinetobacter baumannii 18 0
Enterococcus faecalis 7 6
Enterococcus faecium 2 7
Candida spp. 4 6
Pseudomonas aeruginosa 7 3
Citrobacter freundii 4 0
Proteus spp. 4 1
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Aspergillus Empyema in a Lung Transplant-Recipient
Andreea Moldovan1, Paola Soccal2, Thierry Rochat2, Christian 
Van Delden3.
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Background: Aspergillus spp. empyema is a rare clinical entity asso-
ciated with a particularly high mortality, described mainly in patients 
with Aspergillomas colonizing pre-existing lung cavitations from 
which the fungus gains access to the pleural space through broncho-
pleural ﬁstulas. Apergillus empyema has only rarely been described in 
lung-transplant recipients. We report a patient who developed Asper-
gillus empyema early after lung transplantation.
Materials: Clinical and microbiological charts.
Methods: Chart and literature review.
Results: A 53-year old male underwent double lung transplantation 
for end-stage emphysema. Microbiological pre-transplant screen-
ing of both donor and recipient was negative for fungi. After initial 
anti-IL2-R (basiliximab) induction, maintenance immunosuppressive 
therapy consisted of tacrolimus, mycophenolate and prednisone. The 
early postoperative period was complicated by bilateral bacterial and 
Herpes simplex virus pneumonia, an acute rejection episode treated 
by high-dose steroids. On day + 5, thoracic drain cultures grew Asper-
gillus spp, considered as contaminant. On day + 9, bilateral Asper-
gillus fumigatus pleural infection was suspected and caspofungine 
initiated. Three weeks post-transplantation the patient underwent tho-
racotomy with decortication and pleural lavage. Pleural ﬂuid cultures, 
pleural biopsies and lung nodule biopsies grew Aspergillus fumiga-
tus. Surgical therapy was combined with systemic antifungal treat-
ment consisting initially of voriconazole and caspofungine, as well as 
intra-pleural bethadine and amphotericin B instillation. Caspofungine 
was switched for liposomal amphotericin B, which was continued for 
9 weeks. Voriconazole was continued for 4 months. The patient died 
10 months post-transplantation, in the context of chronic graft rejec-
tion and bacterial pneumonia without evidence of residual fungal 
infection.
Conclusions: This case illustrates the efﬁcacy of combining a surgical 
approach together with systemic and local antifungal therapy to con-
trol Aspergillus empyema despite intense immunosuppression.
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Patient, First Case in Hungary
Zsuzsanna Gerlei1, Levente Gergels1, Marina Varga1, Eva Toronyi1, 
Aniko Smudla1, Attila Doros1, Tamas Mandli1, Zsuzsanna Aranyi3, 
Eniko Ban2, Eniko Sarvary1, Janos Fazakas1.
1Semmelweis University, Transplantation and Surgical Clinic, Budapest, 
HU; 2National Center for Epidemiology, Budapest, HU; 3Semmelweis 
University, Clinic of Neurology, Budapest, HU.
Background: West Nile Virus (WNV) infections are rare but the com-
plications caused by them are more frequently treated on the ICU. 6 
cases of WNV occur annually in Hungary.
Materials: The ﬁrst transplanted Hungarian patient with WNV 
encephalitis was hospitalized for one week with epigastric pain, 
diarrhea, 39-40°C continuous fever and decreasing amount of 
urine. The ﬁrst checkup of the infectious disease was without any 
result. Despite the use of empirical antibiotic, antiviral and antimy-
cotic therapy, the multiorgan failure patient remained continuously 
febrile. On the basis of the clinical signs, meningitis or encephalitis 
was suspected in spite of the negative result of repeated cultures. 
On the 8th day, WNV infection was conﬁrmed by the serological 
examinations.
Methods: With the intravenous immunoglobulin therapy used within 
the conﬁnes of the supportive treatment, the patient became afebrile. 
After 21 day of ICU treatment with a good graft function the patient 
was moved to the ward and he left the hospital after more two weeks 
of treatment. Until now no prophylactic or etiological treatment has 
been developed for WNV.
Results: The early treatment is done with immunoglobulin or inter-
feron therapy; otherwise the therapy has only supportive function.
Conclusions: The disease caused by the virus is more aggressive in 
transplanted patients and could be the cause of death in immunocom-
promised patient.
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Globulin (CMVIG) Use and Long-Term Recipient 
and Graft Survival in Pediatric and Adult Heart 
Transplantation Recipients
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delphia, US; 3The Institute for Transfusion Medicine, Pittsburgh, US; 
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Background: Cytomegalovirus (CMV) is the most common viral 
pathogen in cardiac transplantation, and is associated with cardiac 
vasculopathy, as well as graft loss and increase in mortality. The 
association between use of CMVIG and clinical outcomes in heart 
transplantation has not been evaluated using data derived from large 
national data bases. We examined the association between CMVIG use 
along with antivirals for long-term recipient and graft survival in heart 
transplantation.
Materials: Data from the Scientiﬁc Registry of Transplant Recipients 
(SRTR) included recipients with a transplant date between January 
1, 1995 and October 31, 2008; follow-up data were through March 
31, 2009. All recipients 80 years old, of primary, single-organ heart 
transplants, recorded as receiving CMVIG (n = 2112), other anti-
virals without CMVIG (n = 12089) or no anti-viral (n = 14661) treat-
ment were included. The speciﬁc aim was to examine the relationship 
between CMVIG use and long term recipient graft survival in heart 
transplantation using the SRTR data base.
Methods: Kaplan-Meier analysis was used to examine rates of recipi-
ent death and graft loss at 7 years post-transplantation; Cox propor-
tional hazards models adjusting for donor, recipient and transplant 
characteristics as potential confounders were used to estimate risk of 
graft loss, death and infectious cause of death in recipients on CMVIG 
( + /- other anti-virals) vs. no anti-virals.
Results: CMVIG ( + /- other antivirals) use was associated with 
increased recipient (69% vs. 64%, p < .001) and graft (67% vs. 63%, 
p < .001) survival at 7 years post-transplantation. Using Cox models, 
CMVIG ( + /- other antivirals) was associated with decreased mortality 
(HR 0.82, 95% CI 0.72 to 0.87, p < .001) and graft loss (HR 0.78, 95% 
CI 0.72 to 0.86, p < .001). Findings were similar within the high-risk 
(CMV D + /R-) and pediatric (age < 18 years) cohorts. Comparison of 
CMVIG monotherapy versus ganciclovir monotherapy show no differ-
ence in survival or graft loss, but CMVIG use was associated with less 
rejection (HR 0.53, 95% CI 0.44 to 0.64, p < 0.001).
Conclusions: CMVIG use (with or without antivirals) at discharge 
is associated with increased long-term recipient and graft survival in 
adult and pediatric heart transplant recipients when one examines the 
SRTR data base up to 7 years post heart transplantation.
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Jirovecii Pneumonia in Renal Transplant Recipients
Henrieke Struijk1, Anton-Frans Gijsen1, Si la Yong2, Suzanne 
Geerlings3, Anne van Tellingen1, Karlijn van Donselaar-van de Pant1, 
Ineke ten Berge1, Frederike Bemelman1.
1Academic Medical Center, University of Amsterdam, Renal Trans-
plant Unit, Dept of Nephrology, Div of Internal Medicine, Amsterdam, 
NL; 2Academic Medical Center, University of Amsterdam, Dept of 
 Experimental Immunology, Amsterdam, NL; 3Academic Medi-
cal  Center, University of Amsterdam, Dept of Infectious Diseases, 
 Amsterdam, NL.
Background: Current immunosuppressive drug regimens after 
renal transplantation have improved allograft survival at the 
expense of more profound immunosuppression, as apparent from 
an increased risk of infectious complications like Pneumocys-
tis  jirovecii pneumonia (PCP). Prophylaxis against PCP is only 
 recommended during the early post transplantation period. The 
aim of this study is to investigate the risk factors for PCP in renal 
transplant recipients after the initial post transplant period and to 
identify which renal transplant recipients should receive prolonged 
prophylaxis.
Materials: Nine PCP cases diagnosed between august 2006 and april 
2007 were matched with 18 controls, who received their transplant 
in the same period, did not develop PCP and had a similar follow-up 
period with a comparable immunosuppressive regimen. None of the 
cases or the controls had ever received any PCP prophylaxis.
Methods: We conducted a case-control study to investigate the risk 
factors for PCP in renal transplant recipients.
Results: The mean time from transplantation to PCP was 23 months. 
We observed no signiﬁcant differences in gender, age, donor type and 
number of rejections. PCP cases had signiﬁcant more infectious epi-
sodes during the follow-up period and signiﬁcant lower lymphocyte 
counts in peripheral blood compared to the controls. There was a trend 
towards lower CD4 T-cell counts in the PCP cases, compared to the 
controls. 3/9 cases had received additional immunosuppressive therapy 
with antithymocyte globulin (ATG) or rituximab.
Conclusions: The risk of PCP in renal transplant recipients is related 
to the number of infectious episodes and lymphocyte counts. Con-
tinuing PCP prophylaxis should be considered in renal transplant 
recipients with a low lymphocyte- and CD4 T-cell count and those 
who receive additional immunosuppressive therapy like ATG and 
rituximab.
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Recipients; Results of Three-Year Surveillance
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Division of Nephrology, Antalya, TR; 3Akdeniz University, Faculty of 
Medicine, Medical Microbiology, Antalya, TR; 4Akdeniz University, 
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sity, Faculty of Medicine, Department of Internal Medicine, Antalya, 
TR; 6Akdeniz University, Faculty of Medicine, Infectious Diseases, 
Antalya, TR.
Background: In this study we aimed to analyse risk factors associated 
with CMV infections after renal transplantation, retrospectively.
Materials: Eight-hundred-ninety-eight renal transplant recipients 
who underwent renal transplantation in Akdeniz University Medi-
cal Faculty, Antalya, Turkey, between 2006 and 2009 were included 
in the study (Mean age:37, 18-74). Seven-hundred-forty of them 
received their grafts from living donors (407 from relatives, 333 
from non-relatives) and 158 of them received their allografts from 
cadaveric donors.
Methods: In recipients, at pre-transplant period, CMV IgM and IgG 
antibodies were determined with ELFA method (bioMerieux, Marcy-
l’Etoile, France) and the seropositivity rate found was 99%. CMV 
prophylaxis was given to all transplant recipients for six months as 
acyclovir (4x800 mg/day) or valacyclovir (3x1000 mg/day). Active 
CMV infection was detected with CMV pp65 antigenemia test 
(CINA kit, Argene, France) or quantitative CMV DNA PCR (Cobas 
CMV Monitor, Roche Diagnostics Mannheim, Germany) which was 
applied weekly, biweekly and when clinically indicated for the ﬁrst 
month, for two months and the following period after transplantation, 
respectively.
Results: Active CMV infection was detected in 48 (5.3%) patients 
with a median detection time of 117,5 days (5-595) after transplan-
tation. Two of these patients had developed CMV syndrome. Active 
CMV infections occurred at 55.6% and 4.8% among CMV seronega-
tive and seropositive recipients, respectively (p < 0.0001). The percent-
age of CMV infections among recipients with allografts from relatives, 
non-relatives and cadaveric donors were 2.8, 5.7, 6 and 9.5 (p = 0.018) 
respectively. Seventeen patients (1.9%) developed late onset CMV 
infections and all of them were CMV seropositive before transplan-
tation. HLA mismatches and age were found to be unrelated with 
CMV infections. The percentage of CMV infections among recipients 
with and without at least one acute rejection episode were 8.1 and 4.5 
respectively (p = 0.041). CMV seronegativity and having at least one 
acute rejection episode were found to be undepended risk factors for 
CMV infections (p < 0.001, RR: 25.9 [6.6-101.6] and p = 0.037, RR: 
1.9 [1.0-3.7] respectively).
Conclusions: These results show that acute rejection therapy and sero-
negativity before transplantation are among the strongest risk factors 
for developing CMV infections after renal transplantation.
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Fungal Infections in Patients after Heart Transplantation
Malgorzata Sobieszczańska-MaŁek1, Jadwiga Meszaros2, 
Malgorzata Piotrowska1, Tomasz Zieliński1, Urszula łopaciuk3, Jerzy 
Korewicki1.
1Institut of Cardiology, Heart Failure and Transplantation, 
Warszawa, PL; 2Warsaw Medical University, General, Vascular and 
Transplantation Surgery, Warszawa, PL; 3Institut of Cardiology, 
Microbiology, Warszawa, PL.
Background: Immunosuppressed patients may have generalized form 
of invasive fungal infections, with involvement of various organs and 
may develop general signs of sepsis. Disease may be complicated by 
the creation of distant metastatic foci of infection, with involvement 
of the CNS. The etiology of infections in this group was Candida and 
Aspergillus. Speciﬁc diagnosis of infection is difﬁcult and treatment 
often delayed, because the negative results of cultures even in general-
ized form of disease.
Materials: In Institute of Cardiology from 2005 to 2009 81 recipients 
underwent heart transplantations (OHT). During this period, among 
11 patients (7 men, 4 women) aged 13 - 50 years mean 35.6 diagnosis 
of fungal infection was established: etiology in 7 patients was Asper-
gillus fumigatus and Candida albicans in 5 patients. In 7 patients, heart 
transplantation was preceded by the use of ventricular assist device in 
period 20 - 180 days, in these group prophylactic antibiotic therapy 
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was used. In 7 out of 11 patients, fungal infection was preceded by a 
severe bacterial infections (including S. pneumoniae, P. aeruginosa) 
requiring intensive treatment.
Methods: The diagnosis of fungal infection was based on: exclusion 
of bacterial process as a cause of septic disease, x-ray examination and 
serology with assessment of speciﬁc antigens and antibody.
Results: In 6 patients radiological changes were described. In 5 
patients material from bronchoscopy showed Aspergillus infection, 
but in 3 serological tests were positive for Aspergillus. All patients 
had neutropenia with leukopenia in the period preceding the diagno-
sis. Patients were treated with caspofungin, voriconazole or posakon-
azol, then as maintenance treatment they received itraconazole. The 
duration of treatment ranged from 1 month to one year, an average 
of 7.5 months. 5 patients died: 2 - invasive fungal infection, 1 - graft 
failure because of acute cellular rejection half a year after treatment, 
2 patients died during treatment of fungal infection, because of mul-
tiorgan failure.
Conclusions: Fungal infections develop as serious complications of 
bacterial infections in early and late period after a heart transplant-
severe heart failure, preceding bacterial infections and/or neutropenia, 
can be the factors which conduce to the fungal infection development.
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Evaluation of A Pre-Emptive Strategy for BK Polyomavirus 
Associated Nephropathy (BKPVAN), Based on Prospective 
Monitoring of BK Viremia. A Kidney Transplantation (KT) 
Center Experience
Edith Renoult1, François Coutlée2, Michel Pâquet1, Gilles St-Louis1, 
Catherine Girardin1, Marie-Chantal Fortin1, Héloïse Cardinal1, Renée 
Lévesque1, Walter Shürch3, Mathieu Latour3, Azemi Barama4, Marie-
Josée Hébert1.
1Centre Hospitalier de l’Université de Montréal, Nephrology,Kidney 
and Pancreas Transplantation, Montreal, CA; 2Centre Hospitalier 
de l’Université de Montréal, Microbiology, Montreal, CA; 3Centre 
Hospitalier de l’Université de Montréal, Pathology, Montreal, CA; 
4Centre Hospitalier de l’Université de Montréal, Kidney and Pan-
creas Transplantation Surgery, Montreal, CA.
Background: BKPVAN is a major cause of allograft failure, early 
after KT. The timing of the initial diagnosis is critical for therapeutic 
success and a good outcome. The present study reports on the prelimi-
nary results of the prospective monitoring and pre-emptive strategy for 
BKPVAN proposed in the ﬁrst year of the KT in our center.
Materials: We followed 72 KT recipients who received induction 
immunosuppression, with basilixumab (73%) or ATG, and mainte-
nance immunosuppression, with prednisone, mycophenolate mofetil 
(MMF) and tacrolimus (TAC).
Methods: Plasma BKV DNA was measured at 1, 2, 3 6, 9, and 
12 months after KT. Patients with two or more consecutive positive 
viral load ( > > 10000 copies/ml) were treated with a subsequent 
stepwise decrease of immunosuppression (a reduction in dose or dis-
continuation of MMF eventually followed by a reduction of TAC and 
introduction of leﬂunomide-LEF-). During the ﬁrst year, 55 recipients 
underwent protocol or clinically indicated allograft biopsy.
Results: By one year, 6 (8, 3%) patients had BK sustained viremia 
at a median of 92 days after KT (range, 58 to 349 days). BKPVAN 
was diagnosed histologically in 7 recipients, at a median of 15 weeks 
(range: 11 to 32 weeks) after KT. In 5 cases, BKPVAN was diagnosed 
in patients with stable renal function during their four-month protocol 
biopsy. Biopsy ﬁndings were noted concomitantly with the ﬁrst vire-
mia in 2 subjects and far before the ﬁrst viremia in 2 cases. LEF was 
used in the patients who developed BKPVAN. At 12 months, serum 
negative conversion or decrease of viral titer was achieved in 5 vire-
mic patients. Creatinine levels improved or stabilized in 4 patients 
with BKPVAN. The renal function of patients was 39, 5 ml/min (vs 
60, 22 ml/min in patients who never became viremic, p =  0.0048). 
One patient experienced acute rejection two weeks after reduction of 
immunosuppressive treatment. None of the patients with viremia and/
or BKPVAN lost their graft.
Conclusions: BKPVAN may occur early after KT, at a low or unde-
tectable viremia or concomitantly with the ﬁrst positive viremia. Inten-
sive monitoring during the ﬁrst four months after KT added to early 
protocol biopsies or biopsies prompted by the viremia could help to 
optimize the diagnosis of BKPVAN at a subclinical stage and avoid 
allograft dysfunction.
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KPC-Producing Klebsiella Pneumoniae Infection in Solid 
Organ Transplantation: Clinical and Microbiologic Aspects 
of 12 Cases
Maria Daniela Bergamasco1, Andre Mario Doi2, Doralice Aparecida 
Cortez Araújo1, Eliana de Cássia Zandonadi Vasconcelos1, Vera Lúcia 
de Barros Barbosa1, Cely Saad Abboud1.
1Instituto Dante Pazzanese de Cardiologia, Serviço de Controle de 
Infecção Hospitalar e Seção Médica de Infectologia, Sao Paulo, BR; 
2Universidade Federal de São Paulo, Laboratório Especial de Micro-
biologia - LEMC, Sao Paulo, BR.
Background: KPC-producing Klebsiella pneumoniae is spreading 
globally and represents a challenge in infection control and treatment. 
Solid organ transplant recipients (SOT) are especially at risk of infec-
tion by multidrug-resistant bacteria and little is known about KPC 
infection in this setting. The aim of this study was to describe clinical 
and microbiologic aspects of KPC-producing Klebsiella pneumoniae 
infections in SOT.
Materials: A KPC-producing K.pneumoniae outbreak was  identiﬁed 
in a public, teaching, tertiary care hospital in São Paulo, Brazil in June 
2009.
Methods: During the outbreak, cases of infection in SOT occurred 
between July/2009 and February/2010 and were retrospectively 
reviewed. Infection was deﬁned according to clinical manifestations. 
Identiﬁcation and antibiotic susceptibility testing was performed using 
the Vitek2 system (bioMèrieux), screening test for KPC was made 
using the Modiﬁed Hodge test according to previous CLSI recommen-
dations. KPC-producing K.pneumoniae was conﬁrmed using poly-
merase chain reaction (PCR) to detect bla
KPC
.
Results: Twelve episodes of infection by KPC-producing K.pneumoniae, 
conﬁrmed by PCR, occurred in 2 heart, 4 liver and 6 kidney transplant 
recipients. The incidence of KPC infection was 16.7%, 16.1% and 31.6% 
in heart, liver and kidney transplantation respectively. Infection occurred 
at a median time of 20 days after transplantation. Primary site was: 4 
urinary tract infections (UTI), 4 bloodstream infections (BSI); 2 pneumo-
nias (PNEU) and 2 surgical site infections (SSI). All patients, but one, had 
received antibiotics in the last 30 days, mostly piperacillin-tazobactam 
(50%) and glycopeptides (50%), the recommended empirical therapy 
for hospital-acquired infection in the institute. All strains exhibited sus-
ceptibility to amikacin, gentamicin and tigecycline. Patients were treated 
with tigecycline plus polymyxin B, polymyxin B plus carbapenem and 
polymyxin B alone in 3 cases each and tigecycline in 1 case. In 2 cases 
patients received only carbapenem and death occurred before the ﬁnal 
culture result. Global 30-day mortality rate was 41.7%. According to the 
site of infection 30-day mortality rate was 50% for BSI, PNEU and SSI, 
25% for UTI and 44.4% for any primary site with positive blood culture.
Conclusions: In this largest single-center series of KPC in SOT, infec-
tion incidence was high during an institutional outbreak and poten-
tially life-threatening.
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Epidemiology of Candidemia in Hematologic Malignancies 
and Solid Tumors
Maria Daniela Bergamasco1, Marcia Garnica2, Beatriz Quental 
Rodrigues1, Ana Paula Jafet Ourives1, Arnaldo Lopes Colombo1, 
Marcio Nucci2.
1Universidade Federal de São Paulo, Infectologia, Sao Paulo, BR; 
2Universidade Federal do Rio de Janeiro, Hematologia, Rio de 
Janeiro, BR.
Background: Cancer is one of the most prevalent underlying diseases 
reported in many series of candidemia, and in this particular setting, 
there are some documented geographic variations in etiology and natu-
ral history. Besides, different aspects of this infection occur among 
patients with hematologic malignancies (HM) and solid tumors (ST). 
There is a need of studies in Latin America to better clarify the epide-
miology of candidemia in HM and ST. The aims of this study were to 
describe the epidemiology of candidemia in cancer in Brazilian medi-
cal centers and analyze risk factors for 30-day mortality.
Materials: Three data bases prospectively collected with standard 
forms, from laboratory-based surveillance in 20 tertiary care hospitals 
of 12 cities in Brazil were reviewed.
Methods: A retrospective study was performed using the above 
 mentioned data bases. All patients with cancer and candidemia admit-
ted to the participant hospitals between march/2003 and december/2007 
were selected. Data were analyzed using the SPSS 15.0 software 
(Chicago, IL).
Results: During the study 365 candidemia episodes occurred in 117 HM 
and 248 ST patients. ST patients were older, median age 62 versus 24.5 
years, more likely to have intensive care unit (ICU) admission, mechani-
cal ventilation, parenteral nutrition, surgery (p < 0.001 for each variable), 
dialysis (p 0.028) and central venous catheterization (p 0.005) suggest-
ing they were more critically ill. HM patients were more frequently neu-
tropenic, had mucositis, chemotherapy, prior antifungal (p < 0.001 for 
each variable) and corticosteroids use (p 0.007). C.albicans, C.tropicalis 
and C.parapsilosis were the most frequent species in the 2 populations. 
Decreased ﬂuconazole susceptibility (MIC ≥ 16mg/mL) among all 
isolates was similar in HM and ST (9.1%,12.2% respectively, p 0.388). 
Thirty-day mortality was higher in the ST population, 59.3% vs 36.2%, 
p < 0.001. For the entire population, factors signiﬁcantly associated with 
30-day mortality in logistic regression model were age, ICU admission 
and mechanical ventilation (OR 1.03, 5.27, 2.72 respectively).
Conclusions: In Brazilian centers C.albicans, C.tropicalis and 
C.parapsilosis were the leading causative agents of candidemia in 
cancer. Different predisposing factors for candidemia, more related to 
Table 1. 
Patient  Age Transplante   Time Primary Positive Treatment 30-day
   after site of blood  outcome
   transplant infection culture
   (days)
 1 55 Kidney 13 BSI Yes Imipenem Died
 2 42 Heart 16 PNEU Yes Meropenem Died
       PolymyxinB
 3 74 Liver 27 BSI Yes PolymyxinB Died
 4 50 Kidney 62 UTI Yes Meropenem Died
       PolymyxinB
 5 64 Kidney 12 UTI Yes Imipenem Survived
       PolymyxinB
 6 44 Kidney 7 years SSI No Imipenem Died
 7 60 Kidney 88 UTI No PolymyxinB Survived
 8 54 Heart 163 UTI Yes PolymyxinB Survived
 9 54 Liver 9 BSI Yes Tigecycline Survived
      PolymyxinB
10 69 Liver 23 BSI Yes Tigecycline Survived
      PolymyxinB
11 60 Liver 1 PNEU Yes Tigecycline Survived
      PolymyxineB
12 37 Kidney  17 SSI No Tigecycline Survived
      PolymyxinB
Table 1. 
Candida species HM %(n) N = 117 ST % (n) N = 248 p value
C.albicans 30.8 (36) 40.7 (101) 0.067
C.tropicalis 23.1 (27) 20.2 (50) 0.524
C.parapsilosis 23.1 (27) 14.9 (37) 0.056
C.glabrata 6.0 (7) 12.1 (30) 0.071
C.guilliermondii 6.0 (7) 3.2 (8) 0.216
C.krusei 3.4 (4) 2.8 (7) 0.756
Table 2. 
Variables HM %(n) N = 117 ST % (n) N = 248 p value
Median age, years 24.5 62 <0.001
Male gender 44.4 (52) 58.9 (145) 0.010
Hospital-acquired infection 93.1 (108) 98.0 (243) 0.019
Median n° of days in 16 23 <0.001
 hospital until 
 candidemia
Mucositis 18.9 (20) 4.1 (10) <0.001
Current neutropenia 36.4 (40) 7.4 (18) <0.001
Previous surgery 11.2 (13) 69.6 (167) <0.001
 (last 3 months)
In ICU at diagnosis 20.4 (22) 39.9 (97) <0.001
Mechanical ventilation 17.2 (20) 34.3 (85) 0.001
Parenteral nutrition 12.3 (14) 38.2 (94) <0.001
Dialysis 6.0 (7) 13.8 (34) 0.028
Central venous 76.5 (78) 88.4 (205) 0.005
 catheter (CVC)
Tunnelled CVC 25.2 (26) 12.5 (29) 0.003
Corticosteroids 52.7 (59) 37.4 (89) 0.007
Chemotherapy 54.3 (63) 12.9 (31) <0.001
Previous antibiotic (14 days) 92.9 (105) 93.4 (227)  0.862
Previous antifungal (14 days) 47.8 (54) 14.9 (36) <0.001
Treatment with ﬂuconazole 27.4 (32) 48.0 (119) <0.001
Treatment with 42.7 (50) 22.2 (55) <0.001
 amphotericin 
 B formulation
Figure 1. 
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the underlying disease in patients with HM and invasive procedures in 
ST occurred and were probably associated with the greater mortality 
rate in ST.
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Rapidly Growing Mycobacteria Infection in Patients with 
Cancer
Gil Redelman-Sidi1, Kent Sepkowitz1.
1Memorial Sloan Kettering Cancer Center, Infectious Disease, 
New York, US.
Background: Rapidly growing mycobacteria (RGM) have been 
associated with various clinical syndromes in immunocompetent 
and immunocompromised hosts. While cases have been described in 
patients with cancer, the risk factors and outcome for RGM infection 
in cancer patients have not been clearly deﬁned.
Materials: Data was derived from two distinct sources: we identiﬁed 
all patients at Memorial Sloan-Kettering Cancer Center (MSKCC) 
with a culture positive for RGM between January 1999 and December 
2008. A MEDLINE review was performed for all English-language 
studies describing RGM infection in cancer patients.
Methods: Patients with RGM infections were included if they had an 
underlying cancer diagnosis. Demographic and clinical data was col-
lected for all patients.
Results: During the 10-year period 28 patients with cancer at MKSCC 
had cultures positive for RGM, 14 of who had pulmonary infection, 7 
with bloodstream infection and one patient with disseminated infec-
tion. Most cases occurred in patients with solid tumors. A review 
of the literature identiﬁed 313 additional cancer patients with RGM 
infection. Combining our series data with cases from the literature, we 
deﬁned 3 distinct syndromes: pulmonary disease which occurred in 
158 patients (47%); bloodstream infection, occurring in 151 patients 
(45%); and disseminated infection involving at least one end-organ, 
affecting 26 persons (8%). The syndromes differed by age of onset, 
underlying cancer, main RGM species, and outcome. Persons with 
bloodstream infection typically were young and had an excellent out-
come; those with disseminated infection were older, had pronounced 
immunosuppression and a very poor prognosis [tables 1 & 2].
Conclusions: RGM infections in cancer patients comprise three dis-
tinct disorders with different risk factors, predominant infecting myco-
bacterial species, and prognosis. In turn, the approach to management, 
including number and duration of antimycobacterial drugs, may be 
fundamentally different for patients with cancer diagnosed with RGM. 
In general, patients with pulmonary infection resemble any patient 
with RGM affecting lung; those with bloodstream infection should be 
approached like any patient with a CVC-related bacterial infection; 
while those with disseminated disease may require a very aggressive 
approach with as many antibiotics as can be tolerated.
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Infectious Disease Specialist Impact in Outpatient 
Consultations in a Comprehensive Cancer Center
Georgios Pongas1, George Hamilos1, Kenneth Rolston1, Dimitrios 
Kontoyiannis1.
1MD Anderson Cancer Center, Infectious Diseases, Infection Control 
& Employee Health, Houston, US.
Background: There is scarcity of literature on the impact of Infectious 
Disease (ID) specialists in the outpatient care of cancer patients.
Materials: Records of 598 patients been evaluated by 2 board-certiﬁed 
ID specialists in an outpatient setting over a 10-year period (1998-
2008) in a comprehensive cancer center were studied.
Methods: We retrospectively reviewed data of consecutive cancer 
patients, including demographics, referring department, initial diag-
nosis, purpose of consultation, diagnosis offered by ID, recommenda-
tions and overall impact of consultation in patients outcome.
Results: We identiﬁed 598 such patients. The median WHO score for 
performance status was 1 (range 0-4). Most patients had solid tumors 
(53%) predominantly of breast cancer (10%), but NHL was the most 
common malignancy (16%). Half of patients (45%) had active malig-
nancy, 8% were severely neutropenic ( <  100/mm3 for more than 
10 days), 17% were on corticosteroids ( ≥  600 mg of a prednisone 
equivalent during the month prior to diagnosis of infection) and 22% on 
immunosuppressive medications. Most frequent requests for consulta-
tion included evaluation of pulmonary lesions (nodules 20%, inﬁltrates 
11%), interpretation of a positive culture or serologic test (15%), or 
treatment of cellulitis/surgical wound infections (14%). The median 
duration of symptoms was 53 days (range 1-500). In 337 culture-proven 
infections the most prevalent pathogens were atypical mycobacteria 
(16%), MDR bacteria, predominantly MRSA (13%) and Pseudomonas 
aeruginosa (8%) and molds. ID recommendations included obtaining 
additional diagnostic tests (36%) and imaging studies (30%), starting 
(31%) or modifying (43%) treatment with antibiotics, discontinuing 
antibiotics, (5%), and no need for further evaluation (5%). ID special-
ists provided alternative diagnosis in 53% of cases, including identi-
ﬁcation of another infection (24%), non-infectious etiology (15%), 
colonization (9%) and drug related toxicity (5%). Overall in 61% of 
consultations the contribution of the ID specialist deemed to be useful, 
while in 19% offered new diagnosis or curative treatment.
Table 1.  
 Pulmonary Bloodstream/ Disseminated
 (deﬁnitive/probable)  catheter-related (n = 26)
 (n = 30) (n =  151)
Average age (years) 55 30  44 
Pediatric patients (%) 0% 65%  17% 
Female patients (%) 57% 46%  48% 
Hematologic cancer 40% 58%  83% 
Solid tumor 60% 42%  17% 
HSCT (%) 27% 30% 15%
Other risk factors Underlying lung  CVC (97%) Chemotherapy
 disease (70%) Chemotherapy (87%)
  (91%)  
  Lymphopenia
  (57%) 
RGM species M. abscessus   M. mucogenicum  M. abscessus
 > M. chelonae  > M. fortuitum  > M. chelonae 
 > M. fortuitum > M. chelonae  > M. fortuitum
  > M. abscessus
Prognosis Intermediate Excellent  Poor 
  (with CVC
  removal)
Table 2. 
Type of M.  M.  M.  M.  M.  M.  other
infection fortuitum abscessus chelonae mucogenicum septicum neoaurum
Pulmonary    
All (n = 158) 61 (39%) 39 (25%) 35 (22%) 5 (3%) 7 (4%) 0 (0%) 11  
       (7%)
Deﬁnitive /  12 (20%) 26 (44%) 14 (24%) 4 (7%) 0 (0%) 0 (0%) 3 
 probable       (5%)
 (n = 59)
Bloodstream 34 (23%) 19 (12%) 23 (15%) 46 (30%) 1 (1%) 12 (8%) 16
 (n = 151)        (11%)
Disseminated 6 (23%) 12 (46%) 7 (27%) 0 (0%) 0 (0%) 0 (0%) 1 
 (n = 26)        (4%)
Total 101 (30%) 70 (21%) 65 (19%) 51 (15%) 8 (2%) 12 (4%) 28 
 (n = 335)       (8%)
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Conclusions: ID specialists contribute signiﬁcantly in the outpatient 
care of cancer patients.
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Observational Study of Invasive Fungal Infections in  
Onco-Haematological Patients and Risk Factors of 
Mortality
Rosana Jordan1, Ernesto Efrón1, Gustavo Méndez1, Natalia Enriquez1, 
Jorge Martínez1, Sergio Verbanaz1, Iris Agorio2.
1Hospital Británico de Buenos Aires, Infectious Diseases, Buenos Aires, 
AR; 2Hospital Británico de Buenos Aires, Microbiology Laboratory, 
Buenos Aires, AR.
Background: During the last few years the epidemiology and outcome 
of the onco-haematological patients (OH), with or without hemato-
poietic stem cell transplantation (HSCT) has been modiﬁed because 
of changes in the chemotherapy, new practices in HSCT including the 
source of the stem cells, conditioning regimens, and the strategies for 
prevention, diagnosis and treatment of Invasive Fungal Infections (IFI).
Materials: We analyzed, from 1986 to 2009, our data base of OH patients 
with or without HSCT. A total of 53 patients with proven or probable IFI 
according to EORTC deﬁnitions were included. Variables studied were: 
age, sex, underlying diseases, type of HSCT, risk category according to 
disease status, neutropenia, use of steroids, antifungal therapy, localized 
or disseminated disease, CMV infection, surgical treatment and mortal-
ity. Complete and partial response were evaluated at week 12.
Methods: Categorical variables were compared using Fisher’s Exact 
Test or x2 and continuous variables were compared with Wilcoxon 
Rank Sum Test. Kaplan-Meier estimates of survival time were deter-
mined and Log-Rank Test were used to compare groups. Risk factors 
associated with mortality at day 90 from treatment initiation were ana-
lyzed with Cox’s Proportional Test.
Results: Fifty-three patients with proven or probable IFI were included 
(31 OH no HSCT and 22 with HSCT). HSCT group presented younger 
age (26 versus 54 years; P < 0.0005), higher use of steroids (68% 
versus 9.7%; P < 0.00001), higher frequency of CMV (36.4% versus 
3.2%; P = 0.0026), more frequent disseminated IFI (63% versus 9.4%; 
P = 0.0014) and higher mortality (63.6% versus 35.5%; P = 0.04). 
Mortality at day 90 was 70.9% in HSCT versus 35% in OH no HSCT 
(P = 0.04). The incidence rate was 18.23 death/1000 persons/day of 
follow up in HSCT versus 4.5 death/1000 persons/day of follow up in 
OH no HSCT (P = 0.0064). Cox model for factors associated with mor-
tality was integrated by HSCT (HR 2.85; IC = 1.03-7.86; P = 0.043), 
disseminated IFI (HR 1.92, IC 0.73-5.05; P = 0.18) and treatment with 
voriconazole (HR 0.48, IC 0.17-1.2; P = 0.15).
Conclusions: HSCT patients with IFI were younger, have used more 
steroids, have had more frequent CMV co-infection, disseminated IFI 
and higher mortality than OH no HSCT patients. The HSCT was an 
independent risk factor associated with mortality. Disseminated IFI 
showed a tendency to higher mortality, while voriconazole treatment 
showed a protective tendency.
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Microbial Spectrum from Bloodstream Isolates in Patients 
with Solid Tumors
Vanda Plečko12, Davorin Herceg3, Marija Jandrlić2, Ivana Mareković12, 
Lidija Žele-Starčević2, Vesna Tripković2, Smilja Kalenić12, Stjepko 
Pleťtina2.
1School of Medicine, University of Zagreb, Dpt. for medical microbi-
ology and parasitology, Zagreb, HR; 2CHC Zagreb, Dpt. for clinical 
and molecular microbiology, Zagreb, HR; 3CHC Zagreb, Dpt. for 
oncology, Zagreb, HR.
Background: It is important to identify microorganisms isolated from 
blood in oncological patients to give optimal antibiotic treatment.
Materials: Microorganisms isolated from blood in patients with solid 
tumors treated at the Department for oncology at the Clinical Hospital 
Centre Zagreb, Zagreb, Croatia from Jan 2000 through Dec 2009 were 
examined. There were taken 5905 aerobic blood cultures, 4849 anaero-
bic and 1898 fungal blood cultures.
Methods: All blood samples were incubated in continuously monitor-
ing automated blood culture systems (BacT Alert; Organon Teknika 
Co and BACTEC; Becton Dickinson). Isolation, identiﬁcation and 
sensitivity testing were done by standard microbiological procedures.
Results: A total of 1040 isolates were identiﬁed over the study period. 
997 (95.6%) isolates were aerobic bacteria - 16.88% positive of all 
aerobic cultures. 56 isolates were anaerobic bacteria - 1.1% positive 
anaerobic cultures, 25 isolates were fungi - 1.3% positive fungal cul-
tures. The most common microorganisms were coagulase negative 
staphylococci 192 (18.4%); E. coli 179 (17.2%) with 9 (5%) ESBL 
isolates. Staphylococcus aureus 127 (12.2%) with 38 (29.9) MRSA, 
out of them 26 occured from 2005. 70 (6.7%) isolates were enterococci 
(53 E. faecalis and 17 E. faecium). Pseudomonas aeruginosa 58 (5.5%) 
and K. pneumoniae 59 (5.6%) with 3 (5%) ESBL strains. Acinetobacter 
spp was isolated 38 (3.8%) with 27 isolates from between 2000 and 
2004 and 11 isolates from 2005 till 2009. Streptococci were identiﬁed 
in 56 (5.3%) isolates. Out of them S. pneumoniae was found in 41%. 
Table 1. 
Isolate from blood 2000-2004 2005-2009 Total
 No of isolates No of isolates 
Aeromonas hydrophilla 0 1 1
Acinetobacter spp. 27 11 37
Bacillus spp. 6 4 10
Bacteroides spp. 6 6 12
Candida albicans 4 8 12
Candida spp. 4 8 12
Citrobacter spp. 5 0 5
Clostridium perfringens 2 0 2
Clostridium spp. 3 0 0
Coagulase negative staphylococci 91 101 192
Corynebacterium spp. 12 11 23
Enterobacter spp. 23 16 39
Enterococcus faecalis 20 33 53
Enterococcus faecium 3 14 17
E.coli 99 71 170
E.coli ESBL 0 9 9
Flavobacterium spp. 1 0 0
Fusarium spp. 1 0 1
Gram negative unidentiﬁed bacill 0 2 2
K. pneumoniae 31 23 54
K. pneumoniae ESBL 3 0 0
K. oxytoca 0 4 4
Microccous 0 1 1
Neisseria lactamica 2 4 6
Pseudomonas aeruginosa 28 30 58
Pseudomonas species 10 4 14
Prevotella buccae 0 1 1
Proteus mirabilis 12 17 29
Providentia rettgeri 2 0 2
Peptostreptococcus 3 3 6
Propionibacterium spp. 14 18 32
Salmonella spp. 5 0 5
Serratia spp. 8 12 20
Staphylococcus aureus 58 41 99
MRSA 12 26 38
Stenotrophomonas maltophilia 2 3 5
Streptococcus pneumoniae 13 10 23
Streptococcus pyogenes 1 1 2
Streptococcus disgalactiae 2 2 4
Streptococcus group G 1 1 2
Streptococcus viridans 15 10 25
Total 531 509 1040
Abstracts of the 16th International Symposium on Infections in the Immunocompromised Host s19
Anaerobic bacteria were: Bacteroides spp (12 isolates), Clostridium spp 
(5 isolates), Propionibacterium spp (38 isolates), Peptostreptococcus 
spp. (3 isolates) and Prevotella spp (1 isolate). Fungi were: Candida 
albicans (12 isolates), Candida spp (12 isolates) and Fusarium spp 
(1 isolate). In a period from 2000 till 2004 there were 8 and in the 
period from 2005 till 2009 there were 16 Candida isolated from blood. 
There haas been isolated a number of less frequent gram negative bac-
teria (Stenotrophomonas maltophilia, Aeromonas hydrophilla, P. cepa-
cia, K. oxytoca, P. rettgeri, S. typhimurium).
Conclusions: There is increase in MRSA and fungi during examined 
period. ESBL are not accounting for majority of isolates. There is high 
variety of microorganisms isolated from oncologic patients with differ-
ent antimicrobial susceptibility pattern.
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Investigation and Control of an Outbreak of  
Multidrug-Resistant Acinetobacter Baumannii Among 
Neutropenic Patients in a Department of Hematology
Nikolaos Neokleous1, Damianos Sotiropoulos1, Antonia Syrigou1, 
Alexandros Ikonomidis3, Eleni Tsorlini2, Spyros Pournaras3, Achilleas 
Anagnostopoulos1.
1Georgios Papanicolaou General Hospital, Dept. of Hematology and 
BMT center, Thessaloniki, GR; 2Georgios Papanicolaou General Hos-
pital, Lab of Microbiology, Thessaloniki, GR; 3School of Medicine, 
University of Thessalia, Lab of Microbiology, Larissa, GR.
Background: Acinetobacter baumannii has become a serious cause 
of nosocomial infections. The aim of this report is to describe a multi-
drug resistant A. baumannii (MRBA) outbreak in the Dept. of Hema-
tology “G. Papanicolaou” Hospital in Thessaloniki, Greece, as well 
as the isolation of the responsible strain, its molecular proﬁle and the 
management of the problem.
Materials: All hospitalized patients with positive culture for MRAB 
during the year 2008 were recorded.
Methods: Blood from peripheral vein or CVC, sputum and urine sam-
ples were collected, repeatedly, from all febrile patients. Swab samples 
were collected from skin lesions and ulcers. Samples were collected 
from beds, chairs, toilets, apparatuses, stethoscopes and personnel 
hands. Species identiﬁcation was carried out by PCR and genetic 
relationship was studied by macrorestriction analysis of chromosomal 
DNA with PFGE. Susceptibility testing to various antimicrobials and 
bactericidal assays were also performed.
Results: Twenty-four patients were affected by A. baumannii. Ten, 
seven and seven of them had positive blood, urine and sputum cultures, 
respectively. 15 isolates showed intermediate sensitivity to Merope-
nem, resistance to Imipenem and sensitivity to Colimycin. Four were 
sensitive to carbapenems and to Colimycin, whereas 5 were sensitive 
only to Colimycin. In all patients, Colimycin in combination with other 
antibiotics was administered intravenously without signs of drug-asso-
ciated severe toxicity. All tested isolates were clonally related with one 
environmental isolate and constitute a subclone. The dispersed geno-
type carried the bla
OXA-69
 allele as well as the bla
OXA-58
 gene coding 
for widely disseminated b-lactamases among that species. 19 patients 
died, 5 of them due to sepsis. Infection control measures including 
isolation, contact precautions, cleaning, educational meetings and cul-
ture screening were immediately applied and were accompanied by a 
decrease in incidence of A. baumannii positive cultures.
Conclusions: MRAB pose a formidable threat to neutropenic patients 
with high mortality rates. More data are needed on the pharmacoki-
netics/pharmacodynamics of available antibiotics, especially under 
the light of the discovery of heteroresistance, and, more research and 
greater emphasis are essential for the prevention of health care associ-
ated transmission.
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Heterogeneity of Internal Transcribed Spacer Region 
Sequence in Rhizopus Microsporus: Implications for 
Molecular Diagnosis
Wan Ting Tam1, Patrick C. Y. Woo1, Shui Yee Leung1, Kelvin, K. W. 
To1, Jasper F. W. Chan1, Antonio H. Y. Ngan1, Vincent C. C. Cheng1, 
Susanna K. P. Lau1, Kwok-Yung Yuen1.
1The University of Hong Kong, Department of Microbiology, Hong 
Kong, CN.
Background: In fungi, the 18S rDNA gene and internal transcribed 
spacer region (ITS) the most widely used targets for molecular identi-
ﬁcation. Although ITS sequence heterogeneity has been reported in a 
few fungal species, it has never been described in members of the order 
Mucorales, the etiological agents of the highly fatal mucormycosis. 
Recently, during the outbreak investigation of intestinal mucormycosis 
due to Rhizopus microsporus in patients with hematological malignan-
cies, 28 strains of R. microsporus were subjected to ITS sequencing. 
In four out of 28 strains, double peaks were frequently observed in 
sequence traces.
Materials: Fungal genomic DNA extraction, PCR ampliﬁcation of fungal 
genomic DNA and sequencing of the PCR product were performed.
Methods: PCR on ITS region of 28 strains of R. microsporus were 
performed. All puriﬁed bands were subjected to ITS sequencing.
Results: Four of the 28 R. microsporus strains, P11, P12, D3-1, and 
D4-1, showed thick bands at about 700 bp. Direct sequencing of the 
puriﬁed bands showed frequent double peaks along all of the sequence 
traces and occasional triple peaks for P12, D3-1, and D4-1. The thick 
bands of the four R. microsporus strains were puriﬁed and cloned. 
Sequencing of 10 clones for each strain revealed two different ITS 
sequences for P11 and three different ITS sequences for P12, D3-1, 
and D4-1. Variations in ITS sequence among the different ribosomal 
DNA (rDNA) operons in the same strain were observed in only ITS1 
and ITS2 and not the 5.8S rDNA region. One copy of P11, P12, and 
D4-1, respectively, and one copy of P11, P12, D3-1, and D4-1, respec-
tively, showed identical sequences.
Conclusions: Here we report the ﬁrst evidence of ITS sequence het-
erogeneity in Mucorales. ITS sequence heterogeneity is an obstacle to 
molecular identiﬁcation and genotyping of fungi in clinical microbi-
ology laboratories. When thick bands and double peaks are observed 
during PCR sequencing of a gene target, such a strain should be sent to 
reference laboratories proﬁcient in molecular technologies for further 
identiﬁcation and/or genotyping.
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Immune Proﬁle in a Population of Lymphoma Patients 
Undergoing High-Dose Chemotherapy with Autologous 
Stem Cell Support
Dag Torfoss1, Ernst Arne Hoiby3, Harald Holte1, Johan Bjerner1, Trine 
Bjøro1, Gustav Gaudernack1, Gunnar Kvalheim1, Tom Eirik Mollnes2, 
Stein K. Valøy1.
1Oslo University Hospital, The Norwegian Radium Hospital, Oslo, 
NO; 2Oslo University Hospital, The National Hospital, Oslo, NO; 
3The Norwegian Institute of Public Health, Oslo, NO.
Background: We wanted to study the laboratory immune proﬁle of 
patients during episodes of febrile neutropenia and correlate the ﬁnd-
ings to the clinical course.
Materials: During the clinical study “Tobramycin once versus three 
times daily, given with penicillin G, to febrile neutropenic cancer 
patients in Norway: a prospective, randomized, multicentre trial” 
(J.Antimicrob.Chemother. 2007; 59: 711-7) blood samples were taken 
from lymphoma patients undergoing high-dose chemotherapy with 
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autologous stem cell support when they developed febrile neutropenia 
and one to two days later.
Methods: The samples were tested for procalcitonin, a 17 cytokine 
proﬁle and mannan-binding lectin (MBL).
Results: Sixty-one patients constituted a homologous population with 
a mild and benign course of febrile neutropenia and then recovering 
as expected. Four patients had a positive blood culture (Gram-posi-
tives only). There was a mild, but signiﬁcant, increase in procalcitonin 
(PCT) and the following cytokines: IL-1beta, IL-4, IL-6, IL-7, IL-8, 
G-CSF, GM-CSF, INF-gamma and TNF-alpha. There was a signiﬁcant 
decrease in IL-5 whilst no change were observed in IL-2, IL-10, IL-12, 
IL-13, IL-17, MPC-1 and MIP-1beta. Six patients were MBL deﬁcient 
( <  100 ng/ml) and another six patients had decreased MBL-values, all 
without a signiﬁcant different clinical course.
Conclusions: The proﬁles of procalcitonin, 17 cytokines and MBL 
suggest a mild proinﬂammatory response in lymphoma patients with 
fever of unknown origin and a benign course of febrile neutropenia 
after high-dose chemotherapy with autologous stem cell support.
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The Impact of Fludarabine-Based Combination Therapy 
on Infectious Complications in Previously Untreated 
Patients with Chronic Lymphocytic Leukemia: Results 
From Serial Cooperative Group Clinical Trials
Vicki Morrison1, Bercedis Peterson1, Kanti Rai1, Richard Larson1.
1Cancer and Leukemia group b, University of Minnesota, 
Chicago IL, US.
Background: Infections remain a common complication chronic lym-
phocytic leukemia (CLL) patients (patients), and is affected by speciﬁc 
treatment agents used.
Materials: -
Methods: We examined infectious complications in previously 
untreated CLL patients enrolled on four sequential Cancer and Leuke-
mia Group B [CALGB] treatment trials.
Results: In CALGB 9011, 188 patients received single agent ﬂudara-
bine (F), serving as the comparitor for three subsequent trials in which 
ﬂudarabine-based combinations were utilized. On CALGB 9712, 104 
patients received ﬂudarabine + rituximab (FR). For CALGB 19901, 
patients received four cycles of F, followed by six weeks (wks) of 
alemtuzumab consolidation (FA); 59/85 enrolled patients received 
A consolidation. On CALGB 10101, patients received six cycles of 
FR induction, followed three months later by six wks of A consolida-
tion. Serious infections, as well as infectious deaths, were tabulated. 
Patients receiving FA had more infections during protocol therapy 
(32/85, 38%)  compared to patients receiving single agent F therapy 
(43/188, 23%, p = 0.01) or FR (21/104, 20%, p = 0.0007). Among 
85 patients treated with F followed by A consolidation, 14 (16%) had 
infections only during F, 14 (16%) had infections only during A, and 
4 (5%) had infections during both phases. No CMV and three PCP 
infections were diagnosed among 188 patients receiving F, compared 
to three PCP and one CMV infection in 104 FR-treated patients. For 
CALGB 19901, 12/59 patients developed CMV infection during A 
consolidation. Lastly, among patients who received FR induction fol-
lowed by A consolidation, seven infectious deaths (EBV viremia/hepa-
titis, transfusion-associated GVHD, Listeria meningitis, Legionella 
pneumonia, PCP, “sepsis”, viral meningitis) were reported in prelimi-
nary toxicity analysis of the ﬁrst 51 patients, ﬁve in partial and two in 
complete remission following FR induction.
Conclusions: The addition of rituximab to F does not increase the risk/
severity of infections in previously untreated CLL patients, but A con-
solidation following initial F-based therapy does have signiﬁcant impact. 
CMI defects caused by A persist after discontinuation of therapy, raising 
implications for prophylactic antimicrobial therapy. Not only conven-
tional outcome data, but also infectious complications, are of importance.
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Clinical Success of Polymyxin B and Amikacin 
Association in the Treatment of KPC-producing Klebsiella 
Pneumoniae Infections in Neutropenic Hosts
Lygia Schandert1, Ingvar Ludwig Augusto Souza1, Maria Daniela Di 
Dea Bergamasco1, Janaina Midori Goto1, Raquel Girardello1, Ana 
Cristina Gales1, Maria de Lourdes Lopes Ferrari Chauffaille2, Paola 
Cappellano1, Carlos Alberto Pires Pereira1.
1Universidade Federal de São Paulo - Escola Paulista de Medicina, 
Department of Infectious Diseases, São Paulo, BR; 2Universidade 
Federal de São Paulo - Escola Paulista de Medicina, Department of 
Hematology and Experimental Oncology, São Paulo, BR.
Background: In Brazilian hospitals, Klebsiella pneumoniae is one of 
the most frequent Gram-negative bacteria causing severe infections 
in the febrile neutropenic patients. KPC-producing K. pneumoniae 
(KPC-KPN) is a worldwide emerging pathogen with serious clinical 
and infection control implications. KPC-KPN is a particular concern, 
especially in the setting of immunocompromised hosts, where the use 
of alternative drugs for treatment of KPC infections might constitute 
an additional risk of side effects and represent a special challenge in 
the management of neutropenic patients.
Abstract 46 – Table 1. Characteristics of Patients
Patient - Age - Sex Site of Infection  Site of Infection  Neutrophil Count Antimicrobial Antimicrobial therapy  Treatment outcome Final outcome 
    (cel/mm3)Ψ theraphy for the KPC-KPN   and comments
    before isolation  infection€
    of KPC-KPNΨ Duration of therapy
1-59-male Acute Myelogenous  BSI  <100 CEF, MER, VAN,   Poly B, AMK 17 days  Clinical improvement Discharge
  Leukemia   dAmpB  and negativation of (Providencia
       posterior cultures also isolated
         as CRBSI
       during length
       of stay)
2-38-male T-cell Acute  BSI <100 CEF, CLA, METR,  Poly B, AMK Clinical improvement Death (septic
  Lymphoblastic   MER, VAN, TEIC,  21 days  and by negativation of shock by
  Leukemia   LNZ, FLUC, dAmpB  posterior cultures Pseudomonas
       and
       Enterococcus
       BSI)
AMK: Amikacin; BSI: Blood-stream infection; CRBSI: Catheter related blood-stream infection; dAmpB: Amphotericin B deoxycholate; LNZ: Linezolide; MER: Meropenem; PolyB: Polymycin B; 
VAN: Vancomycin; CEF: Cefepime; CLA: claritromicin; METR: metronidazol; TEIC: Teicoplamine; FLUC: Fluconazol
ψ: at the onset of the infection; €: immediately after the onset of the infection
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Materials: We report two cases of neutropenic patients diagnosed 
with acute leukemia who developed KPC-KPN bloodstream infections 
(BSI) and were successfully treated at our institution, a teaching Bra-
zilian hospital. The clinical characteristics of the patients are described 
in table 1.
Methods: These two patients had at least one recent infection and were 
receiving extended spectrum antimicrobial therapy, including carbap-
enems, when the KPC-KPN BSI was diagnosed. The mean length of 
stay in our hospital before the diagnosis of KPC-KPN BSI was 30 days. 
One of these patients was critically ill, and was hospitalized in the ICU 
at the time of KPC-KPN BSI diagnosis. The bla
KPC
 was detected by 
polymerase chain reaction (PCR) followed by DNA sequencing. The 
patients received polymyxin B and amikacin association during 17 and 
21 days, respectively, with clinical improvement and bacteriological 
response. The susceptibility phenotipic of KPC-KPN isolates are dem-
onstrated in table 2. 
Results: The patient #1 was discharged 12 days after the end of the 
treatment, while patient #2 died 4 weeks later due to septic shock fol-
lowing another polymicrobial infection caused by Pseudomonas spp. 
and Enterococcus spp.
Conclusions: KPC-KPN is an emerging pathogen associated with 
signiﬁcant mortality and fewer terapeutic options. Our patients were 
successfully treated, with fewer side effects. The emergent of this 
pathogen creates an important challenge for clinicians, especially in 
the management of neutropenic patients.
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Bacillus Species Infection in a Patient with Mediastinal 
Mass
Maria Rosario Muñoz1, Veronica Peña1, Jose Luis Chavez1, Franklin 
Paras2, Rosa Ma Elizondo3, Luis Barrientos1.
1Hospital San Jose-Tec de Monterrey, Critical Care Department, 
Monterrey, MX; 2Instituto Mexicano del Seguro Social, Oncologic 
Surgery, Monterrey, MX; 3Instituto Mexicano del Seguro Social, 
Anesthesiology, Monterrey, MX.
Background: Bacillus species is an aerobic, endospore forming, 
Gram-positive rod. The isolation of Bacillus spp. suggests the pos-
sibility of contamination when recovered from clinical specimens. A 
bacillus isolate is generally considered clinically signiﬁcant when it is 
recovered from at least two blood cultures or isolated in pure culture 
obtained from a surgical specimen during an open surgical procedure 
with clinical evidence of infection at the site.
Materials: A 58-year-old male with mediastinal tumor infected from 
Bacillus species. He had history of moderated alcohol and smoking 
abuse, and was admitted to our department because of fever, diaphoresis, 
malaise, weight loss, diffuse abdominal pain and diarrhea stools in recent 
days. He denied other gastrointestinal and respiratory symptoms.
Methods: A CT scan of chest and abdomen reported posterior medias-
tinal mass and two hypodense lesions at right hepatic lobe were found. 
Blood and urine cultures were negatives. A thoracotomy was per-
formed, a posterior mediastinal tumor was found at the lower lobe of 
left lung of approximately 10 cm diameter. This was punctured yield-
ing turbid material wich was send for culture and a wall biopsy was 
taken reporting metastatic adenocarcinoma. Postoperative remaining 
afebrile. The mediastinal culture was positive for Bacillus spp 4 days 
later, starting treatment with Vancomycin. Subsequently he develops 
fever and severe respiratory distress requiring mechanical ventilation 
support. A CT pulmonary angiogram was performed and revealed the 
presence of a left empyema.
Results: An upper gastrointestinal endoscopy found an exophytic, 
ulcerates and friable lesion on posterior wall of esophagus, with histo-
pathologic report of poorly differtentiated adenocarcinoma.
Conclusions: Infection due to Bacillus spp other than anthracis are 
rare but do occur. The possible source of the infection in our patient-
was the gastrointestinal tract as suggested by the history of diarrhea 
and fever, although the tumor could explain the fever. However, esoph-
ageal perforation may have been a potential route of spread by contigu-
ity to the mediastinal space. 
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Failure of Polymyxin B in Multidrug-Resistant 
Pseudomonas Aeruginosa Bacteremia in Febrile Neutropenia
TT Tan1, Andrea LH kwa1, BH Tan1.
1SGH, Dept of Inf Diseases, Singapore, SG.
Background: Bacteremic infections with Multidrug-resistant Pseudo-
monas aeruginosa (MDR PAE) have increasingly become a matter of 
concern with regards to patients receiving intensive myelosuppressive 
therapy for hematologic malignancies. Intravenous polymyxins have 
Table 2. Susceptibility phenotype? of KPC-producing K. pneumonia 
clinical isolates
Drug Patient 1-Interpretation/  Patient 2-Interpretation/ 
 MIC (mcg/ml) MIC (mcg/ml)
Amikacin  S (< = 8)  S (< = 8)
Gentamicin  R (>8)  S (< = 2)
Ceftriaxone  R (>32)  R (>32)
Ceftazidim  R (>2)  R (>2)
Cefotaxime  R (>32)  R (>32)
Cefepime  R (< = 1)  R (< = 1)
Amoxicillin-Clavulanic  R (<16/8)  R (16/8)
 Acid 
Piperacillin-Tazobactam  R (>64/4)  R (>64/4)
Imipenem  R (>8)  R (>8)
Meropenem  R (>8)  R (>8)
Aztreonam  R (4)  R (4)
Ciproﬂoxacin  R (>2)  R (>2)
R: Resistant; S: Susceptible
∫: Susceptibility test by automatized method BD Phoenix™ Automated Microbiology System 
Figure 1. 
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been advocated as the drug of choice. There is however only limited data 
on its clinical efﬁcacy in neutropenia.
Materials: The clinical and microbiological outcomes of hematologi-
cal patients.
Methods: A retrospective review of MDR PAE bacteremia in a hae-
matology service over a 18 mth period was carried out. The clinical 
and microbiological outcomes of all patients treated with IV poly-
myxins alone or with combinations for MDR PAE bacteremia were 
studied.
Results: Nine patients developed MDR PAE bacteremia during febrile 
neutropenia. Five had acute myeloid leukemia and two had acute 
biphenotypic leukemia, one had precursor acute lymphoblastic leuke-
mia and one had T cell lymphoma. They were receiving induction, 
consolidation or salvage chemotherapy. Two patients were known to 
harbor the organism (one had previous pneumonia, one had a chronic 
leg ulcer) prior to bacteremia. They received intravenous polymyxin 
B alone or in combination for MDR PAE bacteremia. Only one (11%) 
had a positive clinical outcome, surviving beyond 30 days. Micro-
biological clearance was demonstrated in 2 of these patients but one 
patient died within 7 days of blood culture clearance from the under-
lying malignancy. The only patient that survived was administered 
granulocyte transfusion and fortuitously, her absolute neutrophil count 
also improved after that. The overall mortality was 89% (n = 9), with 
seven deaths directly attributable to sepsis from MDR PAE.
Conclusions: Despite the successes reported in the literature with 
polymyxin and the good in vitro activity against MDR PAE, its clinical 
efﬁcacy in neutropenia is doubtful. Such patients should be aggres-
sively treated with combination antibiotics, granulocyte transfu-
sion and removal of all possible foci such as indwelling lines. These 
measures may help to lower the high mortality associated with these 
 infections.
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Episodes of Infection Chronic Lymphocytic Leukaemia 
Treated with Rituximab
Aoife Molloy1, Simone Lanini12, Archie Prentice3, Christopher 
Kibbler1.
1Royal Free Hampstead NHS Trust, Department of Medical 
Microbiology, London, GB; 2L’Istituto Nazionale Malattie Infettive 
Lazzaro Spallanzani, Epidemiology and Preclinical Research  
Department, Rome, IT; 3Royal Free Hampstead NHS Trust, 
Department of Haematology, London, GB.
Background: Chronic Lymphocytic Leukaemia (CLL) is the com-
monest leukaemia in Europe and North America1. Infections are 
major complications of CLL accounting for up to 50% of deaths. 
The immune deﬁciency of CLL is caused by hypogammaglobulinae-
mia, and impaired T-cell function and opsonisation. CLL treatment 
regimens are immunosuppressive and increase the risk of infection2. 
Rituximab, a chimeric monoclonal antiCD20 antibody, is a corner-
stone of CLL treatment3. There are few published data on the effect 
of rituximab-based treatments on infection in CLL4. The aim of the 
study was to describe infection in CLL treated with rituximab and to 
ascertain whether infection or reactivation of infection was inﬂuenced 
by epidemiological and clinical features.
Materials: The case deﬁnition was: all patients aged > 18 years treated 
at Royal Free Hampstead NHS Trust between October, 1st 2006 and 
October, 1st 2009 with a CD20 +  hematologic malignancy who under-
went a treatment protocol including rituximab and received at least 
one dose.
Methods: A retrospective observational study on cases of CLL 
treated with rituximab-based regimens was performed. Pharmacy 
records were searched to identify cases. Data were collected using 
chart reviews and laboratory records. Epidemiological data were 
recorded including date of birth, gender, main haematological diag-
nosis, HBV, HCV, HIV, CMV, VZV, CMV, EBV and HSV-1/2 status. 
Clinical data were collected including baseline blood count, neu-
trophil nadir, fever episodes, chemotherapy protocol followed, anti-
infective prophylaxis, and laboratory data on microbial, mycotic, 
and viral infections. Data were recorded from initiation of rituximab 
treatment to six months following cessation of rituximab. Primary 
outcome: overall number of infective events as: a. Probable (without 
laboratory conﬁrmation); b. Proven (with laboratory conﬁrmation). 
Secondary outcomes:
a. Clinical diagnosis of infection
b. Severity of infections
c. Infectious aetiology
d. Mortality
Results: Two-hundred and ninety-three cases were included and ana-
lysed. This represents one of the largest cohorts of cases. Full results 
will be presented in poster-format.
Conclusions: Infection in CLL treated with rituximab is a signiﬁcant 
challenge.
References:
1. Dighiero G et al. Lancet. 2008 Mar 22;371(9617):1017-29.
2. Tsiodras S et al. Mayo Clin Proc. 2000 Oct;75(10):1039-54.
3. Jaglowski SM et al. Semin Hematol. 2010 Apr;47(2):156-69.
4. Koo S et al. J Natl Compr Canc Netw. 2008 Feb;6(2):202-13.
P50
Fungal Colonization in Laryngectomized Patients with 
Indwelled Voice Prosthesis- Prevalence, Enzymatic 
Activity, Susceptibility to Antimycotics
Magdalena Nowak1, Piotr Kurnatowski2.
1Medical University of Lodz, Department of Biology and Medical 
Parasitology, Lodz, PL; 2Medical University of Lodz, Department of 
Biology and Medical Parasitology, Lodz, PL.
Background: Patients who underwent laryngectomy due to larynx 
cancer have a possibility to regain ability to speak with the use of 
silicone voice prosthesis. However, the lifetime of the device is lim-
ited, and lasts for approximately 3-4 months, mainly due to fungal 
bioﬁlm formation, that subsequently causes deterioration of the 
prosthesis and malfunction of the valve mechanisms. Moreover, the 
fungal bioﬁlm can be reservoir for chronic and systemic infections. 
The aim of following study was to evaluate prevalence, enzymatic 
activity and sensitivity to three antifungal drugs of clinical impor-
tance - ﬂuconazole, itraconazole and ketoconazole, of fungal strains 
that were isolated from laryngectomized patients with implanted 
voice prosthesis.
Materials: Fungal strains were obtained from 4 different places: oral 
cavity, the center of the prosthesis, mucous membrane of trachea next 
to implanted device and the skin around the stoma. Morphological 
and biochemical features of isolated fungal strains were evaluated 
by means of following methods: direct microscopic slides, macro-
cultures in solid Sabouraud medium, API 20 C AUX, API ZYM and 
disc diffusion method for determination of fungi susceptibility to 
investigated drugs.
Results: Out of 171 isolated strains, the predominant species were 
Candida albicans, C. krusei, C. glabrata, C. tropicalis and C. kefyr. 
Detailed data, that contains number of fungal strains from different 
ontocenoses are shown in the table 1. All isolated strains were char-
acterized by the strongest activity of following enzymes: leucine 
arylamidase (6), acid phosphatase (11) and naphthol-AS-BI-phospho-
hydrolase (12). The most active hydrolytic enzymes for the most fre-
quently isolated fungal species are shown on the ﬁgure 1. More than 
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70 % and 69% of strains, that belong to the most frequently isolated 
fungal species, were resistant to ketoconazole and ﬂuconazole, respec-
tively (C. kefyr strains are exception); most of the C. glabrata strains 
were resistant to itraconazole, while other fungal species were inter-
mediate ( C. albicans, C. tropicalis) or sensitive (C. kefyr, C. krusei) to 
mentioned antifungal drug.
Conclusions: Presented data throws light on problems concerned 
fungal colonization on indwelled medical devices and may contribute 
to rational antifungal therapy in patients with indwelled voice pros-
thesis.
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Antifungal Prophylaxis in Paediatric Patients with Acute 
Leukaemia: Experience with Posaconazole
Helen Kennedy1, Brenda Gibson2, Karon McDowall3, Craig 
Williams1.
1Royal Hospital for Sick Children, Microbiology, Glasgow, United 
Kingdom; 2Royal Hospital for Sick Children, Haematology/Oncol-
ogy, Glasgow, United Kingdom; 3Royal Hospital for Sick Children, 
Pharmacy, Glasgow, United Kingdom.
Background: Posaconazole is an orally administered, broad spectrum, 
second generation triazole antifungal agent. Little information exists 
on its use in the therapy or prophylaxis of fungal infections in pae-
diatric patients. The objective of this study was to review the use of 
posaconazole over a two year period commencing February 2008 in 
the paediatric haematology/oncology unit of the Royal Hospital for 
Sick Children, Glasgow with the aims of assessing its effectiveness in 
the management and prevention of fungal infections and determining 
the value of monitoring serum posaconazole levels.
Materials: Patients’ case notes, the laboratory TelePath system and the 
hospital HISS system were consulted.
Methods:  Review of microbiology and ward records including results 
of serum posaconazole levels − determined by the Regional Mycology 
Laboratory, Manchester, UK.
Results: Over the two year period, a total of 9 patients (3 male and 
6 female), median age 5 years (range 3−15 years), being treated for 
haematological malignancy (8 ALL and 1 AML) received posacon-
azole. The majority of these patients had previously experienced 
proven or suspected invasive fungal infection; therefore posacon-
azole was used as secondary prophylaxis to prevent recurrence fol-
lowing further courses of chemotherapy or haemopoietic stem cell 
transplantation. Twenty−two posaconazole levels were determined, 
with a median level of 1.32 mg/L (range < 0.125 mg/L to 3.24 mg/L). 
The drug was well tolerated and for 8 of the 9 nine patients no recur-
rence of primary fungal infection or development of new fungal 
infection occurred.
Conclusions: Although this survey was limited to a small number of 
patients, the beneﬁcial clinical outcomes suggest that posaconazole 
is a promising agent for this paediatric patient population. The oral 
formulation is convenient for use in an out−patient setting. However, 
monitoring of serum posaconazole levels would appear advisable 
because a small number of low levels (< 0.7 mg/L) were detected 
amongst our cases. These ﬁndings prompted a change from a twice 
daily dosing regimen to four times daily − with successful results. 
Large prospective clinical and laboratory studies are warranted to 
evaluate further the usefulness of posaconazole for management and 
prevention of fungal infections in paediatric patients with malignant 
disease.
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Table 1. Number of fungal strains from different ontocenoses
fungal oral the center of mucous skin exchanged sum 
species cavity the prosthesis membrane of around the prosthesis (%)
   trachea stoma
C. albicans 24 14 14 15 1 68
      (40%)
C. famata 0 1 1 1 0 3 
      (2%)
C. glabrata 5 8 5 5  23
      (13%)
C. kefyr 2 0 2 0 3 7 
      (4%)
C. krusei 5 13 13 10 6 47
      (27%)
C. lipolytica 0 1 1 0 0 2 
      (1%)
C. parapsilosis 1 0 1 2 1 5 
      (3%)
C. tropicalis 3 3 3 2 2 13 
      (8%)
S. cerevisiae 2 0 0 0 0 2 
      (1%)
T. cutaneum 0 1 0 0 0 1 
      (1%)
sum 42 41 40 35 13 171
      (100%)
s24 Viral infections including H1N1, HIV, Herpes viruses
Viral infections including H1N1, HIV, Herpes viruses
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Oral Ribavirin in Treatment of Adenovirus Infection 
in Hematologic Patients: Experience from a Brazilian 
University Hospital
Ingvar Ludwig Augusto Souza1, Lygia Schandert1, Janaína Midori 
Goto1, Maria Daniela Di Dea Bergamasco1, Nancy Bellei1, Fábio 
Rodrigues Kerbauy2, José Salvador Rodrigues de Oliveira2, Paola 
Cappellano1, Carlos Alberto Pires Pereira1.
1Universidade Federal de São Paulo - Escola Paulista de Medicina, 
Departament of Infectious Diseases, São Paulo, BR; 2Universidade 
Federal de São Paulo - Escola Paulista de Medicina, Departament of 
Hematology and Experimental Oncology, São Paulo, BR.
Background: Adenovirus (Ads) infections in immunocompromised 
individuals, such as patients with hematologic malignancy and recipi-
ents of hematopoietic stem cell transplants (HSCT), often result in 
severe and potentially life-threatening disease. Despite the high mor-
bidity and mortality, there is no established antiviral therapy for ADV. 
Both successful and failure treatments with ribavirin (RBV) and cido-
fovir have been previously reported.
Materials: During the year of 2009 we prospectively followed three 
patients with compatible clinical presentation and isolation of Ads in 
samples by direct immunoﬂuorescence or viral isolation by analysis of 
cytopathic effect. The demographic and clinical characteristics of these 
patients are described in table 1.
Methods: After the diagnosis, oral RBV 20 mg/kg was started every 
6 hours for 5 days followed by 10 mg/kg every 6h for 4 days. The 
patients were closely followed and new samples were taken to monitor 
response to the treatment. Clinical presentation and outcome are show 
in table 2.
Results: Clinical improvement was observed in two of three patients; 
both of them also had negative samples after the end of the treatment. 
Death occurred in one patient and was related to Pseudomonas aerugi-
nosa blood stream infection, gastro-intestinal GVHD and CMV infec-
tion. Worsening of anemia was observed in two patients, although it 
might have some other causes, such as bleeding and other drugs. All 
patients were using immunosupressors drugs at the onset of infection.
Conclusions: There is no controlled-randomized trial supporting the 
use of RBV in treatment of Ads infections. In vitro data are divergent 
and clinical data are all based on retrospective and observational stud-
ies with conﬂicting results. Side effects are also worrisome, especially 
in hematologic patients; however, current therapeutic options for Ads 
infections are very limited by lack of efﬁcacy or high toxicity. In our 
recent experience we observed clinical improvement of the patients, 
suggesting that use of oral RBV might be an alternative therapy to Ads 
infections, especially in limited sources regions, where it is more avail-
able than intravenous RBV and cidofovir. Further studies are needed to 
clarify the role of oral RBV in Ads infections.
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Cytokine Proﬁles of the Novel Swine-Origin Inﬂuenza 
A/H1N1 Virus: Virus Attenuation and Implications on 
Treatment Strategies
Edward T. K. Tung1, Patrick C. Y. Woo1, Kwok-Hung Chan1, Candy 
C. Y. Lau1, Susanna K. P. Lau1, Kwok-Yung Yuen1.
1The University of Hong Kong, Microbiology, Hong Kong, HK.
Abstract 55 – Table 1. Demographic and clinical characteristics of patients with Adenovirus infections
Patient Age (years)/ Sex Underlying Disease Transplant Recipient Type of Transplant GVHD GVHD Clynical
      Treatment/ Syndrome
      Immunosupressors
1 25/male Aplastic Anemia No NA NA CSA;  URI; 
      Predinisone Pneumonitis
2 52/male Multiple Myeloma Yes Alogenic (related  Acute CSA;  URI
    donnor) Bone Marrow GI GVDH Grade II Methylpredinisolone
3 52/male Chronic Lymphocytic  Yes Alogenic (related donnor)  Treated Skin and Sodium Mycophenolate;  Hemorrhagic
  Leukemia  Bone Marrow GI GVHD Grade II CSA; Predinisone Cystitis
CSA: Ciclosporin; GVHD: Graft-Versus Host Disease; NA: not apliable; URI: Uper Respiratory Tract Infection
Abstract 55 – Table 2. Clinical presentation, diagnosis and outcome of patients with Adenovirus infection
Patient Clinical Diagnosis Ribavirin Clinical/  Death in 30 days Cause of Other Concomitant
 Symptoms Conﬁrmation Side Effects Laboratory Response  Death Infections and 
       Comorbidities
1 Fever; Flu-like;  Identiﬁcation of Adsψ No Clincal Improvement;  No NA No
 Dyspnea; Cought in URT and BLA samples;   Negative samplesψ
  Torax CT compatible†  after 10 days of RBV
    ﬁrst dose
2 Flu-like; severe diahrrea Identiﬁcation of Adsψ Anemia No response; treatment  Yes (20 days P.aeruginosa  CMV Infection;  
 (caused by GI GVHD) in URT  interrupted on the third  after diagnosis  Blood stream GI GVHD
    day; negative URT Ads infection)  infection grade II
    sampleψ after 17 days
3 Fever; Macroscopic Isolation of Ads in Anemia; Increase Clincal improvement;  No NA CMV Infection 
 Hematuria; Abdominal urine (analysis in vitro in creatinin levels no subsequent samples
 Pain of CPE)  avaiable
Ads: Adenovirs; BAL: Bronchoaoveolar Lavage; CMV: Cytomegalovirus; CPE: Cytophatic Effect; DIF: Direct Immunoﬂuorescence; GI: Gastro-intestinal; GVHD: Graft-Versus Host Disease; NA: 
Not Apliable; RBV: Ribavirin; URT: Upper Respiratory Tract
†Multiples micronodules 
ψAnalysis by direct immunoﬂuorescence
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Background: The apparent high mortality associated with the novel 
swine-origin inﬂuenza A/H1N1 virus (S-OIV) in Mexico makes it 
important to understand the cytokine proﬁles induced by S-OIV as 
compared to inﬂuenza A/H5N1 virus (H5N1) and seasonal inﬂuenza 
A/H1N1 virus (H1N1), as it will assist the design of treatment strate-
gies on future cases of S-OIV infections.
Materials: Cytokines and mRNA levels in culture supernatants of 
human macrophages and A549 cells were assayed using the Human 
Cytokine Twenty-Five-Plex Panel (Invitrogen) and real-time reverse 
transcription-PCR respectively.
Methods: We assayed the levels of 25 cytokines and mRNA levels of 
six cytokines in culture supernatants of human macrophages infected 
with H5N1, S-OIV-CA, S-OIV-HK and H1N1 and levels of 25 cyto-
kine in culture supernatants of A549 cells induced by soluble mediators 
from the infected macrophages with or without addition of celecoxib 
and mesalazine.
Results: Among the 25 cytokines assayed, 12 showed detectable levels 
at 12 and/or 24 h in macrophages and/or A549 cells. Among these 12 
cytokines, the levels of eight (IL-2R, IL-6, IFN-α, MIP-1α, MIP-1β, 
IP-10, RANTES and MCP-1) induced by H5N1 were markedly higher 
than those induced by H1N1, S-OIV-CA and S-OIV-HK. The levels of 
each of these eight cytokines were similar among cells infected with 
H1N1, S-OIV-CA and S-OIV-HK. For the other four cytokines (IL-
1RA, IL12p40/p70, IL-8 and MIG), their levels were similar among 
H5N1, H1N1, S-OIV-CA and S-OIV-HK. Among the eight cytokines 
induced by H5N1, six (IL-6, IFN-α, MIP-1β, IP-10, RANTES and 
MCP-1) were suppressed by celecoxib (400 μg/ml) + mesalazine (200 
μg/ml). Among the mRNA levels of the six cytokines assayed, the 
levels of three (TNF-α, IFN-γ and IL-6) induced by H5N1 were mark-
edly higher than those induced by H1N1, S-OIV-CA and S-OIV-HK at 
12 h and 24 h. The mRNA levels of all six cytokines induced by S-OIV-
CA were higher than those induced by S-OIV-HK at 24 h.
Conclusions: No major cytokine storm, as in H5N1 infection, is asso-
ciated with S-OIV infection. The mainstay of treatment for uncompli-
cated S-OIV infections should be antiviral agents instead of antiviral 
plus immunomodulators. For individual S-OIV-infected patients with 
severe primary viral pneumonia, severe sepsis, and multiorgan fail-
ure, immunomodulators may be considered as an adjunctive therapy 
in clinical trials.
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Liver Transplantation for Acute Herpes Simplex Virus 
Hepatitis in an Immunocompetent Host. Case Report and 
Literature Review
Juan Ambrosioni1, Emiliano Giostra1, Laurent Kaiser2, Pascal 
Meylan3, Christian Toso1, Christian van Delden12.
1University Hospital Geneva, Service of Transplantation, Department 
of Surgery, Geneva, CH; 2University Hospital Geneva, Service of 
Infectious Diseases, Geneva, CH; 3Centre Hospitalier Universitaire 
Vaudois, Institut de Microbiologie, Lausanne, CH.
Background: Only 144 cases of acute Herpes simplex virus (HSV) 
hepatitis occurring mainly in immunocompromised patients, of which 
seven required liver transplantations have been reported. Prognosis 
is poor and management not clearly established. We report a case of 
primary HSV-1 hepatitis in an immunocompetent host requiring liver 
transplantation and review the literature.
Materials: Clinical chart and literature.
Methods: Analysis of clinical chart, microbiology and pathology of an 
index case. Review of the literature of HSV hepatitis and liver trans-
plantation.
Results: A 64 year old immunocompetent male was admitted for acute 
hepatitis. He had recently consulted for stomatitis in the absence of 
cutaneous lesions. Screening for viral infections, toxic causes and 
auto-immune diseases was negative. Histopathological examination of 
a liver biopsy revealed areas of diffuse necrosis and intranuclear hepa-
tocellular inclusions. Immunohistochemistry was positive for HSV (in 
absence of speciﬁc IgM and IgG). Despite IV acyclovir the evolution 
was unfavourable requiring emergency liver transplantation. HSV-1 
DNA was detected in plasma at 64.5 millions copies/ml. IV acyclo-
vir was continued followed by oral valaciclovir. Transiently, foscarnet 
was added for suspicion of acyclovir resistance (DNA-positive skin 
lesions appearing during acyclovir therapy). Acyclovir resistance was 
not conﬁrmed and foscarnet discontinued. Acyclovir was continued 
at prophylactic dose. Plasma HSV-DNA became undetectable three 
months post-transplantation and immunohistochemistry for HSV-1-2 
in several graft biopsies was negative. The patient presented several 
complications including rejection and infected biliomas with multiple 
bacteremia, requiring right hepatectomy and leading to death seven 
months post-transplantation. HSV infection represents less than 2% of 
all reported acute liver failures. 79/145 patients were immunocompro-
mised, including 45 SOT recipients. Diagnosis was made at autopsy 
in 55% of cases (80/145). HSV-2 was the responsible agent in 62% 
of cases. Liver transplantation was performed in eight cases, of which 
ﬁve died before 1 year.
Conclusions: HSV hepatitis is a rare disease with poor outcome. It is 
more frequent in immunocompromised hosts. Five out of eight reported 
patients transplanted for HSV hepatitis died during the ﬁrst year post-
transplantation. Plasma viral load seems a useful tool to monitor therapy.
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Novel Role(s) of an Epstein-Barr Virus Lytic Cycle 
Enzyme in Viral Pathogenesis
Joyce Fingeroth1, Mingxia Huang2.
1Beth Israel Deaconess Medical Center/Harvard Medical School, 
Infectious Diseases, Boston, US; 2University of Colorado Health Sci-
ences Center, Biochemistry and Molecular Biology, Denver, US.
Background: T-cell immunodeﬁciency promotes uncontrolled 
Epstein-Barr virus (EBV) replication, expanding the pool of cells prone 
to B-lineage tumors. HAART-mediated T-cell reconstitution dramati-
cally reduced occurrence of EBV + non-Hodgkin lymphomas(NHL) - 
but not EBV + Hodgkin lymphoma(HL). Though HL, is distinguished 
from NHL by several criteria, a major difference is the gross aneu-
ploidy of malignant Reed-Sternberg cells, post-germinal center B-cells 
containing abnormal centrosomes and chromosomes.
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Though latent EBV products clearly promote tumorigenesis, 
accumulating evidence suggests abortive replication and lytic cycle 
proteins also play key roles. The lytic enzyme EBVTK-DUB is both 
a modest dT-kinase(TK) and an ubiquitin protease(DUB). Detected 
in the virion, EBVTK-DUB interacts with multiple virus/cellular 
proteins forming a “hub” in the viral interactome. How these interac-
tions regulate virion production is unknown. We found unique among 
herpesvirus(HV) proteins, BVTK-DUB strictly localizes to centro-
somes. Strikingly, upon lytic induction, EBVTK-DUB is detected in 
centrosomes with structural and numerical abnormalities. The centro-
some, master regulator of the microtubular cytoskeleton, controls the 
cell division cycle: perturbation of centrosome content produces errors 
in cycling, cytokinesis and chromosome segregation, promoting aneu-
ploidy and tumorigenesis.
Materials: Uncover the role(s) of EBVTK-DUB in control of lytic 
cycle infection, development of centrosome abnormalities and as an 
antiviral target.
Methods: Recombinant wild type and mutant enzymes were gener-
ated (standard/ eGFP-fused) and expressed in different mammalian 
and yeast cells to determine the relationship between dT-kinase activ-
ity, DUB activity, localization and perturbation of centrosome/micro-
tubule function by functional assay and advanced microscopy.
Results: Unlike alphaHVs, this gammaHV enzyme encompasses 
N-and C-terminal domains. The C-terminus though homologous to 
alphaHV polynucleoside kinases, is a strict dT-kinase, unable to phos-
phorylate purine analogs (e.g. ganciclovir), as demonstrated using puri-
ﬁed enzyme, EBVTK-DUB expressing cells and TK- virus. Although 
the C-terminal kinase is necessary and sufﬁcient for dT phosphoryla-
tion, the N-terminus cooperates to support centrosome localization. 
Localization is highly conserved as transfected enzyme can home to 
the spindle pole body and alter the growth characteristics of yeast 
checkpoint mutants. Mutant analysis indicates kinase, but not DUB 
activity is closely associated with localization, suggesting EBVTK-
DUB may temporally regulate the lytic cycle not only by providing 
dTTP for viral DNA synthesis but also by salvaging critical centro-
somal proteins from degradation – though only so long as cellular dT 
is available to sustain replication.
Conclusions: EBVTK-DUB supports multiple functions that coordi-
nate lytic replication. Abortive replication and/or aberrant EBVTK-
DUB expression may predispose to centrosome dysregulation and 
tumorigenesis. EBVTK-DUB is an important target for development 
of cytotoxic antiviral therapy.
Acknowledgements: We thank Xiaomin Zhao and Anne-Laure Das-
sier for technical assistance.
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Inﬂuenza-Associated Morbidity in Children with Cancer: 
Experience at the University Children’s Hospital of 
Münster, Germany
Sophie Jocham1, Dirk Holzinger1, Birgit Fröhlich1, Andreas H. Groll1.
1Children’s University Hospital, Infectious Disease Research Pro-
gram, Department of Pediatric Hematology/Oncology, Muenster, DE.
Background: Inﬂuenza is an important cause of respiratory tract 
infections. However, little data exist on the impact of inﬂuenza in 
immunocompromised children with cancer and/or HSCT. We therefore 
analyzed morbidity and mortality from inﬂuenza infections at a single 
large pediatric cancer center with 150 new cancer diagnoses per year.
Materials: none
Methods: Cases of laboratory-documented inﬂuenza infection in 
patients receiving care at the Department of Pediatric Hematology/
Oncology between September 2005 and March 2010 were identiﬁed 
by review of laboratory and medical records. Using a standardized case 
report form, we analyzed virologic and demographic characteristics, 
presentation, need for hospitalization, antiviral treatment, delay in anti-
cancer treatment, and outcome.
Results: During the observation period, 26 patients (male, 18; female, 
8) had 29 laboratory-conﬁrmed inﬂuenza infections. Three of the 
infections were nosocomially acquired. The median age at  diagnosis 
was 8.5 years (range, 2 – 18). There were 15 episodes of seasonal 
inﬂuenza A, 7 episodes of new inﬂuenza A (H1N1; all in 2009), and 7 
episodes of inﬂuenza B infection. The majority of patients (n = 23) had 
hematological malignancies or bone marrow failure; 6 of the patients 
were status post allogeneic HSCT and received immunosuppressive 
therapy with cyclosporine A and/or methylprednisolone. The most fre-
quent symptoms at presentation were cough (n = 29), fever (n = 27), 
malaise (n = 15), and vomiting and diarrhea (n = 6). Eleven of the 29 
episodes (38%; two ICU admissions) resulted in hospital admission 
with a median length of stay of 6 days (range: 1 - 43). In 11 of 23 
episodes in patients receiving antineoplastic chemotherapy, antican-
cer treatment was delayed for a median of seven days (range, 4 - 38).
Twelve of 29 inﬂuenza-episodes were treated with antiviral agents. 
Outcome was ultimately favourable in 27 episodes but two patients 
died from respiratory causes in association with the inﬂuenza episode 
(inﬂuenza B; oseltamivir resistant new inﬂuenza; 6.8%).
Conclusions: Inﬂuenza in children with cancer and/or HSCT may 
cause signiﬁcant morbidity resulting in excess hospitalization, delays 
in anticancer treatment, and infectious mortality. Careful attention to 
standard preventative measures and utilization of antiviral chemother-
apy for treatment are readily available but possibly underused tools to 
improve control of the disease.
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Background: In 2009 the world faced the H1N1 pandemic and many 
young children, pregnant women and healthy young adults have 
died. Little is known about the presentation and outcome of H1N1 in 
immunosuppressed patients. Brazil had around 30 thousand conﬁrmed 
H1N1 cases. Our objective is to describe the H1N1 infections diag-
nosed in our hospital within the last year.
Materials: Every year, 300 new patients are admitted to the Pediatric 
Oncology Institute; 35 stem cell transplants are performed, including 
unrelated donor transplants.
Methods: Since June, 2009, every patient with an axillary tempera-
ture > 38oC, cough and dyspnea had a nasal swab sent to Inﬂuenza 
A – H1N1 RT-PCR. Patients who were also neutropenic or who had 
pulmonary inﬁltrates were admitted and received PO Oseltamivir and 
IV broad spectrum antibiotics.
Results: From July, 29 through December 31, 2009, 25 children were 
admitted to the hospital due to severe respiratory symptoms (7), neu-
tropenia (16), or interstitial pulmonary inﬁltrates (8). Three of them 
were transplant patients but H1N1 was not conﬁrmed in any of them. 
The median duration of symptoms prior to investigation was 2 days. 
Five patients had the nasal swab done more than 48h after the onset 
of symptoms (1/6 H1N1 positive and 4/19 H1N1 negative). A total of 
6 patients had H1N1 conﬁrmed. Their mean age was 10 years. Three 
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had solid tumors, two acute leukemia and one lymphoma. Four of the 
six patients with H1N1 were neutropenic. One had diarrhea. Three had 
lobar pulmonary inﬁltrates and one of them also had Haemophylus 
inﬂuenza bacteremia; this was the only positive blood culture. None of 
the patients with conﬁrmed H1N1 pneumonia had either respiratory 
failure or fatal outcome. Symptoms resolved in all patients within 1-7 
days (median 3 days).
Conclusions: The incidence of H1N1 was much lower than expected. 
We speculate that pediatric oncology and stem cell transplantation 
patients and families have a high awareness of health risks and may 
have protected the children from contact with potentially infected 
peers, including the use of N-95 masks in transplant recipients. One 
possible limitation of the study is the lack of systematic nasal swab for 
other respiratory viruses. The incidence of secondary bacterial infec-
tions was low. Half of the H1N1 cases had lobar pulmonary inﬁltrates 
and we do not know if was only due to the viral infection. All, includ-
ing the latter patients had favorable outcome with complete resolution 
of the symptoms within few days.
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Cytomegalovirus Disease in the First Sixth Months after 
Kidney Transplantation
Michael Greiner1, Alexia Cusini1, Melanie Ruesch1, Thomas Fehr2, 
Rudolf Wüthrich2, Bruno Ledergerber1, Nicolas Mueller1.
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Background: The optimal strategy to prevent Cytomegalovirus (CMV) 
disease after kidney transplantation is debated. The pre-emptive approach 
requires regular determination of CMV viremia and prompt initiation of 
therapy.
Materials: Single center study, retrospective analysis with a pre-
deﬁned questionnaire. Ethics approvals was obtained.
Methods: We retrospectively compared two periods at our center: 
A ﬁrst period (P1, n = 84 kidney recipients) where intensity of sur-
veillance was determined by the responsible physician with a second 
period (P2, n = 74), where a stringent protocol of CMV surveillance 
was required for all patients. The pre-emptive approach was applied 
for all CMV risk groups, prophylaxis was optional in case of rejec-
tion treatment or delayed graft function in the intermediate and high 
risk group. Follow-up was truncated at 6 months post-transplant. 
CMV syndrome was differentiated from asymptomatic replication by 
the presence of at least one systemic symptom, while CMV end organ 
disease required histological conﬁrmation. Only biopsy-proven rejec-
tions were used for analysis. Fisher’s exact and Wilcoxon rank-sum 
tests were used to compare periods.
Results: Gender, cause of kidney failure, median age and percentage 
of living donation were comparable between P1 and P2. Percentage 
of CMV risk groups (high: donor (D) + / recipient (R) -, intermediate 
(R + ) and low (D-/R-) were comparable. Initial immunosuppression 
was similar in the two periods. Prophylaxis was used equally (26% in 
both periods). Asymptomatic viremia episodes were detected in 41% 
in P1 and in 39% in P2 (p = ns). More CMV syndromes (14.2% vs 
3%, p = 0.020) were observed during P1, as were end organ disease 
episodes (P1: 7.1% vs. P2: 2.7%), but this difference was not signiﬁ-
cant. Rejection episodes were comparable between episodes (P1: 42% 
vs. P2: 39%).
Conclusions: Using a very stringent protocol, the number of CMV 
disease episodes (CMV syndrome, CMV end organ disease) was 
substantially reduced. The rate of rejection episodes was comparable 
between the two periods. This study highlights the crucial importance 
of a stringent protocol with optimal adherence by all caregivers if the 
pre-emptive strategy is to be successful.
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Background: HIV-infected individuals are considered a group at risk 
for more severe seasonal inﬂuenza infection and therefore should 
receive annual doses of inﬂuenza vaccine. However, the capacity of 
individuals to respond to vaccines with appropriate titers depends 
on the degree of immune compromise at the time of immunization. 
The objectives of this study were: 1)To evaluate the immunogenic-
ity of inﬂuenza vaccine in 38 HIV-infected patients in comparison to 
29 uninfected subjects 2) To identify viral agents causing respiratory 
symptoms during the follow-up.
Materials: Both groups received immunization against seasonal inﬂu-
enza virus recommended to 2008.
Methods: Antibody response against B, H1N1 and H3N2 antigens was 
measured in blood samples drawn 1-2 h before the vaccination and after 
30 to 60 days. Antibody titers ≥ 1:40 were considered protective. Respi-
ratory symptom surveillance was done by phone calls, once a week, 
during 24w after vaccination. In symptomatic subjects, respiratory 
samples were taken for respiratory virus (RV) detection by direct immu-
noﬂuorescence assay and PCR. The following RVs were investigated: 
inﬂuenza (INF) A and B, parainﬂuenza 1, 2 and 3; adenovirus (ADV), 
metapneumovirus (MPV) and respiratory syncytial virus (RSV).
Results: Median age of participants was 13 (10-18) years. RV 
were identiﬁed in 9/63 episodes (14%) of respiratory infection in 
HIV-infected individuals (8 ADV; 1 MPV)., and in 9/33 episodes 
(27%) in HIV uninfected subjects (6 ADV, 1 MPV, 1 INF B and 1 
ADV + MPV co-infection). The vaccine protection according to anti-
gens was: HIV Group: H1N1 Pre = 12(32.4%), Post = 25(67.5%); 
N3N2 Pre = 13(35.1%),Post = 28(75%), B = Pre 28(75.7%), Post = 28 
(75.7%), Control Group: H1N1 Pre = 7(24.1%), Post = 28(96.6%); 
H3N2 Pre = 9(31%), Post = 27(93.1%), B Pre = 17(58.6%), 
Post = 21(72.47%)
Conclusions: There was no difference in pre-vaccination values for all 
3 antigens between the study groups.The control group had a greater 
increase in H1N1 and H3N2 values after immunization. There were 
few episodes of RVs during the follow-up and the adenovirus was the 
most prevalent agent identiﬁed.
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Immunocompromised Patients
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Background: AH1N1 pandemic had its own problematic clinical, 
prognostic and treatment view in immunocompromised patients. The 
aim:to give data from our Clinic of Infectious Diseases about swine 
s28 Viral infections including H1N1, HIV, Herpes viruses
inﬂuenza in immunocompromised patient during May 2009-January 
2010.
Materials: Eighty-four immunocompromised patients from 446 con-
ﬁrmed cases with Inﬂuenza AH1N1.Immunodeﬁciency was because 
of: Diabetes, cardiac diseases (HTA, valve pathology and cardiac 
insufﬁciency), pulmonary diseases, corticoid therapy, transplantations, 
HIV infection, chronic hepatic diseases and chemotherapy.
Methods: We determined the causative illnesses of immuno deﬁ-
ciency, the respiratory involvement (alveolar, interstitial or mixed 
pneumonia), its gravity (Acute Respiratory Insufﬁciency-ARI), etio-
logic therapy, need for supportive therapy, mortality and its cause
Results: Nine from 24 cases with diabetes had bronchopneumonia, 8 
had interstitial and 7 alveolar pneumonia. 6 of them developed ARI:3 
of them got CPAP and 3 invasive oxygen therapies. 2 cases died:1 had 
secondary staphylococcal pneumonia, the other interstitial neumonia; 
16 of 21 patients with cardiac diseases developed alveolar pneumonia, 
5 of them interstitial pneumonia complicated with ARI (2 cases had 
cardiac insufﬁciency, 2 cases have had valve replacements and 1 HTA). 
Oxygen therapy was successful (3 with facial mask and 1invasive); 
1 of 3 chronic hepatitis cases (2 from HVB and 1 from HCV) was 
pre-cirrhotic and developed ARI; 5 of 16 cases with bronchial asthma 
had alveolar pneumonia, 3 cases had mixed and 8 interstitial pneumo-
nia.6 of them were ARI complicated that improved after non-invasive 
oxygen therapy. 2 of 3 cases after transplantation (1 case after bone 
marrow and 2 after renal transplant) developed ARI from interstitial 
pneumonia; CPAP gave good results. None of 8 HIV infected cases (5 
cases HIV positive and 3 cases AIDS under ART) developed ARI, even 
5 of them had interstitial and 3 had alveolar pneumonia. 3 of 7 patients 
under corticoid therapy developed ARI.Facial mask oxygen was suc-
cessful. None of 2 cases under chemotherapy developed severe ﬂu. All 
cases got oseltamivir.
Conclusions: We distinguished 8 reasons of immunodeﬁciency: dia-
betes in 28.5% of cases, cardiac diseases 25%, chronic hepatitis 3.57%, 
pulmonary diseases 19%, transplantation 3.57%, HIV infection 9.5%, 
corticoid therapy 8.3%, chemotherapy 2.3%. 27.3 % of immunocom-
promised patients developed ARI. Oxygen therapy was successful in 
88.3% of ARI patients. Mortality rate was 2.3%.
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Multidermatomal Herpes Zoster in Iris of Visceral 
Leishmaniasis
Entela Kolovani1, Dhimiter Kraja1, Ergys Ramosaco1, Majlinda 
Kokici2.
1University Hospital Center, Infectious Diseases, Tirana, AL; 
2University Hospital Center, Clinic Laboratory, Tirana, AL.
Background: Visceral Leishmaniasis is one of the cellular immuno-
defﬁciency causes. Immune Reconstitution Inﬂammatory Syndrome 
(IRIS) is an immuno-infective event that takes place in patient initiat-
ing ART. There are not enough data about IRIS after VL treatment. 
The aim is to make evident the presence of IRIS even after initiating 
VL treatment in an immunocompromised Leishmania positive patient.
Materials: A case with Visceral Leishmaniasis
Methods: We evaluated the clinical, biological, immunological and 
therapeutic evolution of our patient in clinics and followed him up for 
a month after.
Results: Our patient was admitted to hospital presenting a 7 days 
history of high fever, vomits, weakness, oropharingeal candidiasis, 
hepato-splenomegalia. On laboratory exams he presented anemia and 
leucopenia. He was negative for HIV infection, negative for brucellosis 
and ELISA IgM positive for Leishmaniasis. Bone marrow aspiration 
revealed amastigotes and the presence of hemophagocytosis. CD4 + 
was 290cells/μL. We started treatment with progressive increasing 
doses of Meglumine antimoniate (glucantime), which lasted 28 days. 
The patient had a very good response during therapy. 9 days after 
dehospitalisation (which means 37 days after initiating VL treatment), 
the patient developed a multidermatomal thoracic Herpes Zoster (Th1-
Th4), with conﬂuent, non-haemorrhagic vesicles, painful, not com-
plicated with changes in Cerebrospinal Fluid and well inﬂuenced by 
antiviral treatment with acyclovir. By that time the CD4 +  level was 
486cells/ μL and actually is getting increased (698 cells/ μμL one month 
after).
Conclusions: 1. VL hardly compromised the cellular immunity of 
our patient. 2. IRIS is a possible event during VL. 3. Thoracic Herpes 
Zoster was the manifestation of IRIS. 4. Herpes Zoster gravity was 
mild-to-grave. 5. Acyclovir obviously improved the clinical view of 
Herpes Zoster.
P65
Pregnancy: A Condition that Raised the Mortality from 
AH1N1
Ergys Ramosaco1, Dhimiter Kraja1, Entela Kolovani1, Arben Ndreu1.
1University Hospital Center, Infectious Diseases, Tirana, AL.
Background: Previous seasonal inﬂuenza epidemics and even the 
swine pandemic have shown that pregnant women are subjects of risk 
for severe prognosis. Physical mechanisms (fetal growing inﬂuences 
in pushing up mother’s lungs and reducing their functional abilities) 
and immune mechanisms (pregnancy is accompanied by changes in 
immune system of mother) are involved in those reasons. The aim of 
this study is to introduce Albanian data of AH1N1 pandemics in preg-
nant women as a risk group.
Materials: Twenty-nine pregnant women, of 18-31 years old, part of 
446 conﬁrmed cases with AH1N1 ﬂu, attended during May 2009 till 
January 2010.
Methods: We deﬁned pregnancy age, the clinical variant of pulmo-
nary involvement, the gravity, pulmonary and extrapulmonary com-
plications, etiologic treatment, supportive treatment (oxygen therapy 
with facial mask, CPAP, tracheal intubation), deaths reasons and rate. 
We attended birth process and after birth course of mothers.
Results: We had 10 women on ﬁrst trimester (34.4%), 12 on the 
second (41.2%), 7 on the third (24.2%). On ﬁrst trimester: 5 cases 
with trachea-bronchitis, 3 with bronchopneumonia and 2 with pneu-
monia. 3cases with trachea-bronchitis did not take oseltamivir, 2 cases 
with pneumonia got facial mask oxygen therapy, 1 case with Landry 
Syndrome got invasive oxygen therapy. On second trimester: 6 cases 
with trachea-bronchitis, 3 with bronchopneumonia, 3 with pneumo-
nia, 3 cases with trachea-bronchitis did not take oseltamivir; we had 
1 case that got oxygen therapy with facial mask and 1 with invasive 
oxygen. On third trimester: 4 cases with trachea-bronchitis, 1 with 
bronchopneumonia, 2 with pneumonia.We did not give oseltamivir to 
1 case with trachea-bronchitis. 1 case got oxygen with facial mask, 
1 CPAP and 1 invasive. We had 3 deaths: 1 case 5 months pregnant 
with alveolar-interstitial pneumonia, 1 case 8 months pregnant with 
mix pneumonia and 1case 2 months pregnant with Acute Respiratory 
Insufﬁciency and Landry Syndrome. 2 cases had premature births that 
delivered on 6th and 8th month. It relieved respiratory insufﬁciency of 
mothers.
Conclusions: 
1.  We distinguished 3 respiratory involvements: trachea-bronchitis 
51.6%, bronchopneumonia 24.2% and pneumonia 24.2%
2.  69% of cases got oseltamivir
3.  We had two severe complications: ARI 27%, Landry syndrome 
3.4%.
4. Mortality in pregnant women from AH1N1was 25%.
5. Mortality in invasive oxygen therapy women was 100%.
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6.  Mortality in pregnant women was 18% of total mortality from 
AH1N1.
7. Birth relieved ARI of pregnant women.
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Inﬂuenza a H1N1 Pandemic Infection in Oncologic 
Patients
Ligia Camera Pierrotti12, Cilmara Polido Garcia1, Marcelo Bellesso1, 
José Antonio Atta1, Ludhmila Abrahão Hajjar1, Juliana Pereira1, Maria 
Del Pilar Estevez1, Paulo Marcelo Gehm Hoff1, Maria Aparecida 
Shikanai-Yasuda2, Edson Abdala12.
1Instituto do Cancer do Estado de São Paulo, Sao Paulo, BR; 2Facul-
dade de Medicina da Universidade de Sao Paulo, Molestias Infeccio-
sas, Sao Paulo, BR.
Background: Epidemiological, virological and clinical data about 
H1N1 pandemic infection in immunocompromised patients are 
needed.
Materials: Describe a series of oncologic patients with H1N1 pan-
demic infection that required hospitalization.
Methods: Review from institutional database and electronic patients 
charts. Speciﬁc diagnosis deﬁned as a positive nasal swab PCR. Flu 
syndrome deﬁned as fever, cough and/or sore throat; severe respiratory 
disease as fever higher than 38oC, cough and dyspnea.
Results: From July 24th to September 30th 2009, 114 patients were 
investigated; 18 (15.8%) conﬁrmed. Clinical manifestations in table 1. 
Five patients (27.8%) died. Oncologic diseases were: gastrointestinal 
(4), breast (3) and hematological (5). Four patients had metastases; 6 
received chemotherapy and 1 radiotherapy in the last three months. 
Radiological ﬁndings were mainly interstitial-alveolar (44.4%). Lym-
phocytes less than 1000 cel/mm3 was detected in 11 patients; 3/5 obits 
had lymphopenia. Nine patients required ICU; 5 of 6 who required 
mechanical ventilation died. Time between symptoms onset and start 
of oseltamivir in table 2; mean therapy length was 6.2 days (2-10); 3.75 
days among 5 obits. Prolonged viral shedding was investigated in 6 
patients - 3 negative (5, 7 and 15 days after ﬁrst oseltamivir dose) and 
3 positive (5, 7 and 8 days after).
Conclusions: We did not include outpatients because in our country 
most of the time PCR was available only for those requiring hospi-
talization a despite of clinical suspicion and oseltamivir prescription. 
An important challenge was recognized atypical clinical presentation 
including acute respiratory distress without fever among our patients 
leading us to consider that we probably lost opportunity to make diag-
nosis in some other cases. For both reasons, we were not able to know 
the real impact of H1N1 pandemic infection. We recognize however 
that, among our hospitalized patients, mortality rate was higher than 
reported recently in hematological cancer patients.
References:
Redelman-Sidi et al. 2009 H1N1 inﬂuenza infection in cancer patients and he-
matopoietic stem cell transplant recipients. J Infect 2010;60(4):257-63.
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Comparison of Current Standard Testing and PCR for the 
Diagnosis of CMV Pneumonia by Bronchoalveolar Lavage 
in HCT recipients
Giovanna Travi12, Steven Pergam13, Hu Xie1, Terry Stevens-Ayers1, 
Tracy Hayes1, Meei-Li Huang14, Veronique Erard5, Michael Boeckh13.
1Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer 
Research Center, Seattle, US; 2San Raffaele Scientiﬁc Institute, De-
partment of Infectious Diseases, Milan, IT; 3University of Washing-
ton, Department of Medicine, Seattle, US; 4University of Washington, 
Department of Laboratory Medicine, Seattle, US; 5Centre Hospitalier 
Universitaire Vaudois, Lausanne, CH.
Background: A diagnostic test for cytomeglovirus pneumonia (CMV-
IP) needs to be both rapid and sensitive, as prompt diagnosis and treat-
ment improves survival. The purpose of our study was to assess how 
PCR from bronchoalveolar lavage (BAL) in hematopoietic cell trans-
plant (HCT) patients with known CMV-IP compared with rapid non-
molecular tests for viral infection.
Materials: We utilized a single center retrospectively collected cohort 
of HCT recipients who were diagnosed with CMV-IP by standard 
methods (Ljungman CID 2002), had stored BAL ﬂuid available for 
analyses, and were transplanted between 1988-2007.
Methods: For the purposes of analyses standard BAL tests were 
categorized as rapid tests (shell vial [SV], cytology, and/or direct 
ﬂuorescent antigen testing [DFA]), and late tests (tube culture and 
histopathology). To compare PCR to standard tests, CMV viral load 
(log10) was assessed on archived BAL samples, and the median viral 
loads for rapid tests and late tests were compared by the Wilcoxon rank 
sum test.
Results: We identiﬁed 112 subjects with CMV-IP in this cohort, of 
whom standard rapid tests (SV, DFA and/or cytology) from BAL 
were positive in 105/112 (94%) subjects; SV was positive in 103/109 
(94%) samples, DFA in 26/89 (29%), and cytology in only 8/112 
(7%). PCR could be quantiﬁed in 107/112 (96%) of samples, with a 
median of CMV viral load of 4.29 log10 copies/ml (IQR 2.78-6.29); 
in an addition, 2 patients had CMV DNA detected but viral load was 
Table 1. Clinical manifestations of H1N1 pandemic infection
Clinical manifestations Total N (%) Mortality N (%)
Flu syndrome 6 (33.3%) 1 (16.7%)
Severe respiratory disease 9 (50.0%) 4 (44.4%)
Others (cough; cough/dyspnea; no fever) 3 (16.7%) 0
Table 2. Time between symptoms onset and antiviral 
therapy
Time (hours) Total N (%) Mortality N (%)
Less 48 9 (50.0%) 0
48 to 96 6 (33.3%) 3 (50.0%)
More than 96 3 (16.7%) 2 (66.7%)
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below level of quantiﬁcation. Median viral load among those posi-
tive for SV (4.85 [IQR 3.09-6.40]) was similar those detected by 
tube culture (4.87 [IQR 3.17-6.49]), but different in those positive by 
DFA (6.58 [IQR 5.66-6.96]) and cytology (6.97 [IQR 5.96-7.71]). A 
delayed diagnosis of CMV-IP occurred in 7/112 (7%) samples with 
negative rapid tests but positive late tests; PCR detected 5/7 (71%) of 
these late cases. CMV-IP cases detected by standard rapid tests had 
a signiﬁcantly higher median viral load (4.79 [IQR 3.04-6.37]) com-
pared to those diagnosed by late testing 2.09 (IQR 0-3.64) (p = 0.003) 
(Figure 1).
Conclusions: CMV PCR in BAL identiﬁed the majority of CMV-IP 
cases, as well as most that were missed by standard non-molecular 
methods. Additional studies are needed to deﬁne the threshold that 
separates CMV-IP from pulmonary shedding.
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Causative Pathogens of Fever in Neutropenic Patients at 
King Chulalongkorn Memorial Hospital
Chusana Suankratay1, Pitiya Roongpoovapatr1.
1Chulalongkorn University Hospital, Division of Infectious Diseases, 
Department of Medicine, Bangkok, TH.
Background: Infections cause substantial morbidity and morbidity in 
neutropenic patients. In our institute, Gram-negative bacteria remained 
the most common causative pathogen of febrile neutropenia in all three 
studies conducted before 2002. However, Gram-positive bacteria have 
become more commonly isolated etiologic pathogens, and the inci-
dence of fungal infection has been increasing since 2005.
Materials: Our study was aimed to determine the infectious etiology 
of fever in neutropenic patients at King Chulalongkorn Memorial Hos-
pital, Bangkok, Thailand.
Methods: A retrospective chart review of all medical records of febrile 
neutropenic patients hospitalized at Dept. of Medicine during a 1-year 
period in accompanying with microbiologic, radiologic, and serologic 
results was analyzed.
Results: There were 125 patients (61 males and 64 females) and 172 
episodes of febrile neutropenia with a mean age of 46.5 ± 18.5 years 
(range: 15-81 years). The three most common primary diseases associ-
ated with neutropenia were acute myeloid leukemia, non-Hodgkin’s 
lymphoma,and acute lymphoblastic leukemia (36.6%, 33.1%, and 
10.5%). Infections could be documented microbiologically and clini-
cally in 84 episodes (48.8%), and primary bacteremia or fungemia was 
the most common cause of infection (40.5%). Gram-negative bac-
teria were the most frequently isolated pathogens (63.9%), followed 
by Gram-positive bacteria (29.9%) and fungi (6.2%). Escherichia 
coli (46.8%) and coagulase-negative Staphylococcus (27.6%) were 
the most common isolates among Gram-negative and Gram-positive 
bacteria, respectively. Among 53 episodes (30.8%) of bloodstream 
infections, Gram-negative bacteria were the most commonly isolated 
pathogens (38 episodes, 71.7%), followed by Gram-positive bacteria 
(19 episodes, 35.8%) and Candida tropicalis (1 episode, 1.9%). Sur-
prisingly, invasive mold infections were noted in 8 episodes (5, 1, and 
2 episodes of proven, probable, and possible infections, respectively). 
The overall mortality was 19.2%.
Conclusions: Although Gram-negative bacteria are still the most 
common etiology of fever in neutropenic patients, the occurrence of 
infections caused by coagulase-negative Staphylococcus and molds 
has been increasing in comparison with the observations from previ-
ous studies in our institute. To our knowledge, our study is the ﬁrst 
in Thailand to determine the occurrence of invasive fungal infections 
using the standard criteria recommended by EORTC/MSG.
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Investigation of Hepatitis B Virus and  
Hepatitis C Virus Infections by Using Serological and 
Molecular Methods among the Hemodialysis  
Patients
Ayla Ergani1, Hadiye Demirbakan2, Huseyin Kocak3, Murat Tuncer4, 
Gozde Ongut5, Halide Akbas6, Asuman Yavuz7, Bulent Yildirim8, 
Dilek Colak5.
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CNRS,, Paris, FR; 2Sehitkamil State Hospital, Central Laboratory 
Division of Microbiology, Gaziantep, TR; 3Mardin State Hospital, 
Internal Medicine, Nephrology Unit, Mardin, TR; 4Medical Park, 
Nephrology, Antalya, TR; 5Akdeniz University School of Medicine, 
Medical Microbiology, Antalya, TR; 6Akdeniz University School of 
Medicine, Biochemistry, Antalya, TR; 7Ataturk State Hospital, Inter-
nal Medicine, Antalya, TR; 8Akdeniz University School of Medicine, 
Internal Medicine, Gastroenterology, Antalya, TR.
Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) 
are the most common cause of hepatitis in hemodialysis (HD) patients 
with end stage renal disease. Atipical serologic proﬁles are seen when 
diagnosing these infections in hemodialysis patients. Aim of this study 
was detection of serological HBV and HCV markers, viral loads, 
serum aminotransaminases levels and identiﬁcation of HBV and HCV 
genotypes in HD patients.
Materials: Two hundred and one HD patients from three different HD 
centre in Antalya are included to our study. The HBV and HCV sero-
logic proﬁles, ALT and AST levels, viral load analysis of HBV and 
HCV of the patients are investigated. Also the genotypic analysis of the 
positive results for HBV and HCV is performed.
Methods: ALT and AST levels were measured by spectrophotomet-
ric methods (Roche Modular System, Mannheim, Germany) quan-
titatively. HBsAg, anti-HBs, anti-HBc total antibody and anti-HCV 
were invesitigated by enzyme immunoassays (Roche Modular Analyt-
ics E170 Assay, Mannheim, Germany for HBV markers and Abbott 
AxSYM, Abbott Park, IL, USA for anti-HCV, respectively) accord-
ing to manufacturers recommendation. Nucleic acids were extracted 
automatically by BioRobot EZ1 System (Qiagen, USA) using with 
EZ1 Virus Mini Kit (Qiagen, USA). HBV DNA and HCV RNA were 
investigated by real-time PCR methods (RealArt HBV RG RT PCR, 
Qiagen, Germany and RealArt HCV RG RT PCR, Qiagen, Germany).
In addition, HBV DNA was investigated in all sera by nested PCR 
for detection of occult HBV infection. Positive PCR products were 
sequenced (Beckman Coulter DNA Sequencer, USA) for genotype 
analysis.
Results: According to our results; at least one HBV marker sero-
positivity rate was calculated as 49.8% without vaccinated patients’ 
results. HBsAg and HBV DNA positivity rates were 2.5% and 2.5% 
respectively. Out of 22 of 38 anti-HCV positive patients were HCV 
RNA positive. However anti-HCV antibody negative three patients had 
positivity of HVC RNA, too. Anti-HCV and/or HCV RNA positivity 
rate was 20.4%. HBV and HCV coinfection rate was 11.9%. Occult 
HBV infection was detected in one patient. Genotype D in HBV DNA 
positive samples and genotype 1b in HCV RNA positive samples were 
detected.
Conclusions: In conclusion; HBV DNA and HCV RNA investigation 
is necessary in HD patients even other viral serological markers are 
negative.
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The Interaction between Ampicillin/Sulbactam and Assays 
for Aspergillus Galactomannan and 1,3-Beta-D-Glucan in 
Patients without Risk Factors for Invasive Aspergillosis
Gokhan Metan1, Cigdem Agkus1, Ayse Nedret Koc2.
1Erciyes University, Infectious Diseases and Clinical Microbiology, 
Kayseri, TR; 2Erciyes University, Microbiology and Clinical Microbi-
ology, Kayseri, TR.
Background: Antibiotics derived from fungi including ampicillin/sul-
bactam might be associated with false positivity of assays for aspergil-
lus galactomannan (GM) and 1,3-Beta-D-Glucan (BDG). The purpose 
of this study was to investigate the interaction between intravenous 
ampicillin/sulbactam treatment and GM and BDG tests.
Materials: Patients without known risk factors for IFI and who were to 
receive ampicillin/sulbactam monotherapy were considered eligible.
Methods: Serum samples were obtained both before and after antibi-
otic infusion on the ﬁrst, third, seventh and tenth days of a ampicillin/
sulbactam treatment course and four days after the last dose. GM was 
determined by Platelia Aspergillus ELISA (Bio-Rad Laboratories) and 
BDG was assayed using the Fungitell kit (Associates of Cape Cod, 
East Falmouth, MA) according to manufacturers’ speciﬁcations. Four 
vials of ampicillin/ sulbactam were also tested for GM and BDG. 
Statistical analyses were performed with SPSS for Windows (version 
15.0; SPSS, Chicago, IL). Median and interquartile ranges were used 
as descriptive methods.
Results: Nine patients with a median age of 56 (16-81) were included 
in the study. Five of the patients were female. All patients received a 
daily dose of 3 × 2 g ampicillin/ sulbactam from different batches for 
soft tissue infections and surgical debridmant was performed in three 
patients. A total of 81 serum samples were collected from 9 patients. 
When a cut-off level of ≥ 0.5 (1) was used for GM positivity, six serum 
samples were positive. There were no statistically signiﬁcant differ-
ences in the median GM indices or median BDG levels of the various 
sampling times. However, 31 of 78 serum samples were positive for 
BDG at athreshold of 80 pg/mL (2). None of the ampicillin/sulbactam 
vials tested positivefor GM or BDG.
Conclusions: After rulling out fungal infections and all known poten-
tial causes of false BDG positivity, surgical gauzes and environmental 
contamination remained possible causes of BDG reactivity. We didn’t 
observe any signiﬁcant interaction between ampicillin/ sulbactam 
administration and Aspergillus GM and BDG assays. Positive results 
for these tests should be evaluated cautiously in patients at high risk for 
IFI receiving ampicillin/ sulbactam.
Acknowledgements: This study was supported with a grant from Erci-
yes University Scientiﬁc Research Unit.
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Gram-Negative Bacilli Bacteremia Cause False Positivity of 
1,3-Beta-D-Glucan Test?
Gokhan Metan1, Ayşe Nedret Koç2, Cigdem Agkus1, Emine Alp1, 
Fatih Kurnaz3, Serdar şıvgın3, Leyla Gul Kaynar3, Orhan Yildiz1, 
Bulent Eser3, Mustafa Cetin3, Ali Unal3.
1Erciyes University, Faculty of Medicine, Infectious Diseases and 
Clinical Microbiology, Kayseri, TR; 2Erciyes University, Faculty of 
Medicine, Microbiology and Clinical Microbiology, Kayseri, TR; 
3Erciyes University, Faculty of Medicine, Hematology, Kayseri, TR.
Background: Measurement of 1,3-beta-D-glucan (BDG), a cellwall 
polysaccharide component of most fungi in serum is an important 
method for the diagnosis of invasive fungal infections (IFI). However, 
there are some clinical circumtances which cause false positivity of 
BDG.
Materials: The purpose of this study was to investigate the interaction 
between Gram-negative bacilli bacteremia and BDG test.
Methods: The records of the Infection Control Comittee was reviewed 
to identify the patients with bacteremia who were hospitalized in 
heamatology ward and stem cell transplantation unit between Septem-
ber 2008 and November 2009. BDG was assayed using the Fungitell 
kit (Associates of Cape Cod, East Falmouth, MA) according to manu-
facturers’ speciﬁcations. The cut-off for BDG positivitiy was 80 pg/
mL (1). Patients who had at least one BDG measurement in 3 days 
before or after the positive blood culture were included in the study. IFI 
was classiﬁed as proven or probable on the basis of criteria established 
by the European Organization for Research and Treatment of Cancer/
Mycoses Study Group (2)
Results: Sixty bacteremic episodes (34 Escherichia coli, 10 Klebsi-
ella pneumoniae, 2 Klebsiella oxytoca, 2 Enterobacter cloacae, 1 E. 
coli + E. cloacae, 6 Pseudomonas aeruginosa, 3 Acinetobacter bau-
mannii, 1 Stenotrophomonas maltophilia, 1 Burkholderia cepacia) 
were identiﬁed in 54 patients. Ten patients with one bacteremic epi-
sode were excluded due to unavailability of BDG, and two excluded 
due to missing clinical data. BDG positivity was detected in serum of 
two patients with E. coli bacteremia, in two with K.pneumoniae, one 
with K. oxytoca and one with polymicrobial (E. coli + E. cloacae) bac-
teremia. Of the six patients, only one patient had BDG levels over 80 
pg/mL despite having no evidence of IFI.
Conclusions: Our study suggests that Gram-negative bacilli bactere-
mia is a very rare clinical condition associated with BDG reactivity.
References:
1) Persat F, Ranque S, Derouin F, et al. Contribution of the (1-- > 3)-beta-D-
glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 
2008; 46: 1009-13.
2) De Pauw B, Walsh TJ, Donnely JP, et al. Revised Deﬁnitions of Invasive 
Fungal Disease from the European Organization for Research and Treat-
ment of Cancer/Invasive Fungal Infections Cooperative Group and the Na-
tional Institute of Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–21.
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Sepsis Caused by Coagulase Negative Staphylococci is 
Associated with the lcaA and Aap Genes
Tatjana Tracevska12, Iveta Liduma12, Ugis Bers2, Diana Platace3, Aija 
Zilevica1.
1University of Latvia, Faculty of Medicine, Riga, LV; 2Bionalytical 
Methods Laboratory, Riga, LV; 3Riga Stradins University, Dept of 
Microbiology, Riga, LV.
Background: Coagulase Negative Staphylococci (CoNS) are the main 
cause of intravascular or catheter-related infections (bacteraemia, 
sepsis) in intensive care and surgery units. We attempt to develop a 
PCR based diagnostic tool for virulent staphylococci, particularly, for 
methicillin resistant CoNS, using bioﬁlm formation factors encoded 
by the icaA and aap genes.
Materials: In this study, 22 among 46 isolates were clinical specimens 
of CoNS, mostly Staphylococcus epidermidis, isolated from i.v. cath-
eter or blood of patients in case of bacteraemia and sepsis were anal-
ysed. The clinical group was presented by 15 male and 7 female from 
four hospitals of Latvia, with the mean age of 61. The control group 
of 24 cultures of S.epidermidis from normal ﬂora (nose epithelium) 
was included. It was represented by 20-22 years old healthy people not 
involved in public health care.
Methods: Susceptibility was tested by the standard agar disk diffusion 
test. Methicillin susceptibility was conﬁrmed by the mecA gene PCR, 
the icaA and aap genes were detected by PCR.
Results: The results of methicillin susceptibility by cefoxitin disc 
diffusion method and mecA-PCR correlated in 100 % for resistant 
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isolates. There was disagreement in 3 cases; the isolates detected by 
disc as methicillin susceptible were positive for mecA gene, pointing 
at resistance. The presence of potential markers such as ica and aap 
genes were compared between clinical and control groups. In clinical 
group, 13.6% of isolates were positive for icaA (icaA + ) and 40.9% of 
isolates were positive for aap gene (aap + ). In control group, 12.6% of 
specimens were icaA +  and 25% were aap + .
Conclusions: The results of mecA-PCR indicate that it is a reliable 
tool for methicillin resistance in CoNS. Our data indicates that strains 
involved in sepsis infections were more positive for icaA and aap 
genes, but rare for two genes together (icaA + /aap + ). The percent of 
aap gene was higher in clinical group comparing to the control group, 
pointing on the role of aap gene in bloodstream infections. In previous 
studies, were showed the prevalence of icaA + /aap +  in case of wound 
infections. Therefore, additional screening will be done. We suppose 
that detection of colonization by icaA + /aap +  strains after the ﬁrst 
eight hours of admission to the unit could help to evaluate the potential 
risk of infection by CoNS.
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Rhinocerebral Mucormycosis in a Patient without Risk 
Factors
Maria del Rosario Muñoz1, Natalia Elias2, Jose Luis Chavez1, 
Ezequiel Herrera4, Yolanda Arce3, Luis Barrientos1.
1Instituto Tecnologico y de Estudios Superiores de Monterrey, Critical 
Care Department, Monterrey, MX; 2Hospital Christus Muguerza, U 
de Monterrey, Internal Medicine Division, Monterrey, MX; 3Univer-
sidad Autonoma de Nuevo Leon, Infectious Diseases, Monterrey, MX; 
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Background: Mucormycosis infection is the second most common 
cause of ﬁlamentous fungal infection in the immunosuppressed 
patient. Neutropenia due to hematologic diseases or chemptherapy is 
one of the most important risk factors, as well as uncontrolled diabe-
tes, HIV, organ transplantation, drug abuse, glucocorticoid treatment, 
deferoxamine use, burns and trauma. The diagnosis of mucormycosis 
without immunosuppresion is rare.
Materials: We present the case of a 35-years old male with fatal rhino-
cerebral mucormycosis and without predisposing medical conditions. The 
patient is admited to our unit two weeks after he participates in a motor 
vehicle accident in wich he suffers a grade II hepatic laceration, pulmo-
nary contusion, pelvic and femur fractures without any trauma facial.
Methods: Five days prior to his arrival to our medical center he pres-
ents progressive color changes in his nasal septum next to the NG tube 
and growing facial edema. At his arrival to our unit the patient was 
conscient, hemodynamically stable with SpO2 > 95% while breathing 
room air and had diffuse non-tender swelling involving both cheeks 
and eyelids. The swelling did not permit the patient to open his eyes or 
swallow. Amphotericin B and wide spectrum antibiotics were initiated 
in advance to performed a wide surgical debridement and tracheos-
tomy. In the ICU the patient is kept under mild sedation, opioid based 
analgesia and multiorgan support, maintaining glucose levels at 120-
140 mg/dl. His HIV status was negative and testing was positive for 
mucormycosis. Thirthy six hours after his ﬁrst debridment there was 
an increase of the necrotic area and a CT scan of paranasal sinuses 
reports pansinusitis. Therefore, a second debridement is carried out 
and Amphotericin B is substituted for Posaconazole.
Results: His course is torpid and complicated by progressive multi-
organ failure, including neurologic symptoms and dies ten days later
Conclusions: This case is an atypicial presentation and shows the 
changing spectrum of invasive fungal infections in immunocompetent 
patients. Tha lack of risk factors for mucormycosis can delay an early 
diagnosis and timely treatment, thereby increasing its mortality.
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Effects of Human Polymorphonuclear Neutrophils Alone 
or in Combination with Amikacin against Pseudomonas 
Aeruginosa Bioﬁlms
Athanasios Chatzimoschou1, Elpiniki Georgiadou1, Thomas J. Walsh2, 
Emmanuel Roilides1.
1Aristotle University of Thessaloniki, 3rd Department of Pediatrics, 
Thessaloniki, GR; 2National Institute of Health, Immunocompromised 
Host Section,, Pediatric Oncology Branch, Bethesda, MD, US.
Background: Chronic Pseudomonas aeruginosa airway infections 
remain the primary cause of morbidity and mortality in the cystic ﬁbro-
sis (CF) patients. The growth state of Pseudomonas aeruginosa in CF 
airways consists of a bioﬁlm (BF), which differs from that exhibited 
under conventional susceptibility testing conditions. Within the BF, P. 
aeruginosa cells are protected from Polymorphonuclear neutrophils 
(PMN), and exhibit a high level of resistance to antimicrobial agents. 
We examined the in vitro activity of PMNs alone and in combination 
with Amikacin (AMK) against P. aeruginosa BF and compare them to 
their planktonic (PL) counterparts.
Materials: Two clinical P. aeruginosa isolates, a resistant (AMKR, 
MIC:64mg/l) and a susceptible (AMKS, MIC:8mg/l), derived from 
two CF patients.
Methods: Both isolates were grown by incubation in cation-adjusted 
Mueller-Hinton broth in 96-well ﬂat-bottomed plastic plates under 
constant shaking for 48 hours at 37oC in order to form BF. PMNs from 
healthy donors at an effectors to target (E:T) ratio of 1:10 or 1:20 were 
incubated further for 24 hours alone or in combination with 2, 8 or 
32mg/l of AMK. Percent damage of BF or PL was assessed by XTT 
assay. Damage > 50% indicated drug susceptibility. Synergy was con-
cluded when the observed bacterial damage was signiﬁcantly higher 
to the expected sum of damages, respectively; whereas, additivity was 
deﬁned when the observed bacterial damage was signiﬁcantly higher 
than each component but where synergy was not achieved. ANOVA 
(n = 6) with Dunnett’s test was performed.
Results: PMNs induced lower percent damage to BF than to PL cells 
of both isolates (at 1:10 ratio, mean ± SE: 20.0 ± 3.3 versus 15.0 ± 2.4, 
p < 0.05 for AMKR; 27.0 ± 2.9 versus 13.0 ± 1.8, p < 0.001 for AMKS). 
AMK at 8mg/l for AMKS (54.0 ± 3.2 versus 26.0 ± 5.8) and at 32mg/l 
for both isolates (42.0 ± 2.5 versus 33.0 ± 1.6 for AMKR and 57.0 ± 4 
versus 40.0 ± ± 4.6 for AMKS) induced lower damage (p < 0.001) to 
BF than to PL cells. The combined effects of PMNs with various con-
centrations of AMK for both isolates on damage of BF was lower than 
that on the damage of PL cells (p < 0.005). Synergy was observed 
when PMNs (at 1:10) were combined with AMK (8 or 32mg/l) for both 
AMKR and AMKS isolates in BF and PL cells.
Figure 1. 
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Conclusions: BF of both resistant and susceptible isolates are signiﬁ-
cantly less susceptible to PMNs and to AMK than are PL cells. Both 
PL and BF growth forms of the resistant P. aeruginosa are less suscep-
tible to AMK than that of the susceptible organism. Synergy is exhib-
ited between PMNs and AMK in BF and PL cells.
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In Vitro Activities of Three Antipseudomonal Antibiotics 
Against Pseudomonas Aeruginosa Bioﬁlms
Athanasios Chatzimoschou1, Elpiniki Georgiadou1, Emmanuel 
Roilides1.
1Aristotle University of Thessaloniki, 3rd Department of Pediatrics, 
Thessaloniki, GR.
Background: Pseudomonas aeruginosa is the main cause of chronic 
airway infection in cystic ﬁbrosis (CF) patients. CF airway bacteria 
are rarely eradicated by antibiotics due to their ability to form bioﬁlms 
(BFs). We aimed to examine the in vitro activities of 3 antipseudo-
monal antibiotics, amikacin (AMK), ceftazidime (CEF) and ciproﬂox-
acin (CIP), against P. aeruginosa BF and compare these activities to 
those of their planktonic (PL) counterparts.
Materials: Six CF clinical isolates of P. aeruginosa, either resistant 
to AMK (AMKR), CEF (CEFR), CIP (CIPR), or susceptible to AMK 
(AMKS), CEF (CEFS), CIP (CIPS) were used.
Methods: The isolates were grown by incubation in cation-adjusted 
Mueller-Hinton broth in 96-well plastic plates under constant shaking 
for 48h at 37oC in order to form BF. BFs were then incubated with no 
drug (controls) or with two-fold dilutions of AMK, CEF or CIP rang-
ing from 0.5-512 mg/l further for 24 hours susceptibility testing of PL 
cells for all antibiotics was performed using the CLSI broth micro-
dilution and XTT methods. Percent BF damage was assessed colori-
metrically by XTT assay. BF MIC was deﬁned as the least antifungal 
concentration causing > 50% reduction in the metabolic activity of BF 
compared to controls. Measurements were performed 6 times [table 1].
Results: BF MICs of resistant isolates were similar to those of PL 
MICs, whereas in the case of susceptible isolates BF MICs were rela-
tively higher than those of P. aeruginosa MICs. Eradication of PA BFs 
was not achieved even at the highest concentrations of antibiotics used.
Conclusions: Variable differences were found among MICs of the 
three antipseudomonal agents for BFs and PLs of susceptible and 
resistant P. aeruginosa isolates. Even very high concentrations do not 
achieve eradication of P. aeruginosa, suggesting a possible mechanism 
of P. aeruginosa persistence in the respiratory tract of CF patients.
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Disseminated Invasive Aspergillosis in a Transient 
Immunocompromised Host
Valentina Ruxandra Moroti Constantinescu1, Victoria Arama1, 
Adriana Hristea1, Arthur Istvan Luka1.
1Matei Bals National Institute for Infectious Diseases, Bucharest, RO.
Background: Aspergillus spp., ubiquitous microorganisms, are one of 
the most frequent causes of invasive infection in immunocompromised 
hosts, with a high mortality rate, caused partly by the subjacent pathol-
ogy, by the difﬁcult early diagnosis and treatment management.
Materials: We present a case of a disseminated invasive aspergillosis 
(cerebral, ocular, pulmonary and soft tissues determinations) in a mild 
transient immunocompromised patient, previously healthy, having as 
risk factors a hepatic failure due to an acute hepatitis B and a 3 weeks 
corticoid therapy. A 53 year old male was admitted in Matei Bals INBI 
for a severe form of acute hepatitis B. Physical exam revealed jaun-
dice. Lab ﬁndings: ALT 4000 U/L, total bilirubin 14mg/dl, INR 2, pos-
itive HBsAg and IgM HBc. Due to the hepatic failure and the severe 
and progressive jaundice, he received prednisone 0.5 mg/kg.
Abstract 75 – Table 1. 
mg/l AMKR AMKS CEFR CEFS CIPR CIPS
PL MIC (CLSI) 64 8 64 4 32 2
PL MIC (XTT) 128 8 128 4 32 2
BF MIC (XTT)  128 32 128 8 64 8
Concentration at 512 512 128 256 512 512
 maximal BF 
 damage
Maximal BF  92.4 + /   92.3 + / 78.0 + /  97.4 + /  95.1 + /  94.2 + /
damage -2.3% -3.2% -1.9% -4.3% -5.6% -2.9% Figure 2. 
Figure 1. 
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A routine chest Xray 3 weeks for admission revealed multiple nod-
ules up to 5 cm in both lungs. He was stable, jaundice was almost 
remitted, had no complaints, no fever, no rales. The bronchoscopy and 
BAL were not conclusive. 4 weeks after admission he complained of 
acute loss of left eye vision with pain, objectively iridocyclitis and 
hypopion. After 2 other weeks he developed subcutaneous lesions on 
the abdomen and calf which spontaneously drained important amount 
of gray creamy puss, revealing numerous fungal ﬁlaments with posi-
tive cultures for Aspergillus ﬂavus. We completed the exams with a 
cerebral MRI (showing multiple cortico and subcortical lesions up to 
2.5 cm) and galacto-mannan serum antigen (GM) - positive
Methods: The diagnosis of invasive disseminated aspergilosis was 
conﬁrmed by the detection of Aspergillus ﬂavus in the soft tissues 
septic metastases, the serial GM positive, suggestive thoracic scan and 
cerebral MRI.
Results: We ceased steroids and initiated treatment with voriconazole 
for 18 months, monitored by serial weekly GM (negative after one 
month) and imagistic exams. The evolution was slowly favorable. At 
the end and 6 months after treatment, cerebral MRI and thoracic CT 
scan revealed complete resolution.
Conclusions: The optimal treatment duration in invasive aspergillosis 
with cerebral involvement remains unclear, order of years. Prolonga-
tion of therapy beyond the resolution of all lesions appears to be a 
meaningful approach.
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The impact of Human Factors and Devices in reducing the 
incidence of Catheter Associated Bloodstream Infections 
(CA-BSI)
Carlos I Bustamante1, Simon E Edelstein1, Catherine Copeland1, 
Jacqueline Grant1, Lilian Martinez1, Mary Prinzivalli1, Doris 
Webberly1.
1Memorial Regional Hospital, Infection Control, Hollywood, 
Florida, US.
Background: Memorial Regional Hospital (MRH) is a 690 Facility 
providing complex acute medical care services to adults and children. 
In 2006 the yearly rate for CA-BSI was 6.38 per 1000 central line 
days. MRH committed to reducing patient morbidity and mortality by 
at least 20% over two years. MRH targeted CA-BSI. Data in this pre-
sentation relates to the adult inpatient population.
Materials: From Jan 2006- Sept 2007, hospital-wide CA-BSI incidence 
trended downwards, following implementation of catheter insertion and 
care bundles, decreasing rates of CA-BSI to 3.47 per 1000 lines days. 
Targeting Zero CA-BSI rates MRH introduced a neutral displacement 
needleless valve connector, with some concerns regarding the valve’s 
surface design and possible contamination of the syringe or IV tubing 
tips during connection which required a 45 degree angle approach. 
Within 3 months the incidence of CA-BSI rose to previous levels.
Methods: The temporal association between the new device and 
increasing CA-BSI rates prompted Hospital Administration and Infec-
tion Control to seek and implement an alternate safer device, introduc-
ing a second luer-access split septum device. A three month trial of the 
new device began January 2008.
Results: In the ﬁrst three months of the trial (Jan-Mar 2008) the 
CA-BSI rate fell to 2.32 per 1000 line days. At the end of 2008 our 
rate rate was 1.97 and in 2009 the rate dropped even furher to 1.22 
per 1000 central line days, due to ongoing education on line care and 
access and continued use of the split-septum IV connector. To date, 
a lower mean monthly incidence of CA-BSI has been sustained. We 
subsequently introduced the new split-septum device into our Pediat-
ric Hospital.
Conclusions: Ongoing surveillance of hospital-wide CA-BSI inci-
dence allows real-time recognition of and response to increased infec-
tions. MRH’s experience highlights the importance of monitoring 
the impact of any new device and demonstrates that committed and 
accountable Adninistrative Leadership and Infection Prevention Teams 
are critical in our quest for zero infections.
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Multi-Drug Resistant Acinetobacter Baumannii Infections 
in ICU and the Use of Polymyxins
Ling Li Min1, Joey Chan2, Michelle WL Tan3, Ng Tat Ming3, Jonathan 
Tan4.
1Tan Tock Seng Hospital, Infectious Diseases, SIngapore, SG; 2Tan 
Tock Seng Hospital, Microbiology, SIngapore, SG; 3Tan Tock Seng 
Hospital, Pharmacy, SIngapore, SG; 4Tan Tock Seng Hospital, Anaes-
thesiology, SIngapore, SG.
Background: To optimize management of multi-drug resistant organ-
isms associated infections within ICUs at TTSH; a multi-disciplinary 
initiative was commenced from January 2009. We observed a signiﬁ-
cant number which are multi-drug resistant Acinetobacter baumannii 
(MDR AB) related and describe these infections
Materials: nil
Methods: 23.4% of the local ICU isolates with Acinetobacter bau-
mannii are multi-drug resistant; susceptible only to polymyxin. The 
multi-disciplinary approach allows regular reviews of patients with 
MDR AB infections by a team of infectious diseases(ID) physician, ID 
pharmacist and microbiologist.
Results: From January to December 2009, 46 patients sustained infec-
tions from MDR AB; 5 patients had ≥ 2 infections. The most common 
were respiratory infections (n = 40), followed by bacteraemias (n = 4) 
and urinary tract infections (n = 4). Others include intra-abdominal 
infections (n = 3), osteomyelitis (n = 3), soft tissue infections (n = 3) 
and meningitis (n = 2). All were nosocomial infections. 26 of 46 
patients were post surgery, 13 had diabetes, 5 had malignancies and 
4 were HIV positive. 28 patients received polymyxin B, 5 had inhaled 
colistin and 8 received polymyxin and colistin. Duration of therapy 
with polymyxin B and colistin ranged from 1 to 35 days and 1 to 14 
days, respectively. Polymyxin B dosing were adjusted to creatinine 
clearance. Adverse effects such as neurotoxicity and nephrotoxicity 
were not documented. 5 patients did not receive therapy. All patients 
had been in ICU for a mean of 26 days. APACHE II scores ranged from 
13 to 40. All were ventilator dependent and 18 were on inotropes. All 
received antibiotics prior to developing MDR AB infections; carbap-
enems and beta-lactam/beta-lactamase inhibitor combinations were 
most commonly prescribed. Crude mortality was 76%.
Conclusions: MDR AB-related nosocomial infections within TTSH’s 
ICUs are signiﬁcant. Treatment options are limited and outcomes remain 
poor. Adverse effects associated with polymyxins seem infrequent in our 
series. Combined efforts of ICU multi-disciplinary team, anti-microbial 
stewardship and infection control to reduce these infections are ongoing. 
However, until this is achieved, it is necessary to derive an algorithm for 
empiric polymyxin and routine susceptibility testing for tigecycline for 
MDR AB in clinically signiﬁcant isolates from ICUs.
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Elastase and Alkali Protease Enzyme Activity Research in 
Pseudomonas Bacteria which were Isolated from Clinical 
Samples
Güven Uraz1, Berrin Çelik2.
1Gazi University, Biology, Ankara, TR; 2Gazi Mustafa Kemal Devlet 
Hastanesi, Microbiology, Ankara, TR.
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Background: Pseudomonas are the opportunist pathogen microorgan-
isms. These bacteria realize their infection by the help of virulence 
factors produced by them. Elastase and alkali protease enzymes play 
a fundamental role in pathogenesis of pseudomonades. Proteases 
(elastase, alkali protease) affect IgG, elastin, collagen and proteins. In 
this study, for this reason, elastase and alkali enzyme activities play-
ing a fundamental role in virulence of Pseudomonas bacteria were 
studied. 104 Pseudomonas were isolated from clinical samples. 100 
P.aeruginosa, 3 P.ﬂuorescents, and 1 P.putida were studied in these 
bacteria. BD BBL Crystal ID semiautomatic system was used as well 
as classical methods for deﬁning of bacteria.
Materials: Medium that contains nutrient agar, noble agar and elastin 
enzyme was used in the research of elastase existence in Pseudomonas 
bacteria in this study.
Methods: Elastase activity of each isolate was evaluated as semi-
quantitative by measuring of precipitation zone diameter BHI was 
used for research of alkaline protease existence in the study. Superna-
tant liquid which was prepared from bacteria suspension was separated 
and dilutions in PBS (Phosphate Buffer Saline) were made. Skim milk 
as 3% and BHI bouillon were mixed then the prepared bacteria suspen-
sion put in to the tiny pits opened on the medium that was prepared 
by adding agar in proportion of 1.5%. Following this, zone diameters 
were evaluated by measuring.
Results: Elastase enzyme activity of 104 clinical Pseudomonas bac-
teria was found positive at 82 strain (78.84%). In this study, alkaline 
protease activity was found positive (71.15) in 74 Pseudomonas iso-
lates out of 104.
Conclusions: Alkaline protease and elestase activity are very impor-
tant in Pseudomonas isolates.
References:
Leone, I., Chirillo, M, G., Raso, T., Zucca, M., Savoia, D., “Phenotypic and ge-
notypic characterization from cystic ﬁbrosis patients”, Eur. Journal of Clinical 
Microbiology Infection Diseases., 27: 1093-1099 (2008)
Burke,V., Robinson, J, D., Richardson, C, J,L., “Bundell,C,S., Longitudinal 
studies of virulence factors of Pseudomonas aeruginosa corneal infections”, 
Pathology., 23: 145-148 (1991)
Rust, L., Pesci, E, C., Iglewski, B., “Analysis of the Pseudomonas aeruginosa 
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Determination of Brucella Presence using 
Spectrophotometer and Comparison to the Milk Ring Test
Güven Uraz, Pelin Özdemir, Gülseren S¸en, Ebru Yilmaz
Gazi University, Faculty of Art and Science, Department of Biology, 
06500 Teknikokullar/Ankara, Turkey.
Background: Brucellosis is one of the most important zoonotic in the 
world. Brucellosis is transmitted through contaminated and untreated 
milk and by direct contact with infected animals. In Turkey, especially 
in rural areas milk is an important source of infection. The Milk Ring 
Test (MRT) is an important test for determining Brucellosis. The fac-
tories which process milk have been using this test for many years. 
Brucella antibodies can be determinated in infected animals milk with 
MRT. Therefore, IgG in milk can be determinated the presence of Bru-
cella with ELISA method. ELISA method is often used for determina-
tion of Brucellosis.
Methods: In this study milk samples were collected in  diffferent regions 
of Ankara and Brucella was determinated by ELISA method and MRT. In 
this study; totally 90 milk samples were analysed by ELISA method and 
MRT in order to determinate Brucella presence. Each milk sample was 
brought in 100 ml of sterile bottles to the laboratory. Each milk sample 
was taken into 2 ml sterile Eppendorf tubes using pipette. After that, 
milk samples were kept in the deep freeze at -20 ° C. NovaTec Immun-
diagnostica GmbH (Germany) was used in this study for ELISA. The 
test values obtained from the Nova Tec Immundiagnostica GmbH were 
measured spectrophotometrically in ELISA reader with 450/620 nm 
wave length. Brucella Milk Ring Test antigen is a painted suspension 
which is used for diagnosis of B.abortus and B.melitensis. In this test 
1 ml milk is placed in a test tube and a drop of Brucella antigen was 
dropped on milk. After that,  tubes were incubated  at 37 OC, 1 hour. At 
the end of incubation the reactions were positive which shown the dark 
red colour on top of the milk.
Results: Ninety milk samples were studied using the Brucella IgG 
positivity by ELISA method and MRT. None of the milk samples 
were positive for Brucella IgG antibodies by ELISA. 16 (17.8%) 
of 90 samples were determined as positive (+) for Brucella with 
MRT.
Conclusion: IgG, IgM, IgA can determinate in milk of infective ani-
mals with MRT.  Only IgG  can be determined in milk with ELISA 
method.
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The Research of Bioﬁlm in Staphylococcus Isolated from 
Clinical Samples by using Spectrophotometer
Güven Uraz, Derya Ünal
Gazi University, Faculty of Art and Science, Department of Biology, 
06500 Teknikokullar/Ankara, Turkey.
Background: The extracellular matrix structure formed by microor-
ganisms that ensures adhesion to the surfaces and each other and has 
different phenotypes is a bioﬁlm. The microorganisms in this bio-
logical structure are protected from the effects of antibiotics. Also, 
bioﬁlm structure protecting the microoorganisms from phagocyto-
sis and degranulation, obstructing chemotaxis, inhibition to effect 
of neutrophile, reducing activity of lymphocyte and in this way, 
increasing virulence of the microorganisms. In the last 10 years, 
number of researches about bioﬁlm structure and phenotype have 
increased. Even though some of bioﬁlms protect the organisms, they 
may cause serious disease, especially in immunosuppressed patients 
or in patients with medical appliances. Staphylococcus species 
adhering and forming bioﬁlm on these medical appliances cause 
most diseases. 
Methods: In this research we studied biofilms in Staphylococ-
cus isolated from different clinical samples and supposed as 
 contaminants. In bood, wound, conjunctival swab, pus, urine, 
nasal swab, tracheal aspirate, tissue culture, eye swab, catheter and 
peritoneum fluid sources a total of 23 S.aureus, 11 S.epidermidis, 
6 S.haemolyticus, 5 S.saprophyticus, 2 S.warneri, 2 S.cohnii, 2 
S.vitulus, 1 S.capitis, 1 S.hominis, 1 S.intermedius, 1 S.lugdunensis 
was isolated from total 55 Staphylococcus. Biofilm formation in 
Staphylococcus was studied by used crystal violet dye. Bacteria 
suspension was added 200 microliter in every microplate wells and 
microlates was kept into incubator during 24 – 48 hours. At the 
end of the time, contents of wells was emptied and washed with 
distillate water. 200 microliter of 0.1% crystal violet solution was 
added in every wells and waited 15 minutes. End of this process, 
contents of wells was emptied and washed again. 200 microliter of 
95% ethanol was added ever wells and readed at the wavelenght 
540 nm. by the spectrophometer.
Results and Conclusion: A total of 55 clinical samples were read 
at the end of 24 hours, 76.36% were positive, reading in the end of 
48 hours, 94.55% were positive for formation of bioﬁlm. As a result, 
in different Staphylococcus species isolated from different clinical 
sources were high level for presencing of bioﬁlm.
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Pandemic 2009 Inﬂuenza A (H1N1) Virus Infection 
in Cancer and Hematopoietic Stem Cell Transplant 
Recipients. A Multicenter Observational Study
M. Cecilia Dignani, Patricia Costantini, Rosana Jordán, Claudia 
Salgueira, Alejandra Valledor, Graciela Guerrini, Fabián Herrera, 
Andrea Nenna, Claudia Mora, José Cozzi, Ana Laborde, Ernesto 
Efrom, Javier Altclas, Edith Carbone, Amadeo Esposto, Daniel 
Stecher, Aníbal Calmaggi.
Commission of Infections in Cancer  Patients of the Argentinean Soci-
ety of Infectious Diseases (SADI).
Background: During March 2009 a novel Inﬂuenza A virus emerged 
in Mexico. As of February 26th, 2010, there were 616 conﬁrmed deaths 
in Argentina. Two thirds of these had underlying conditions, including 
cancer. Cancer patients have higher rates of hospitalization and death 
(9 to 33%) during the inﬂuenza seasons. In Argentina, seasonal Inﬂu-
enza in oncohematological patients is associated to a 12% incidence of 
pneumonia and to a 5% of 30-day mortality.
Objectives: To describe the clinical picture of the pandemic Inﬂuenza A 
(H1N1) Inﬂuenza in cancer patients during the 2009 inﬂuenza season.
Methods: Centers from Buenos Aires (10) and La Plata (2) par-
ticipated in a multicenter observational descriptive study of cancer 
patients with conﬁrmed disease by the 2009 H1N1 virus, deﬁned as 
inﬂuenza like illness or pneumonia with positive PCR for this virus in 
respiratory secretions. Two PCR protocols were considered valid: the 
InﬂuenzaA/H1N1DetectionSet, by Roche Diagnostics GmbH, and the 
WHO protocol. Data on underlying disease, history of inﬂuenza vacci-
nation, clinical presentation, and outcome were obtained and analyzed.
Results: From May to August 2009, 12 centers sent data on 61 cancer 
patients with 2009 H1N1 virus disease conﬁrmed by positive PCR in 
BAL (3) or nasopharyngeal wash (58). Median age was 55 (17-81), 
56% were females. The majority of patients (43) had oncohematologi-
cal cancer (70%) and 18 (30%) had solid tumors. Cancer treatment 
included chemotherapy (43), SCT (15), no treatment (2) and surgery 
(1). History of 2009 seasonal Inﬂuenza vaccination was present in 
19/60 patients. No patient had received inﬂuenza chemoprophylaxis. 
Clinical presentation and outcome in table:
Clinical presentation 
 Upper respiratory infection 21 (34%)
 Pneumonia 40 (66%)
 Documented bacterial co-infection 7 (11%)
  4 pneumonias (S. pneumoniae 3, M. catharralis 1)
  3 bacteremias (MRCNS, Streptococcus, K. pneumoniae)
 Documented viral co-infection (Inﬂuenza B and Parainﬂuenza 3) 2 of 42 (5%)
 Lymphocyte count/uL, median (range) 720 (30-3948)
 Neutrophils count, median, (range) 3056 (28-28000)
Treatment
 Oseltamivir 52 (85%)
 Oseltamivir + amantadine 7 (12%)
 No treatment (patients in terminal phase of underlying disease) 2 (3%)
 Duration of oseltamivir treatment in days, median (range) 9 (1-22)
Outcome
 Required hospital admission 43 of 57 (75%)
 Required mechanical ventilation 12 (20%)
 Global 30-d mortality 11 (18%)
 30-day mortality in vaccinated patients 0 of 19 (0%)
 30-day mortality in non-vaccinated patients  11 of 41 (27%)
By univariate analysis, the only signiﬁcant risk factor for death was 
lymphopenia (<1000 lymphocytes/uL), with a Cox ratio of 3.95 (1.05-
14.9). The apparent role of vaccination as a beneﬁt in survival could 
not be conﬁrmed by statistical analysis and, in addition, there might 
be a bias because in cancer patients vaccination is indicated when the 
period of major immunesuppression has ﬁnished.
Conclusions: In our cancer patient population, the pandemic 2009 
Inﬂuenza A (H1N1) virus was associated high incidence of pneumonia 
(66%), and 30-day mortality (18%). These values are 3 times higher 
than those associated to seasonal inﬂuenza in the same population. 
Lymphopenia was a risk factor for death. Cross protection by seasonal 
Inﬂuenza vaccination cannot be ruled out.
